[go: up one dir, main page]

EP3218406A1 - Molécules de liaison spécifiques du cd73 et leur utilisation - Google Patents

Molécules de liaison spécifiques du cd73 et leur utilisation

Info

Publication number
EP3218406A1
EP3218406A1 EP15791298.1A EP15791298A EP3218406A1 EP 3218406 A1 EP3218406 A1 EP 3218406A1 EP 15791298 A EP15791298 A EP 15791298A EP 3218406 A1 EP3218406 A1 EP 3218406A1
Authority
EP
European Patent Office
Prior art keywords
antibody
seq
antigen
amino acid
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15791298.1A
Other languages
German (de)
English (en)
Other versions
EP3218406B1 (fr
EP3218406B2 (fr
Inventor
Ralph Minter
Steven RUST
Sandrine GUILLARD
Lutz U Jermutus
Carl Hay
Kris Sachsenmeier
Erin SULT
Qihui HUANG
Peter Pavlik
Melissa DAMSCHRODER
Li Cheng
Gundo Diedrich
Jonathan Rios-Doria
Scott Hammond
Robert E Hollingsworth
Nicholas DURHAM
Ching Ching Leow
Mary ANTONYSAMY
James Geoghegan
Xiaojun LU
Kim Rosenthal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3218406(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SI201531619T priority Critical patent/SI3218406T1/sl
Priority to PL15791298.1T priority patent/PL3218406T5/pl
Priority to RS20210770A priority patent/RS62003B2/sr
Priority to EP21157088.2A priority patent/EP3901176A1/fr
Priority to SM20210353T priority patent/SMT202100353T1/it
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Priority to HRP20210888TT priority patent/HRP20210888T4/hr
Publication of EP3218406A1 publication Critical patent/EP3218406A1/fr
Publication of EP3218406B1 publication Critical patent/EP3218406B1/fr
Publication of EP3218406B2 publication Critical patent/EP3218406B2/fr
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • CD73 or ecto-5'-nucleotidase (5'-NT) is ubiquitously expressed in a number of tissues.
  • This protein is anchored to the cell membrane through a glycosylphosphatidylinositol (GPI) linkage, has ecto-enzyme activity, and plays a role in signal transduction.
  • GPI glycosylphosphatidylinositol
  • the primary function of CD73 is the conversion of extracellular nucleotides (e.g., 5'-AMP), to which cells are generally impermeable, to their corresponding nucleosides (e.g., adenosine), which can readily enter most cells.
  • CD73 production of adenosine by the dephosphorylation of AMP has been shown to regulate adenosine receptor engagement in many tissues, indicating that adenosine functions in cytoprotection, cell growth, angiogenesis and immunosuppression, and also plays a role in tumorigenesis.
  • CD73 expression on tumor cells has been reported in several types of cancer, including colorectal cancer, pancreatic cancer, bladder cancer, leukemia, lymphoma, glioma, glioblastoma, melanoma, ovarian cancer, thyroid cancer, esophageal cancer, prostate cancer, and breast cancer. Elevated CD73 expression has also been associated with tumor invasiveness, metastasis, and reduced patient survival time. CD73 generates an immunosuppressed environment, characterized by increased adenosine levels, which promote the development and progression of cancer. Notably, CD73 expression has been associated with a prometastatic phenotype in melanoma and breast cancer.
  • Immune-checkpoint inhibitors hold great potential as cancer therapeutics. Nevertheless, clinical benefits from immune -checkpoint inhibition have been modest. One potential explanation is that tumors use nonoverlapping immunosuppressive mechanisms to facilitate immune escape.
  • compositions and methods for reducing tumor-mediated immunosuppression are urgently required.
  • the present invention provides isolated binding molecules or antigen-binding fragments thereof which specifically bind to CD73.
  • CD73-binding molecules are, e.g., antibodies or antigen-binding fragments thereof.
  • anti-CD73 antibodies of the invention e.g., MEDI9447 are useful for reducing tumor-mediated immunosuppression.
  • the present invention also provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and other agents targeting additional aspects of the cancer immunity cycle (i.e. anti-PD-1 or anti-PD-Ll antibodies; anti-CTLA4 antibodies, A2aR antagonists, STAT-3 inhibitors) and methods of using such combinations is useful for reducing tumor-mediated immunosuppression.
  • anti-CD73 antibodies e.g., MEDI9447
  • other agents targeting additional aspects of the cancer immunity cycle i.e. anti-PD-1 or anti-PD-Ll antibodies; anti-CTLA4 antibodies, A2aR antagonists, STAT-3 inhibitors
  • methods of using such combinations is useful for reducing tumor-mediated immunosuppression.
  • the invention provides an isolated binding molecule or antigen-binding fragment thereof which specifically binds to a CD73 epitope, where the binding molecule specifically binds to the same CD73 epitope as an antibody or antigen-binding fragment thereof having the heavy chain variable region (V H ) and light chain variable region (V L ) of an antibody selected from
  • the invention provides an isolated binding molecule or antigen- binding fragment thereof which specifically binds to CD73, and competitively inhibits CD73 binding by an antibody or antigen-binding fragment thereof comprising the V H and V L of CD730002, CD730003, CD730004, CD730008, CD730010, CD730011, CD730021, CD730042, CD730046, CD730047, or CD730058.
  • the invention provides an isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 comprising an antibody V L , where the V L has the amino acid sequence:
  • X 3 represents amino acid residues Glutamine (Q) or Leucine (L);
  • X 4 represents amino acid residues Leucine (L) or Proline (P);
  • X 5 represents amino acid residues Glycine (G) or Serine (S);
  • X 6 represents amino acid residues Leucine (L) or Histidine (H);
  • X 7 represents amino acid residues Lysine (K), Proline (P), Isoleucine (I) or Asparagine (N); and, X 8 represents amino acid residues Leucine (L) or Threonine (T).
  • the invention provides an isolated binding molecule or antigen binding fragment thereof which specifically binds to CD73 comprising an antibody VH, where the V H has the amino acid sequence:
  • X 9 represents amino acid residues Methionine (M) or Tyrosine (Y);
  • Xio represents amino acid residues Leucine (L) or Alanine (A);
  • X u represents amino acid residues Tryptophan (W) or Serine (S);
  • Xi2 represents amino acid residues Tryptophan (W) or Glycine (G);
  • X 13 represents amino acid residues Serine (S) or Arginine (R);
  • X 14 represents amino acid residues Glycine (G) or Serine (S);
  • X 15 represents amino acid residues Arginine (R) or Threonine (T);
  • X 16 represents amino acid residues Valine (V) or Isoleucine (I);
  • X 17 represents amino acid residues Tyrosine (Y), Lysine (K), Methionine (M), Leucine (L) or Glutamic acid (E).
  • the invention provides an isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 comprising an antibody V L and an antibody V H , where the V L comprises the amino acid sequence:
  • Xi represents amino acid residues Proline (P), Glutamic Acid (E) or Aspartic Acid (D);
  • X 2 represents amino acid residues Asparagine (N) or Aspartic Acid (D);
  • X 3 represents amino acid residues Glutamine (Q) or Leucine (L);
  • X 4 represents amino acid residues Leucine (L) or Proline (P);
  • X 5 represents amino acid residues Glycine (G) or Serine (S);
  • X 6 represents amino acid residues Leucine (L) or Histidine (H);
  • X 7 represents amino acid residues Lysine (K), Proline (P), Isoleucine (I) or Asparagine (N); and, X 8 represents amino acid residues Leucine (L) or Threonine (T);
  • V H comprises the amino acid sequence:
  • X 9 represents amino acid residues Methionine (M) or Tyrosine (Y);
  • Xio represents amino acid residues Leucine (L) or Alanine (A);
  • Xii represents amino acid residues Tryptophan (W) or Serine (S);
  • Xi 2 represents amino acid residues Tryptophan (W) or Glycine (G);
  • Xi3 represents amino acid residues Serine (S) or Arginine (R);
  • Xi4 represents amino acid residues Glycine (G) or Serine (S);
  • Xi5 represents amino acid residues Arginine (R) or Threonine (T);
  • Xi6 represents amino acid residues Valine (V) or Isoleucine (I);
  • Xi7 represents amino acid residues Tyrosine (Y), Lysine (K), Methionine (M), Leucine (L) or Glutamic acid (E).
  • the invention provides an isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 having an antibody V L , where the V L has a V L complementarity determining region-2 (VL-CDR2) amino acid sequence identical to, or identical except for four, three, two or one amino acid substitutions to SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51 or SEQ ID NO: 52.
  • VL-CDR2 V L complementarity determining region-2
  • the invention provides an isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 having an antibody V L , where the V L has a complementarity determining region-3 (VL-CDR3) amino acid sequence identical to, or identical except for four, three, two, or one amino acid substitutions to: SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, or SEQ ID NO: 56.
  • VL-CDR3 complementarity determining region-3
  • the invention provides an isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 having an antibody V H , where the V H has a complementarity determining region- 1 (VH-CDR1) amino acid sequence identical to, or identical except for four, three, two, or one amino acid substitutions to SEQ ID NO: 35 or SEQ ID NO: 36.
  • VH-CDR1 complementarity determining region- 1
  • the invention provides an isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 having an antibody V H , where the V H has a complementarity determining region-2 (VH-CDR2) amino acid sequence identical to, or identical except for four, three, two, or one amino acid substitutions to: SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, or SEQ ID NO: 40.
  • VH-CDR2 complementarity determining region-2
  • the invention provides an isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 having an antibody V H , where the V H has a complementarity determining region-3 (VH-CDR3) amino acid sequence identical to, or identical except for four, three, two, or one amino acid substitutions to SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, or SEQ ID NO: 45.
  • VH-CDR3 complementarity determining region-3
  • the invention provides an isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 having an antibody V L , where the V L has VL- CDR1, VL-CDR2, and VL-CDR3 amino acid sequences identical to, or identical except for four, three, two, or one amino acid substitutions in one or more of the VL-CDRs to: SEQ ID NOs: 46, 49 and 53; SEQ ID NOs: 47, 49, and 53; SEQ ID NOs: 47, 49, and 54; SEQ ID NOs: 46, 50, and 54; SEQ ID NOs: 46, 51, and 55; SEQ ID NOs: 48, 52, and 54; SEQ ID NOs: 46, 49, and 56; SEQ ID NOs: 47, 49, and 56; SEQ ID NOs: 46, 50, and 56; SEQ ID NOs: 46, 51, and 56; or SEQ ID NOs: 48, 52, and 56, respectively.
  • the invention provides an isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 having an antibody V H , where the V H has VH- CDR1, VH-CDR2, and VH-CDR3 amino acid sequences identical to, or identical except for four, three, two, or one amino acid substitutions in one or more of the VH-CDRs to: SEQ ID NOs: 35, 37 and 41; SEQ ID NOs: 36, 37, and 42; SEQ ID NOs: 36, 38, and 43; SEQ ID NOs: 36, 39, and 44; SEQ ID NOs: 36, 40, and 44; SEQ ID NOs: 35, 37, and 45; SEQ ID NOs: 36, 37, and 45; SEQ ID NOs: 36, 38, and 45; SEQ ID NOs: 36, 39, and 45; or SEQ ID NOs: 36, 40, and 45 respectively.
  • the invention provides an isolated antibody or antigen-binding fragment thereof which specifically binds to CD73 having a V L and a V H having VL-CDR1, VL-CRD2, VL- CDR3, VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences identical or identical except for four, three, two, or one amino acid substitutions in one or more CDRs to: SEQ ID NOs: 46, 49, 53, 35, 37, and 41 ; SEQ ID NOs: 47, 49, 53, 35, 37, and 41 ; SEQ ID NOs: 47, 49, 54, 36, 37, and 42; SEQ ID NOs: 46, 50, 54, 36, 38, and 43; SEQ ID NOs: 46, 51, 55, 36, 39, and 44; SEQ ID NOs: 48, 52, 54, 36, 40, and 44; SEQ ID NOs: 46, 49, 56, 35, 37, and 41; SEQ ID NOs: 46, 49, 53,
  • the invention provides an isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 having an antibody V L and an antibody V H , where the V L has an amino acid sequence at least about 90% to about 100% identical to a reference amino acid sequence selected from SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO:
  • SEQ ID NO: 66 SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, and SEQ ID NO: 70.
  • the invention provides an isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 having an antibody V L and an antibody V H , where the V H has an amino acid sequence at least about 90% to about 100% identical to a reference amino acid sequence selected from SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83 and SEQ ID NO: 84.
  • the invention provides an isolated antibody or antigen-binding fragment thereof which specifically binds to CD73, where the antibody or antigen binding fragment has a V L having a sequence at least about 90% to about 100% identical to a reference amino acid sequence selected from SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO:
  • the invention provides an isolated antibody or antigen-binding fragment thereof, which has a V L consisting essentially of SEQ ID NO: 57 and a V H consisting essentially of SEQ ID NO: 71.
  • the invention provides an isolated antibody or antigen-binding fragment thereof, which has a V L consisting essentially of SEQ ID NO: 68 and a V H consisting essentially of SEQ ID NO: 82.
  • the invention provides an isolated antibody or antigen-binding fragment thereof, which has a V L consisting of SEQ ID NO: 57 and a V H consisting of SEQ ID NO: 71.
  • the invention provides an isolated antibody or antigen-binding fragment thereof, which has a V L consisting of SEQ ID NO: 68 and a V H consisting of SEQ ID NO: 82.
  • the invention provides a composition containing an isolated antibody or antigen-binding fragment thereof in accordance with the invention, and a carrier.
  • the invention provides a nucleic acid having a sequence encoding the isolated antibody or antigen-binding fragment thereof in accordance with the invention.
  • the invention provides a composition including a nucleic acid in another aspect.
  • the invention provides a vector containing a nucleic acid in accordance with the invention.
  • the invention provides a host cell comprising a nucleic acid sequence, composition, or the vector in accordance with the invention.
  • the invention provides a method of making an antibody or antigen- binding fragment thereof in accordance with the invention, involving culturing a cell containing a nucleic acid sequence, composition, or vector in accordance with the invention; and isolating the antibody or antigen-binding fragment thereof.
  • the invention provides a diagnostic reagent containing an isolated
  • the invention provides a kit containing an isolated antibody or antigen- binding fragment thereof, composition, or the diagnostic reagent in accordance with the invention.
  • the invention provides a method of inhibiting the growth of a cell
  • CD73 involving contacting the cell with an antibody or antigen-binding fragment thereof in accordance with the invention.
  • the invention provides a method of treating cancer in a subject in need thereof, involving administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof in accordance with the invention.
  • the invention provides a method of treating cancer in a subject involving administering to the subject a therapeutically effective amount of a first agent, which is an antibody or antigen-binding fragment in accordance with the invention, in combination with a therapeutically effective amount of a second agent, which is an anti-cancer agent other than the first agent.
  • the invention provides a method of treatment involving administering an anti-CD73 antibody, or an antigen binding fragment thereof, to a subject identified as having a tumor that has increased expression of CD73 relative to a reference.
  • the invention provides a method of treatment involving administering an anti-CD73 antibody, or an antigen binding fragment thereof, and an anti-PD-1, anti-PD-Ll, or anti- CTLA4, or an antigen binding fragment thereof, to a subject identified as having a tumor that has increased expression of CD73 compared to a reference.
  • the invention provides a method of treatment involving administering
  • nivolumab (Keytruda®) or nivolumab (Opdiva®), or an antigen binding fragment thereof, to a subject identified as having a tumor that has increased expression of CD73 compared to a reference.
  • the invention provides a method of treatment involving administering
  • the invention provides a method of treatment involving administering
  • the invention provides a method of identifying a subject having a
  • cancer responsive to anti-CD73 therapy the method involving detecting an increased level of CD73 expression or activity in a tumor cell or blood cell of the subject, relative to a reference, thereby identifying said cancer as responsive to anti-CD73 therapy.
  • the invention provides a method of identifying a subject having a
  • cancer responsive to anti-CD73 therapy in combination with one or more of an anti-PD-1, anti-PD- Ll, or anti-CTLA4 therapy the method involving detecting an increased level of CD73 expression or activity in a tumor cell or blood cell of the subject, relative to a reference, thereby identifying said cancer as responsive to anti-CD73 therapy in combination with one or more of an anti-PD-1, anti-PD- Ll, or anti-CTLA4 therapy.
  • the invention provides a method of identifying a subject having a cancer responsive to anti-PD-1, anti-PD-Ll, or anti-CTLA4 therapy, the method involving detecting a decreased level of CD73 expression or activity in a tumor cell or blood cell of the subject, relative to a reference, thereby identifying said cancer as responsive to anti-PD-1, anti-PD-Ll, or anti-CTLA4 therapy.
  • the invention provides a method of inhibiting tumor growth in a
  • the method involving administering to a subject in need thereof an anti-CD73 antibody, or an antigen binding fragment thereof, and one or more of an anti-PD-1 antibody, anti-PD-Ll antibody, anti-CTLA4 antibody, or antigen binding fragment thereof.
  • the invention provides a method of increasing an anti-tumor immune response in a subject, the method involving administering to a subject in need thereof an anti-CD73 antibody, or an antigen binding fragment thereof, and one or more of an anti-PD-1 antibody, anti-PD- Ll antibody, anti-CTLA4 antibody, or antigen binding fragment thereof to the subject.
  • the invention provides a method of treating a tumor in a subject, the method involving administering to a subject in need thereof an anti-CD73 antibody, or an antigen binding fragment thereof, and one or more of an anti-PD-1 antibody, anti-PD-Ll antibody, anti- CTLA4 antibody, or antigen binding fragment thereof.
  • the invention provides a pharmaceutical formulation containing an effective amount of an anti-CD73 antibody, or antigen binding fragment thereof and an anti-PD-1 antibody, or an antigen binding fragment thereof.
  • the invention provides a pharmaceutical formulation containing an effective amount of MEDI9447, or antigen binding fragment thereof and pembrolizumab
  • the invention provides a pharmaceutical formulation containing an effective amount of MEDI9447, or antigen binding fragment thereof and nivolumab (Opdiva®), or an antigen binding fragment thereof.
  • the invention provides a pharmaceutical formulation containing an effective amount of Phen0203 hlgGl, or antigen binding fragment thereof and pembrolizumab (Keytruda®), or an antigen binding fragment thereof.
  • the invention provides a pharmaceutical formulation containing an effective amount of Phen0203 hlgGl, or antigen binding fragment thereof nivolumab (Opdiva®), or an antigen binding fragment thereof.
  • the invention provides a pharmaceutical formulation containing an effective amount of an anti-CD73 antibody, or antigen binding fragment thereof and an anti-PD-Ll antibody, or an antigen binding fragment thereof.
  • the invention provides a pharmaceutical formulation containing an effective amount of MEDI9447, or antigen binding fragment thereof and MEDI4736, or an antigen binding fragment thereof.
  • the invention provides a pharmaceutical formulation containing an effective amount of Phen0203 hlgGl, or antigen binding fragment thereof and MED 14736, or an antigen binding fragment thereof.
  • the invention provides a pharmaceutical formulation containing an effective amount of an anti-CD73 antibody, or antigen binding fragment thereof and an anti-CTLA4 antibody, or an antigen binding fragment thereof.
  • the invention provides a pharmaceutical formulation containing an effective amount of MEDI9447, or antigen binding fragment thereof and tremelimumab, or an antigen binding fragment thereof.
  • the invention provides a pharmaceutical formulation containing an effective amount of MEDI9447, or antigen binding fragment thereof and ipilimumab, or an antigen binding fragment thereof.
  • the invention provides a pharmaceutical formulation containing an effective amount of Phen0203 hlgGl, or antigen binding fragment thereof and tremelimumab, or an antigen binding fragment thereof.
  • the invention provides a pharmaceutical formulation containing an effective amount of Phen0203 hlgGl, or antigen binding fragment thereof and ipilimumab, or an antigen binding fragment thereof.
  • the invention provides a kit for increasing anti-tumor activity, the kit comprising an anti-CD73 antibody or antigen binding fragment thereof and an anti-PD-1 antibody, or an antigen binding fragment thereof.
  • the invention provides a kit for increasing anti-tumor activity, the kit comprising an anti-CD73 antibody or antigen binding fragment thereof and an anti-PD-Ll antibody, or an antigen binding fragment thereof.
  • the invention provides a kit for increasing anti-tumor activity, the kit comprising an anti-CD73 antibody or antigen binding fragment thereof and an anti-CTLA4 antibody, or an antigen binding fragment thereof.
  • the VL and VH of CD730002 is or includes SEQ ID NOs: 1 and 2, respectively, and the VL and VH of CD730010 are or include SEQ ID NOs: 1 and 2, respectively, and the VL and VH of CD730010 are or include SEQ ID NOs: 1 and 2, respectively, and the VL and VH of CD730010 are or include SEQ ID NOs: 1 and 2, respectively, and the VL and VH of CD730010 are or include SEQ ID NOs: 1 and 2, respectively, and the VL and VH of CD730010 are or include SEQ
  • the isolated binding molecule or antigen-binding fragment thereof includes an antibody or antigen-binding fragment thereof.
  • the binding molecule is affinity matured.
  • FW5 is or includes SEQ ID NO:
  • FW6 is or includes SEQ ID NO: 32
  • FW7 is or includes SEQ ID NO: 33
  • FW8 is or includes SEQ ID NO: 34.
  • FW1 is or includes SEQ ID NO:
  • FW2 is or includes SEQ ID NO: 27 or 28
  • FW3 is or includes SEQ ID NO: 29
  • FW4 is or includes SEQ ID NO: 30
  • FW5 is or includes SEQ ID NO: 31
  • FW6 is or includes SEQ ID NO: 32
  • FW7 is or includes SEQ ID NO: 33
  • FW8 is or includes SEQ ID NO: 34.
  • the VL includes a VL
  • VL-CDR1 complementarity determining region- 1 amino acid sequence identical to, or identical except for four, three, two or one amino acid substitutions to: SEQ ID NO: 46, SEQ ID NO: 47, or SEQ ID NO: 48.
  • the isolated antibody or antigen- binding fragment thereof has a VL having SEQ ID NO: 57 and a VH having SEQ ID NO: 71.
  • the isolated antibody or antigen- binding fragment thereof has a VL having SEQ ID NO: 68 and a VH having SEQ ID NO: 82.
  • the isolated antibody or antigen- binding fragment thereof includes a heavy chain constant region or fragment thereof.
  • the heavy chain constant region or fragment thereof is an IgG constant region, including for example an IgGl constant region, an IgG2 constant region, an IgG3 constant region or an IgG4 constant region.
  • the isolated antibody or antigen- binding fragment thereof includes a light chain constant region selected from a human kappa constant region and a human lambda constant region.
  • the IgG constant region has one or more amino acid substitutions relative to a wild-type IgG constant region where the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type IgG constant region.
  • the IgG constant region has one or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385- 389, and 428-436, where the numbering is according to the EU index as set forth in Kabat.
  • At least one IgG constant region amino acid substitution is selected from: (a) substitution of the amino acid at position 252 with Tyrosine (Y), Phenylalanine (F), Tryptophan (W), or Threonine (T);
  • the human IgG constant region has amino acid substitutions relative to a wild-type human IgG constant region at positions 252, 254, and 256, where
  • the amino acid at position 434 is substituted with an amino acid selected from Tryptophan (W), Methionine (M), Tyrosine (Y), and Serine (S), and where the numbering is according to the EU index as set forth in Kabat.
  • the amino acid at position 428 is substituted with an amino acid selected from Threonine (T), Leucine (L), Phenylalanine (F), and Serine (S), and where the numbering is according to the EU index as set forth in Kabat.
  • the amino acid at position 257 is substituted with Leucine (L), and the amino acid at Kabat position 434 is substituted with Tyrosine (Y), and where the numbering is according to the EU index as set forth in Kabat.
  • amino acid at Kabat position the amino acid at Kabat position
  • the human IgG constant region has amino acid substitutions relative to a wild-type human IgG constant region at positions 252, 254, and 256, where the numbering is according to the EU index as set forth in Kabat, and where
  • the antibody is a fully human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a multispecific antibody, or an antigen-binding fragment thereof.
  • the isolated antibody or antigen- binding fragment thereof is conjugated to at least one heterologous agent, including for example an anticancer agent.
  • composition in accordance with the invention further contains an anticancer agent.
  • the isolated antibody or antigen- binding fragment thereof does not induce antibody dependent cell mediated cytotoxicity (ADCC).
  • the isolated antibody or antigen- binding fragment thereof is an antagonist of CD73.
  • the isolated antibody or antigen-binding fragment thereof is an antagonist of CD73 in cells selected from MB-MDA-231, 4T1, MKl, or a combination of two or more of the recited cells.
  • the CD73 is human CD73.
  • binding of the antibody or antigen binding fragment to CD73 can reduce cell proliferation.
  • the antibody or antigen binding fragment to CD73 can bind to human CD73, cynomolgus monkey CD73, and mouse CD73.
  • the cancer is selected from
  • colorectal cancer pancreatic cancer, bladder cancer, leukemia, lymphoma, glioma, glioblastoma, melanoma, ovarian cancer, thyroid cancer, esophageal cancer, prostate cancer, and breast cancer.
  • the cancer has a prometastatic phenotype, including melanoma or breast cancer
  • the subject is human.
  • the combination of the first agent and the second agent has superior antitumor activity; may be additive or synergistic.
  • the second agent is an antibody or antigen binding fragment thereof.
  • the second agent specifically binds to PD-1 (programmed death
  • PD-Ll programmed death 1 protein ligand 1
  • PD-L2 programmeed death 1 protein ligand
  • CTLA-4 cytotoxic T lymphocyte antigen 4 protein
  • the second agent is an anti-
  • CTLA-4 antibody or antigen-binding fragment thereof including for example ipilimumab, tremelimumab (ticilimumab, CP-675,206), or antigen-binding fragments thereof.
  • the second agent is an anti-PD-1 antibody or antigen-binding fragment thereof, including for example pembrolizumab (Keytruda®, lambrolizumab, MK-3475), nivolumab (Opdiva®, BMS-936558, MDX-1106, ONO-4538), AMP-
  • the second agent is an anti-PD-
  • Ll antibody or antigen-binding fragment thereof including for example MEDI4736, BMS-936559,
  • MPDL3280A or antigen-binding fragments thereof.
  • the anti-CD73 antibody is N-CD73
  • the subject is undergoing, has undergone, or will undergo an anti-PD-1, anti-PD-Ll , or anti-CTLA4 therapy.
  • the anti-PD-1, anti-PD-Ll, or anti-CTLA4 therapy involves administering an anti-PD-1, anti-PD-Ll, or anti-CTLA4 antibody or antigen binding fragment thereof, respectively.
  • the anti-PD-1 antibody is pembrolizumab (Keytruda®,
  • the anti-PD-Ll antibody is MEDI4736, BMS-936559,
  • MPDL3280A or antigen binding fragments thereof.
  • the anti-CTLA-4 antibody is ipilimumab, tremelimumab
  • the tumor is a colon cancer, melanoma, breast cancer, lymphoma, non-small cell lung carcinoma Hodgkin's lymphoma, non-
  • CD73 expression or activity is detected in a tumor sample, blood sample, or lymph sample.
  • CD73 expression is detected in a tumor cell or peripheral blood cell, including lymphoid or myeloid cell subsets (i.e. one or more of a
  • B lymphocyte CD4+, FoxP3+ lymphocyte, or myeloid-derived suppressor cell (MDSC)).
  • MDSC myeloid-derived suppressor cell
  • CD73 expression is detected by flow cytometry, immunohistochemistry (IHC) or CD73 enzyme activity or soluble CD73 levels in samples.
  • antigen binding fragment thereof and the anti-PD-1, anti-PD-Ll, or anti-CTLA4 antibody, or antigen binding fragment thereof are administered concurrently.
  • the method induces or increases a tumor-specific immune response.
  • the method reduces the
  • the tumor is a CD73
  • the invention provides an isolated binding molecule or antigen- binding fragment thereof which specifically binds to CD73 having an antibody VL and an antibody VH, which specifically binds to an epitope of a CD73 protein having one or more amino acids corresponding to Vall44, Lysl80, and Asnl85.
  • the isolated binding molecule or antigen-binding further contains one or more amino acids corresponding to Tyrl35, Lysl36, and Asnl87.
  • the isolated binding molecule or antigen-binding fragment thereof contains the amino acids corresponding to Tyrl35, Lysl36, and Asnl87.
  • the isolated binding molecule or antigen-binding fragment thereof contains the amino acids corresponding to Tyrl35, Lysl36, Asnl87, Tyrl35, Lysl36, and Asnl87.
  • the isolated binding molecule or antigen-binding fragment thereof binds an epitope within one or more of the following regions of a CD73 protein: Tyrl32-Vall44 and/or Lysl80-Asnl87.
  • the isolated binding molecule or antigen-binding fragment thereof contains or is within the amino acid sequences at Tyrl32-Vall44 and/or Lysl80-Asnl87.
  • the invention provides a conformational epitope on the surface of a
  • CD73 protein having one or more amino acids corresponding to Vall44, Lysl80, and Asnl85, where a CD73 protein containing the epitope can be specifically bound by monoclonal antibody MED 19447 or an antigen-binding fragment, variant, analog or derivative thereof.
  • theconformational epitope further contains one or more amino acids corresponding to Tyrl35, Lysl36, and Asnl8.
  • the conformational epitope of contains the amino acids corresponding to Tyrl35, Lysl36, and Asnl87.
  • the conformational epitope contains the amino acids corresponding to Tyrl35, Lysl36, Asnl87, Tyrl35, Lysl36, and Asnl87.
  • the conformational epitope is within one or more of the following regions of a CD73 protein: Tyrl32-Vall44 and/or Lysl80-Asnl87.
  • the conformational epitope contains or is within the amino acid sequences at Tyrl32-Vall44 and/or Lysl80- Asnl87.
  • MEDI9447 binds the CD73 protein in an inactive or catalytically active state or open or closed state.
  • the CD73 protein is human CD73.
  • isolated binding molecule or antigen-binding fragment thereof wherein the VL and VH are the VL and VH of MED 19447.
  • compositions and articles defined by the invention were isolated or otherwise manufactured in connection with the examples provided below. Other features and advantages of the invention will be apparent from the detailed description, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES
  • Figure 1 A shows the nucleotide sequence and amino acid translation of MEDI9447 VH domain with CDRs shown based on Kabat numbering convention.
  • Figure IB shows the nucleotide sequence and amino acid translation of MEDI9447 VL domain with CDRs shown based on Kabat numbering convention.
  • Figure 1C shows an alignment of MEDI9447 VH with closest human VH and JH
  • Figure ID shows an alignment of MEDI9447 VL with closest human VL and JL germline sequences. CDRs based on Kabat numbering convention are highlighted and residues different from germline sequences are boxed.
  • Figure 2 provides two graph showing antibody-mediated internalization of a cytotoxic
  • Figure 3 A is a graph showing inhibition of 5' ectonucleotidase by the anti-CD73 antibody
  • Figure 3B is a graph showing inhibition of AMP hydrolysis by anti-CD73 antibody
  • Figure 4 is a graph showing that MEDI9447 inhibited tumor growth in a CT26 syngeneic tumor model.
  • Murine CT26 tumor cells were implanted subcutaneously on the right flank of female Balb/C mice. Tumors were allowed to grow for 3 days and treated with MEDI9447 or an isotype control twice weekly for two weeks. At Day 16, tumors were harvested for flow cytometry analysis.
  • Figure 5 is a graph showing that MEDI9447 inhibited tumor-infiltrating myeloid-derived suppressor cells (MDSCs).
  • MDSCs tumor-infiltrating myeloid-derived suppressor cells
  • Figure 6 includes six spider plots showing the effect of MEDI9447 mlgGl, anti-PD-1 or the combination on tumor volume.
  • Control antibodies include rIgG2a, which is a Rat IgG2a control monoclonal rat antibody specific for E. coli ⁇ -galactosidase ( ⁇ -Gal), and Isotype control murine IgGl.
  • Tumor volumes from each group of animals were plotted for individual animals out to study day 40. No control group mice were tumor free by the end of the 40 day study period.
  • Anti-CD73 treatment alone resulted in 10% tumor free animals at the end of study.
  • Anti-PDl treatment alone also resulted in 10% tumor free animals at the end of study.
  • Figure 7 is a graph showing the effect of MEDI9447 mlgGl, anti-PDl or the combination on survival.
  • Figure 8 is a graph showing that the combination of MED 19447 and anti-PD-1
  • mice were injected subcutaneously with syngeneic MC38-OVA colorectal carcinoma cells and treated twice weekly with 10 mg per kg of MED 19447 or 10 mg per kg anti-PD-1 antibody alone or a combination of both antibodies. Tumor volume was measured twice weekly.
  • Figure 10 is a graph showing that anti-PD-1 induced a CD73-rich tumor
  • mice myeloid-derived suppressor cells isolated from tumor-bearing mice.
  • tumors were isolated, tumor cells were isolated, peripheral whole blood cells were harvested and analyzed for surface CD73 expression by flow cytometry.
  • Figure 11 is a graph showing that anti-PD-1 induced a CD73-rich tumor
  • Figure 12 is a graph showing that the combination of MEDI9447 and anti-PD-Ll
  • mice were injected subcutaneously with syngeneic B16F10 melanoma cells and treated twice weekly with 10 mg per kg of MEDI9447 or 10 mg per kg anti-PD-Ll antibody alone or a combination of both antibodies. Tumor volume was measured twice weekly.
  • Figure 13 is a graph showing that the combination of MEDI9447 and anti-PD-Ll
  • mice were injected subcutaneously with syngeneic EG7-OVA lymphoma cells and treated twice weekly with 10 mg per kg of MEDI9447 or 10 mg per kg anti-PD-Ll antibody alone or a combination of both antibodies. Tumor volume was measured twice weekly.
  • Figure 14 is a graph showing that anti-PD-Ll induced a CD73-rich tumor
  • Figure 15 is a graph showing that anti-PD-Ll induced a CD73-rich tumor
  • Figure 16 A and B are graphs showing that MEDI9447 alone or in combination with anti-
  • PD-Ll reduced CD73 expression on tumor infiltrating lymphoid cells.
  • Mice bearing colorectal CT26 syngeneic tumors were treated twice weekly (Day 12 and D16) with either 30 mg/kg MED 19447 or 30 mg/kg anti-PD-Ll alone or combination of both MEDI9447 and anti-PD-Ll.
  • tumors were harvested and analyzed for surface CD73 expression by flow cytometry.
  • CD73 expression on tumor infiltrates A) CD4+ FoxP3+ Treg and (B) CD8+ T cells.
  • Figure 17 A and B are graphs showing that MEDI9447 alone or in combination with anti-
  • PD-Ll reduced CD73 activity on (A) tumor cells and (B) peripheral whole blood cells.
  • Mice bearing colorectal CT26 syngeneic tumors were treated twice weekly (Day 12 and D16) with either 30 mg/kg MEDI9447 or 30 mg/kg anti-PD-Ll alone or combination of both MEDI9447 and anti-PD-Ll.
  • tumors and peripheral whole blood cells were harvested and analyzed for surface CD73 expression for enzymatic activity by using Cell-Titre Glo.
  • Figure 18 are a set of graphs depicting cytokine profiles of peripheral blood mononuclear cells treated with MEDI9447 and antibodies or fusion proteins specific for CTLA4, OX40, PD-1, and PD-L1.
  • Primary human peripheral blood mononuclear cells were incubated for 72 hrs in a mixed leukocyte reaction with MED 19447 and/or antibodies or fusion proteins specific for the indicated targets.
  • Cytokines IFN- ⁇ , IL- ⁇ , TNF-a
  • Data shown represent optimal dose combinations of anti-CD73 antibody with the 4 different partner agents.
  • FIGS 19A and 19B depict results of hydrogen deuterium exchange MS (HDX-MS) analysis of CD73 in complex with MEDI9447.
  • Figure 19A depicts a hydrogen-deuterium exchange heat map showing those regions of CD73 (N- to C-terminal) that undergo decreased deuterium uptake when bound to MEDI9447.
  • Relative exchange between antibody-bound and unbound CD73 is depicted as a function of exposure time with decreased exchange in red, increased exchange in blue, and no change in white.
  • the N-terminal regions at positions 132-143 and 182-187 exhibited the highest degree of differential exchange.
  • Figure 8B shows a crystal structure of the CD73 monomer depicting the location of the HDX-identified binding interface (cyan) within the N-terminal domain (yellow).
  • the CD73 linker region and C-terminal domain are represented in orange and blue, respectively.
  • Figures 20A-20E depict the results of hydrogen deuterium exchange MS (HDX-MS) analysis indicating regions of CD73 and MEDI9447 that undergo differential hydrogen exchange in free versus bound states.
  • Figure 20A depicts plots representing relative deuterium uptake (mass change in daltons) as a function of deuterium exposure time within peptides encompassing the 132- 143 region.
  • Figure 20B depicts plots representing relative deuterium uptake (mass change in daltons) as a function of deuterium exposure time within peptides encompassing the 182-187 region.
  • uptake for CD73 alone is shown in squares and uptake for CD73 bound to MEDI9447 Fab is shown in red.
  • FIG. 20C depicts a DynamX difference chart for MEDI9447 Fab heavy chain.
  • Figure 20D depicts a DynamX difference chart for MEDI9447 Fab light chain.
  • each data point indicates the difference in deuterium uptake between the CD73+Fab complex (positive values on y-axis) and Fab alone (negative values on y-axis).
  • the vertical bar represents the sum of the uptake differences across the exposure time-points.
  • the CDRs showing lower relative uptake when Fab was bound to CD73 are indicated.
  • Figure 9E depicts a DynamX difference chart of CD73 alone (negative values on y-axis) versus CD73 bound to Fab (positive values on y-axis). Regions El (aa 132-143) and E2 (aa 182-187) are indicated.
  • the horizontal axis corresponds to the analyzed peptides from the N- to C-terminus (left to right).
  • a dotted line is overlaid on the chart showing the 1.6 dalton, 98% confidence interval cut-off for statistically significant changes.
  • Figures 21A-21H depict sensor chip data showing that the MEDI9447 epitope resides within the N-terminal domain of CD73.
  • Figure 21 A is a graph depicting sensor chip data for wild- type CD73 protein. Wild-type CD73 protein was immobilized on a HTG sensor chip and binding of MEDI9447 dilutions (5 nM to 0.3 nM) was measured by surface plasmon resonance (SPR).
  • Figure 21B is a graph depicting sensor chip data for N-terminal domain-swapped CD73 protein.
  • N-terminal domain-swapped CD73 protein was immobilized on an HTG sensor chip and binding of MEDI9447 dilutions (5 nM to 0.3 nM) was measured by SPR. MEDI9447 did not bind to CD73 when the N- terminal domain was swapped.
  • Figure 21C is a graph depicting sensor chip data for N-terminal and C-terminal domain-swapped CD73 protein. N-terminal and C-terminal domain-swapped CD73 protein was immobilized on an HTG sensor chip and binding of MEDI9447 dilutions (5 nM to 0.3 nM) was measured by SPR.
  • FIG. 21D is a graph depicting sensor chip data for linker region-swapped CD73 protein.
  • Linker region-swapped CD73 protein was immobilized on an HTG sensor chip and binding of MEDI9447 dilutions (5 nM to 0.3 nM) was measured by SPR. Swapping only the linker region did not affect binding.
  • Figure 21E is a graph depicting sensor chip data for C-terminal domain-swapped CD73 protein.
  • FIG. 21F is a graph depicting sensor chip data for interface El (aa 132-143)-swapped CD73 protein.
  • Interface El (aa 132-143) -swapped CD73 protein was immobilized on an HTG sensor chip and binding of MEDI9447 dilutions (5 nM to 0.3 nM) was measured by SPR.
  • Figure 21G is a graph depicting sensor chip data for interface E2 (aa 182-187)-swapped CD73 protein.
  • Interface E2 (aa 182-187)-swapped CD73 protein was immobilized on an HTG sensor chip and binding of MEDI9447 dilutions (5 nM to 0.3 nM) was measured by SPR.
  • Figure 21H is a graph depicting sensor chip data for interface El (aa 132-143)- and interface E2 (aa 182-187)-swapped CD73 protein.
  • Interface El (aa 132-143)- and interface E2 (aa 182-187)-swapped CD73 protein was immobilized on an HTG sensor chip and binding of MEDI9447 dilutions (5 nM to 0.3 nM) was measured by SPR.
  • Figure 22 depicts the alignment of human and chicken CD73 protein sequences. Only the mature protein sequences are shown. Non-conserved residues are highlighted in the chicken sequence. Regions swapped between chicken and human to generate the knock-out variants are annotated (e.g. DSla, DSlb, etc.).
  • Figures 23 depict binding of MEDI9447 to CD73 variants.
  • Figure 23 is a table of data showing binding of MEDI9447 to CD73 variants.
  • K D for variants highlighted in blue are >2-fold changed from the WT or KO parent construct.
  • Figures 24A-24F depict that the MEDI9447 epitope is positioned at the apex of the N- terminal domain.
  • Figure 13A shows that an evaluation of MEDI9447 binding to a panel of CD73 variants (see Figures 22 and 23) revealed six positions that constitute the interaction site. Two of the three most impactful residues (highlighted blocks) are located outside the HDX interface regions (highlighted in blue). Three less important residues (pink blocks) are located within the HDX interface.
  • Figure 24B is table showing that knocking-in N185 and V144 (K180 is conserved) to a CD73 construct containing chicken N- and C-terminal domain sequence restored binding to less than 20-fold the K D for wild-type CD73 (MEDI9447 dilutions from 5 nM to 0.3 nM; compare to Figure 10B).
  • Figure 24C depicts a close-up of the epitope residues located within the N-terminal domain of CD73. The most important residues for binding are shown highlighted and less impactful positions (Y135, K136, and N187) are in pink. The HDX interface is overlaid in blue.
  • Figure 24D depicts a surface representation showing that the epitope forms a near contiguous binding surface.
  • Figure 24E depicts a crystal structure of the open conformation of CD73 showing the position of the epitope at the apical, lateral surface of the N-terminal domain.
  • Figure 24F shows that the location of the epitope is distant from the substrate binding site (adenosine depicted in spheres) and the zinc ion (grey sphere) coordination site (side chains in cyan).
  • the CD73 N-terminal domain, linker region, and C-terminal domain are depicted in yellow, orange, and blue, respectively.
  • FIGS 25A-25C show that MEDI9447 is a non-competitive inhibitor of CD73
  • FIG. 25A is a graph depicting the kinetics of CD73 phosphohydrolysis of AMP measured in the presence of MEDI9447 or an isotype matched control mAb.
  • Figure 25B is a graph showing that MEDI9447 acts as a non-competitive inhibitor in that it equivalently inhibits hydrolysis regardless of substrate concentration.
  • APCP a known competitive inhibitor of CD73, increases K m but did not V max .
  • Figure 25C is a graph depicting dose response of MEDI9447 IgG, Fab, or control IgG on the inhibition of CD73 hydrolysis of AMP.
  • MEDI9447 IgG reached maximal inhibition at a 1 : 1 molar stoichiometry with CD73 dimer (arrow). At high concentrations, where MEDI9447 IgG is in excess (>10 nM), a loss of inhibition or "hook effect" was observed. MEDI9447 Fab and control IgG did not inhibit CD73. All experiments were performed using the CellTiterGlo assay as described herein (RLU, relative light units) .
  • Figures 26A-26C show that anti-CD73 mAb (clone 0069) binding is dependent on CD73
  • Figure 26A is a graph showing sensor chip data for histidine tagged CD73. Histidine tagged CD73 was immobilized on a HIS2 biosensor and binding by mAb A was measured by bio-layer interferometry (BLI). Binding of mAb A to WT CD7 (blue sensorgram), N-terminal domain swap knockout CD73 (KO_l-291, green sensorgram) and C-terminal domain swap knockout CD7 (KO_311-523 cyan sensorgram) show that mAb binding is impacted by residues in both the N- and C-terminal domain.
  • Figure 26B Crystal structure of open and closed CD73 showing position of mAb A binding hot spot highlighted (aa 114-134 and 153-170), which is positioned near the N- and C-terminal domain interface (N-terminal domain in yellow, linker in orange, and C-terminal domain in blue). Mapping was based on binding data from Figures 26A and 26C.
  • Figure 26C shows binding sensorgrams of mAb A to different domain swap knockout variants of CD73. Swapping sub-regions DS2c (aa 114-134) or DS3a (aa 153-170) knocked out binding. All binding analysis was performed on an Octet QK384 instrument as described herein.
  • Figures 27A-27C show that MEDI9447 inhibited the transition of CD73 to the
  • FIG. 27A is a graph showing biosensor data for wild type CD73. Wild type CD73 was immobilized on a HIS2 biosensor and binding of MEDI9447 (blue sensorgram) and anti-CD73 mAb A (brown sensorgram) was measured by BLI on an Octet QK384. When CD73 was pre-incubated with Zn 2+ and APCP, MEDI9447 retained binding (black sensorgram) but mAb A binding was lost (orange sensorgram).
  • Figure 27B is a graph showing that although Zn 2+ and APCP pre -incubation with CD73 caused a loss in mAb A binding (orange sensorgram), pre-incubation with MEDI9447 before addition of Zn 2+ and APCP restored binding (purple sensorgram). Binding of mAb A to CD73 alone and CD73 pre-incubated with MEDI9447 (but not Zn 2+ and APCP) are shown in the blue and brown sensorgrams, respectively.
  • Figure 27C shows a proposed model depicting how MEDI9447 prevents CD73 from adopting the fully closed, active conformation induced by Zn 2+ and APCP. MEDI9947 may restrict transition to an intermediate state with lower affinity for mAb A.
  • Figures 28A and 28B show binding of MEDI9447 or mAb A to CD73 under different conditions measured by BLI as described herein, unless otherwise noted below.
  • Figure 28A is a graph depicting binding of anti-CD73 mAb A to histidine -tagged wild-type CD73 immobilized on a HIS2 biosensor. After a 100 sec baseline, captured CD73 was incubated with Zn 2+ , APCP, and/or EDTA for 900 sec, and then the biosensor was incubated in 30 nM mAb A for 600 sec to measure binding. mAb A bound to CD73 (blue sensorgram) but not CD73 pre-incubated with Zn 2+ and APCP (purple sensorgram).
  • FIG. 28B is a graph showing that MEDI9447 Fab or control IgG did not rescue binding of mAb A to CD73 pre- incubated with Zn 2+ and APCP. The assay was performed as in Figure 27B. MEDI9447 Fab or isotype-matched control IgG were pre-incubated with CD73 before addition of Zn 2+ and APCP.
  • mAb A immobilized on the biosensor bound to CD73 alone blue sensorgram
  • Figures 29A and 29B show that anti-CD73 mAb B binding is dependent on residues in sub-regions DS2b (aa 92-134) or DS2c (aa 114-134).
  • Figure 29A is a table showing SEC-MALS data corresponding to Figures 30A-30C. For each mixture of CD73 and either MEDI9447 or mAb B, the corresponding SEC retention time, Mw, and polydispersity of the formed complexes are shown.
  • Figure 29B depicts the determination of the binding hot spot of mAb B on CD73.
  • mAb B binding to CD73 variants immobilized on HIS2 biosensors was measured by BLI as described for mAb A (clone 0069) in Figures 26A-26C according to the methods herein. Binding sensorgrams showed that swapping either sub-region DS2b (aa 92-134) or DS2c (aa 114-134) knocked out binding by mAb B.
  • Figures 30A-30C show that MEDI9447 forms inter-dimer bridges between soluble CD73 molecules.
  • CD73 was incubated with varying amounts of MEDI9447 or anti-CD73 mAb B and analyzed by SEC-MALS. Shown are SEC UV chromatograms with protein retention time on the x- axis and molar mass determined by MALS on the y-axis.
  • Figure 30A is a chromatogram showing that at a 1: 1 molar ratio (green trace), MEDI9447 formed complexes with CD73 of -1.7 ( ⁇ ) and -6.6 (+) megadaltons.
  • FIG. 30B is a top-down view of the crystal structure of CD73 dimer showing the mAb B binding hot spot (purple) and MEDI9447 epitope (magenta and pink).
  • mAb B binds to a site close to the central groove between the dimers in the open conformation.
  • Figure 30C is a chromatogram showing that when CD73 is bound to mAb B a single predominant complex of -270- 290 kD (peak at -7.2 min) was formed. UV traces shown represent 1 : 1 mAb B:CD73 (red), 0.5: 1 (blue), and 0.1: 1 (green).
  • mAb A and CD73 alone are in magenta and black, respectively.
  • Figures 31A-31D depict that surface -bound CD73 was inhibited by IgG and Fab formats of MEDI9447.
  • Figure 31 A is a graph depicting inhibition of AMP hydrolysis of immobilized CD73 by MEDI9447 IgG, Fab or control antibodies.
  • CD73 was immobilized via a C-terminal histidine tag to a nickel-coated microtiter plate and inhibition of AMP hydrolysis by MEDI9447 IgG, Fab or control antibodies was measured using the Malachite Green assay as described herein.
  • MEDI9447 IgG, but not control IgG inhibited CD73 hydrolysis of AMP in a dose-dependent manner.
  • MEDI9447 Fab also inhibited CD73 activity, but to a much lower extent.
  • Figure 3 IB depicts complexes comprising MEDI9447 Fab (green) bound to anti-Fd antibody (xFd, red).
  • MEDI9447 Fab green was bound to one arm of an anti-Fd antibody (xFd, red) and the other arm bound to a non-specific polyclonal Fab (pFab, orange) inhibition increased to that comparable with MEDI9447 IgG (Fab+xFd+pFab vs. MEDI9447 IgG and MEDI9947 IgG+xFd+pFab) (see Figure 31 A).
  • Figure 31C a graph depicting inhibition of AMP hydrolysis of GPI-anchored CD73 by MEDI9447 IgG, Fab or control antibodies. Enzyme activity of endogenously expressed CD73 in MDA-MB-231 cells was measured by CellTiterGlo assay.
  • FIG. 3 ID is a graph depicting inhibition of AMP hydrolysis of soluble CD73 (sCD73) by MEDI9447 IgG, Fab or control antibodies.
  • Figure 32 is a graph showing that MEDI94447 IgG and Fab inhibited CD73 hydrolysis of
  • CD73 activity was measured in the presence of increasing concentrations of antibody using the Malachite Green assay, as described herein.
  • MEDI9447 IgG inhibited CD73 hydrolytic activity in a dose-dependent manner and no hook effect, or loss of inhibition, was observed.
  • MEDI9447 Fab also inhibited CD73 function, but to a lower level of maximal inhibition. The experiment was performed twice with comparable results. Data from only one experiment are shown.
  • Figure 33 depicts a model showing that inhibition of CD73 hydrolytic activity by
  • MEDI9447 occurs through a dual mechanism.
  • MEDI9447IgG green
  • Monovalently bound IgG or Fab does not inhibit soluble CD73.
  • inhibition can occur through bridging of adjacent CD73 dimers, or steric blocking from monovalently bound IgG or Fab/xFd (red) complex.
  • the present invention provides isolated binding molecules or antigen-binding fragments thereof which specifically bind to CD73.
  • such molecules are antibodies and antigen- binding fragments thereof that specifically bind to CD73.
  • Related polynucleotides, vectors, pharmaceutical compositions comprising the anti-CD73 antibodies or antigen-binding fragments thereof, are also provided.
  • methods of making as well as methods of using the anti- CD73 antibodies and antigen-binding fragments disclosed herein for example, diagnostic methods and methods of treating cancer in a subject (as direct therapy, adjuvant therapy, or in combination therapy).
  • the invention also provides antibody-drug conjugates derived from the CD73 binding molecules disclosed herein.
  • the invention provides therapeutic combinations featuring anti- CD73 antibodies (e.g., MEDI9447) and one or more of agents targeting additional aspects of the cancer immunity cycle such as anti-PD-1 antibodies, anti-PD-Ll antibodies (e.g., MEDI4736), anti- CTLA4 antibodies; and methods of using such combinations for reducing tumor-mediated immunosuppression.
  • anti- CD73 antibodies e.g., MEDI9447
  • agents targeting additional aspects of the cancer immunity cycle such as anti-PD-1 antibodies, anti-PD-Ll antibodies (e.g., MEDI4736), anti- CTLA4 antibodies
  • CD73 polypeptide refers to the CD73 (Cluster of CD73
  • Differentiation 73) protein also referred to as 5 '-nucleotidase (5' -NT) or ecto-5' -nucleotidase in the literature, which is encoded by the NT5E gene.
  • 5'-NT 5 '-nucleotidase
  • ecto-5' -nucleotidase in the literature, which is encoded by the NT5E gene.
  • the respective sequences of the human and murine forms of CD73 are available at the Uniprot database under accession numbers P21589 and Q61503, respectively.
  • the amino acid numbering used represents the amino acid residue of the mature CD73 protein which does not contain the signal sequence residues. Accordingly, an antibody binding amino acids Vall44, Lysl80, and Asnl85, for example, refers to the amino acid positions after cleavage of the signal sequence, ie., the amino acid in the mature protein.
  • CD73 polypeptide is provided below:
  • the full-length CD73 protein comprises 574 amino acids.
  • the mature CD73 protein is produced after removal of a signal sequence (positions 1 to 26) and the C-terminal region of the propeptide (positions 550-574).
  • amino acids 404 to 453 are removed in isoform 2 of CD73 after alternative splicing.
  • Natural variants are also known, for example, variant C358Y, variant T376A, and variant M379T. See Misumi et al., Eur. J. Biochem.
  • Typical diseases leading to a change in the patient's CD73 level in tissue fluids, especially in serum are: tissue trauma; reperfusion injuries resulting from myocardial infarction or stroke, organ transplantations or other surgical operations; cancer or cancer metastasis; or inflammatory conditions resulting from the aforesaid traumas or reperfusion injuries or from chronic conditions including allergic conditions, autoimmune diseases, and inflammatory diseases.
  • arthritis As examples of such chronic conditions can be mentioned arthritis, allergic conditions such as asthma, inflammatory conditions such as inflammatory bowel disease or an inflammatory condition of the skin, psoriasis, Parkinson's disease, Alzheimer's disease, autoimmune diseases, type I or type II diabetes, atherosclerosis, multiple sclerosis, Crohn's disease, or rejection reactions due to organ transplantations.
  • inflammatory diseases systemic inflammatory response syndrome (SIRS), acute lung injury (ALI), multi-organ failure (MOF), ischemia reperfusion injury (IRI) and adverse drug reaction (ADRS) lead to alterations of tissue fluid CD73 protein.
  • SIRS systemic inflammatory response syndrome
  • ALI acute lung injury
  • MOF multi-organ failure
  • IRI ischemia reperfusion injury
  • ADRS adverse drug reaction
  • the CD73-binding molecules disclosed herein can be used for example to treat or diagnose cancer (e.g., colon cancer, melanoma, breast cancer, lymphoma, non-small cell lung carcinoma Hodgkin's lymphoma, non-Hodgkin's lymphoma, and Burkitt's lymphoma, ovarian cancer, breast cancer, head and neck cancers, and pancreatic cancer).
  • cancer e.g., colon cancer, melanoma, breast cancer, lymphoma, non-small cell lung carcinoma Hodgkin's lymphoma, non-Hodgkin's lymphoma, and Burkitt's lymphoma
  • the measurement of the levels of CD73 in a sample from a patient e.g., a tissue fluid
  • a sample from a patient e.g., a tissue fluid
  • inhibitors can refer to any statistically significant decrease in biological activity, including full blocking of the activity.
  • “inhibition” can refer to a decrease of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% in biological activity. Accordingly, when the terms “inhibition” or “suppression” are applied to describe, e.g.
  • an effect on the enzymatic activity of CD73 refers to the ability of an anti-CD73 antibody or antigen binding fragment thereof to statistically significantly decrease the 5 '-nucleotidase activity of CD73 (catabolizing the hydrolysis of adenosine monophosphate, AMP, to adenosine), relative to the CD73-mediated 5 '-nucleotidase activity in an untreated (control) cell.
  • the cell which expresses CD73 can be a naturally occurring cell or cell line (e.g., a cancer cell) or can be recombinantly produced by introducing a nucleic acid encoding CD73 into a host cell.
  • an anti-CD73 antibody or antigen binding fragment thereof can statistically significantly decrease the 5 '-nucleotidase activity of a soluble form of CD73 in a biological fluid.
  • the anti-CD73 binding molecule e.g.
  • an antibody or antigen binding fragment thereof inhibits CD73-mediated 5 '-nucleotidase activity by at least 10%, at least 15%, or at least 20%, at least 25%, or at least 30%, at least 35%, or at least 40%, at least 45%, or at least 50%, at least 55%, or at least 60%, at least 65%, or at least 70%, at least 75%, or at least 80%, at least 85%, or at least 90%, at least 95%, or about 100%, as determined, for example, by the methods described in the Examples infra, and/or methods known in the art.
  • suppress CD73 activity refers to the ability of anti-CD73
  • the suppression of CD73 activity can be a decrease of at least 10%, or at least 15%, or at least 20%, or at least 25%, or at least 30%, or at least 35%, or at least 40%, or at least 45%, or at least 50%, or at least 55%, or at least 60%, or at least 65%, or at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or about 100% when cells or a sample are contacted with an anti-CD73 binding molecule, e.g. , an antibody or antigen-binding fragment thereof of the present disclosure, relative to the CD73 activity measured in the absence of the anti-CD73 binding molecule, e.g. , an antibody or antigen-binding fragment thereof (
  • antibody or “immunoglobulin,” as used interchangeably herein, include whole antibodies and any antigen binding fragment or single chains thereof.
  • a typical antibody comprises at least two heavy (H) chains and two light (L) chains
  • Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH or V H ) and a heavy chain constant region.
  • the heavy chain constant region is comprised of three domains, CHI, CH2, and CH3.
  • Each light chain is comprised of a light chain variable region (abbreviated herein as VL or V L ) and a light chain constant region.
  • the light chain constant region is comprised of one domain, CL.
  • the VH and VL regions can be further subdivided into regions of hypervariability, termed Complementarity Determining Regions (CDR), interspersed with regions that are more conserved, termed framework regions (FW).
  • CDR Complementarity Determining Regions
  • Each VH and VL is composed of three CDRs and four FWs, arranged from amino-terminus to carboxy- terminus in the following order: FW1, CDR1, FW2, CDR2, FW3, CDR3, FW4.
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
  • the constant regions of the antibodies can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g. , effector cells) and the first component (Clq) of the classical complement system.
  • Exemplary antibodies of the present disclosure include anti-CD73 antibodies (original and germlined), affinity optimized clones, optimized antibodies lacking ADCC, conjugated antibodies (e.g., ADC), and other optimized antibodies (e.g., serum half-life -optimized antibodies including, for example, YTE mutations, see Dall'Acqua et al., J. Biol. Chem. 281 :23514-24 (2006) and U.S. Patent No. 7,083,784, which are hereby incorporated by reference in their entireties).
  • the term "germlining” means that amino acids at specific positions in an antibody are mutated back to those in the germ line.
  • antibody means an immunoglobulin molecule that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site within the variable region of the immunoglobulin molecule.
  • antibody encompasses intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments (such as Fab, Fab', F(ab')2, and Fv fragments), single chain Fv (scFv) mutants, multispecific antibodies such as bispecific antibodies generated from at least two intact antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antigen determination portion of an antibody, and any other modified immunoglobulin molecule comprising an antigen recognition site so long as the antibodies exhibit the desired biological activity.
  • antibody fragments such as Fab, Fab', F(ab')2, and Fv fragments
  • scFv single chain Fv mutants
  • multispecific antibodies such as bispecific antibodies generated from at least two intact antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antigen determination portion of an antibody, and any other modified immunoglobulin molecule comprising an antigen recognition site so long as the antibodies exhibit the desired biological activity.
  • An antibody can be of any the five major classes of immunoglobulins: IgA, IgD, IgE,
  • IgG, and IgM or subclasses (isotypes) thereof (e.g. IgGl, IgG2, IgG3, IgG4, IgAl and IgA2), based on the identity of their heavy-chain constant domains referred to as alpha, delta, epsilon, gamma, and mu, respectively.
  • the different classes of immunoglobulins have different and well known subunit structures and three-dimensional configurations.
  • Antibodies can be naked or conjugated to other molecules such as toxins, radioisotopes, etc. to form ADCs.
  • blocking antibody or an “antagonist” antibody is one which inhibits or reduces biological activity of the antigen it binds, such as CD73.
  • blocking antibodies or antagonist antibodies substantially or completely inhibit the biological activity of the antigen.
  • the biological activity is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%,at least 85%, at least 90%, at least 95%, or even 100%.
  • CD73 antibody refers to an antibody or antigen binding fragment thereof that is capable of binding CD73 with sufficient affinity such that the molecule is useful as a therapeutic agent or diagnostic reagent in targeting CD73.
  • the extent of binding of an anti-CD73 antibody to an unrelated, non-CD73 protein is less than about 10% of the binding of the antibody to CD73 as measured, e.g. , by a radioimmunoassay (RIA),
  • an antibody that binds to CD73 has a dissociation constant (K D ) of ⁇ 1 ⁇ , ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 10 pM, ⁇ 1 pM, or ⁇ 0.1 pM.
  • K D dissociation constant
  • the term "anti-CD73” also broadly encompasses molecules comprising, e.g., the CDRs of the antibodies disclosed herein incorporated into a scaffold.
  • isolated binding molecule or antigen binding fragment thereof which specifically binds to CD73 would refer not only to antibodies and antigen-binding fragments thereof, but also would refer to a molecule comprising, for example, one or more scaffolds (such as a fibronectin III domain from fibronectin or tenascin-3) incorporating the CDRs of the antibodies disclosed herein. See, for example, U.S. Patent Publ. No. 20150098955, which is herein incorporated by reference in its entirety.
  • an anti-CD73 antibody refers to an antibody in IgGl-TM format such that the IgGl Fc domain comprises mutations L234, L235E and P331, binds soluble and cell-surface displayed CD73, and inhibits CD73 enzymatic activity.
  • Figures 1A-1D provide the nucleotide and amino acid sequences of MED 19447 VH and VL domains.
  • CTLA4 polypeptide is meant a polypeptide having at least 85% amino acid
  • AAL07473.1 sequence identity to GenBank AccessionAAL07473.1 or a fragment thereof having T cell inhibitory activity.
  • the sequence of AAL07473.1 is provided below:
  • CTLA4 polypeptide sequence [Homo sapiens]
  • CTLA4 nucleic acid molecule is meant a polynucleotide encoding a CTLA4
  • CTLA4 nucleic acid molecule sequence is provided at GenBank
  • anti-CTLA4 antibody an antibody that selectively binds a CTLA4
  • Tremelimumab is 11.2.1, therein), which are herein incorporated by reference.
  • Tremelimumab is an exemplary anti-CTLA4 antibody.
  • Tremelimumab sequences are provided in a sequence listing herein below (SEQ ID NOs: 130-137).
  • PD-1 polypeptide is meant a polypeptide or fragment thereof having at least about
  • NP_005009 85% amino acid identity to NCBI Accession No. NP_005009 and having PD-L1 and/or PD-L2 binding activity.
  • sequence of NP_005009 is provided below.
  • PD-1 nucleic acid molecule is meant a polynucleotide encoding a PD-1 polypeptide.
  • An exemplary PD-1 nucleic acid molecule sequence is provided at NCBI Accession No. NM_005018.
  • anti-PD-1 antibody an antibody or antigen binding fragment thereof that selectively binds a PD-1 polypeptide.
  • exemplary anti-PD-1 antibodies include for example pembrolizumab (KEYTRUDA®, lambrolizumab, MK-3475), nivolumab (OPDIVA®, BMS-936558,
  • PD-L1 polypeptide is meant a polypeptide or fragment thereof having at least about
  • NP_001254635 The sequence of NP_001254635 is provided below.
  • PD-Ll nucleic acid molecule is meant a polynucleotide encoding a PD-Ll
  • polypeptide An exemplary PD-Ll nucleic acid molecule sequence is provided at NCBI Accession No. NM_001267706.
  • anti-PD-Ll antibody an antibody or antigen binding fragment thereof that selectively binds a PD-Ll polypeptide.
  • exemplary anti-PD-Ll antibodies are described for example at US20130034559 / US8779108 and US20140356353, which is herein incorporated by reference.
  • MEDI4736 is an exemplary PD-Ll antibody. Sequences of MEDI4736 are provided in a sequence listing herein below (SEQ ID NOs: 138-145).
  • antigen binding fragment refers to a molecule comprising a portion of an intact antibody, and in particular refers to a molecule comprising the antigenic determining variable regions of an intact antibody. It is known in the art that the antigen binding function of an antibody can be performed by fragments of a full-length antibody. Examples of antibody fragments include, but are not limited to Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, single chain antibodies, and multispecific antibodies formed from antibody fragments.
  • a "monoclonal antibody” refers to a homogeneous antibody population involved in the highly specific recognition and binding of a single antigenic determinant, or epitope. This is in contrast to polyclonal antibodies that typically include different antibodies directed against different antigenic determinants.
  • monoclonal antibody encompasses both intact and full-length monoclonal antibodies as well as antibody fragments (such as Fab, Fab', F(ab')2, Fv), single chain variable fragments (scFv), fusion proteins comprising an antibody portion, and any other modified
  • immunoglobulin molecule comprising an antigen recognition site.
  • “monoclonal antibody” refers to such antibodies made in any number of ways including, but not limited to, by hybridoma, phage selection, recombinant expression, and transgenic animals (e.g. , expression of a human antibody in a transgenic mouse).
  • humanized antibody refers to an antibody derived from a non-human (e.g. , murine) immunoglobulin, which has been engineered to contain minimal non-human (e.g. , murine) sequences.
  • humanized antibodies are human immunoglobulins in which residues from the CDRs are replaced by residues from the CDR of a non-human species (e.g.
  • the framework (FW) amino acid residues of a human immunoglobulin are replaced with the corresponding residues in an antibody from a non-human species that has the desired specificity, and/or affinity, and/or capability.
  • the humanized antibody can be further modified by the substitution of additional residues either in the Fv framework region and/or within the replaced non-human residues to refine and optimize antibody specificity, affinity, and/or capability.
  • the humanized antibody will comprise substantially all of at least one, and typically two or three, variable domains containing all or substantially all of the CDR regions that correspond to the non-human immunoglobulin, whereas all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
  • the humanized antibody can also comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically that of a human immunoglobulin. Examples of methods used to generate humanized antibodies are described in U.S. Pat. Nos. 5,225,539 or 5,639,641.
  • variable region of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination.
  • the variable regions of the heavy and light chain each consist of four FW regions connected by three CDR regions.
  • the CDRs in each chain are held together in close proximity by the FW regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies.
  • the Kabat numbering system is generally used when referring to a residue in the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) (e.g. , Kabat et al , Sequences of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).
  • grammatical variants thereof refer to the numbering system used for heavy chain variable domains or light chain variable domains of the compilation of antibodies in Kabat et al. , Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Using this numbering system, the actual linear amino acid sequence can contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FW or CDR of the variable domain.
  • a heavy chain variable domain can include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (e.g., residues 82a, 82b, and 82c, etc. according to Kabat) after heavy chain FW residue 82.
  • the Kabat numbering of residues can be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a "standard” Kabat numbered sequence. Chothia refers instead to the location of the structural loops (Chothia and Lesk, J. Mol. Biol. 196:901- 917 (1987)).
  • the end of the Chothia CDR-H1 loop when numbered using the Kabat numbering convention varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertions at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35 A is present, the loop ends at 33; if both 35 A and 35B are present, the loop ends at 34).
  • the AbM hypervariable regions represent a compromise between the Kabat CDRs and Chothia structural loops, and are used by Oxford Molecular 's AbM antibody modeling software.
  • IMGT immunoglobulin variable regions
  • CDR the numbering system for the immunoglobulin variable regions. See e.g., Lefranc, M.P. et al, Dev. Comp. Immunol. 27: 55- 77(2003), which is herein incorporated by reference.
  • the IMGT numbering system was based on an alignment of more than 5,000 sequences, structural data, and characterization of hypervariable loops and allows for easy comparison of the variable and CDR regions for all species.
  • VH-CDR1 is at positions 26 to 35
  • VH-CDR2 is at positions 51 to 57
  • VH- CDR3 is at positions 93 to 102
  • VL-CDR1 is at positions 27 to 32
  • VL-CDR2 is at positions 50 to 52
  • VL-CDR3 is at positions 89 to 97.
  • the EU index or EU numbering system is based on the sequential numbering of the first human IgG sequenced (the EU antibody). Because the most common reference for this convention is the Kabat sequence manual (Kabat et al, 1991), the EU index is sometimes erroneously used synonymously with the Kabat index. The EU index does not provide insertions and deletions, and thus in some cases comparisons of IgG positions across IgG subclass and species can be unclear, particularly in the hinge regions. Nonetheless, the convention has sufficed at enabling straightforward comparison between Fc regions in numerous Fc structure function studies. Accordingly, the numbering scheme used for substitutions and insertions in Fc regions in this specification is the EU index as in Kabat. In contrast, the numbering scheme used for the variable regions (VH and VL) in this specification is the regular Kabat numbering.
  • VH CDRs sequences described correspond to the classical Kabat numbering locations, namely Kabat VH-CDR1 is at positions 31-35, VH-CDR2 is a positions 50-65, and VH-CDR3 is at positions 95-102.
  • VL-CDR1, VL-CDR2 and VL-CDR3 also correspond to classical Kabat numbering locations, namely positions 24-34, 50-56 and 89-97, respectively.
  • the Fc region includes the polypeptides comprising the constant region of an antibody excluding the first constant region immunoglobulin domain.
  • Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, and the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge N-terminal to these domains.
  • IgA and IgM Fc can include the J chain.
  • Fc comprises immunoglobulin domains Cgamma2 and Cgamma3 (Cy2 and Cy3) and the hinge between Cgammal (Cyl) and Cgamma2 (Cy2).
  • the human IgG heavy chain Fc region is usually defined to comprise residues C226 or P230 to its carboxyl-terminus, wherein the numbering is according to the EU index as set forth in Kabat (Kabat et al. , Sequences of Proteins of
  • Fc can refer to this region in isolation, or this region in the context of an antibody, antibody fragment, or Fc fusion protein. Polymorphisms have been observed at a number of different Fc positions, including but not limited to positions 270, 272, 312, 315, 356, and 358 as numbered by the EU index, and thus slight differences between the presented sequence and sequences in the prior art can exist.
  • human antibody means an antibody produced by a human or an antibody having an amino acid sequence corresponding to an antibody produced by a human made using any technique known in the art (e.g., recombinant expression in cultures cells, or expression in transgenic animals).
  • human antibody also encompasses an antibody having an amino acid sequence corresponding to an antibody originally produced by a human (or an engineered variant or derivative thereof) but expressed in a non-human system (e.g., produced by chemical synthesis;
  • an antibody obtained from a human subject or from human cells e.g., hybridoma or cell line expressing a recombinant antibody or fragment thereof
  • an animal e.g., mice
  • a human antibody includes intact or full-length antibodies, fragments thereof, and/or antibodies comprising at least one human heavy and/or light chain polypeptide such as, for example, an antibody comprising murine light chain and human heavy chain polypeptides.
  • chimeric antibodies refers to antibodies wherein the amino acid sequence of the immunoglobulin molecule is derived from two or more animal species.
  • the variable region of both light and heavy chains corresponds to the variable region of antibodies derived from one species of mammals (e.g., mouse, rat, rabbit, etc.) with the desired specificity, and/or affinity, and/or capability while the constant regions are homologous to the sequences in antibodies derived from another specie (usually human) to avoid eliciting an immune response in that species.
  • epitope refers to an antigenic protein determinant capable of binding to a CD73 antibody or CD73 binding molecule disclosed herein.
  • Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
  • the part of an antibody or binding molecule that recognizes the epitope is called a paratope.
  • the epitopes of protein antigens are divided into two categories, conformational epitopes and linear epitopes, based on their structure and interaction with the paratope.
  • a conformational epitope is composed of discontinuous sections of the antigen's amino acid sequence.
  • antibody binding site refers to a region in the antigen (e.g., CD73) comprising a continuous or discontinuous site (i.e. , an epitope) to which a complementary antibody specifically binds.
  • the antibody binding site can contain additional areas in the antigen which are beyond the epitope and which can determine properties such as binding affinity and/or stability, or affect properties such as antigen enzymatic activity or dimerization. Accordingly, even if two antibodies bind to the same epitope within an antigen, if the antibody molecules establish distinct intermolecular contacts with amino acids outside of the epitope, such antibodies are considered to bind to distinct antibody binding sites.
  • Binding affinity generally refers to the strength of the sum total of non-covalent
  • binding affinity refers to intrinsic binding affinity which reflects a 1 : 1 interaction between members of a binding pair (e.g., antibody and antigen).
  • the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (K D ). Affinity can be measured by common methods known in the art, including those described herein. Low-affinity antibodies generally bind antigen slowly and tend to dissociate readily, whereas high-affinity antibodies generally bind antigen faster and tend to remain bound longer. A variety of methods of measuring binding affinity are known in the art, any of which can be used for purposes of the present disclosure.
  • IC 50 is normally expressed as an IC 50 value, in nM unless otherwise stated.
  • IC 50 is the median inhibitory concentration of an antigen-binding molecule.
  • IC 50 is the concentration that reduces a biological response by 50% of its maximum.
  • IC 50 is the concentration that reduces receptor binding by 50% of maximal specific binding level.
  • IC 50 can be calculated by any number of means known in the art. Improvement in potency can be determined by measuring, e.g., against a parent antibody (for example, the parent antibody prior to germlining or the parent antibody prior to affinity optimization).
  • disclosure as compared to a parent antibody can be at least about 2-fold, at least about 4-fold, at least about 6-fold, at least about 8-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 40-fold, at least about 50-fold, at least about 60-fold, at least about 70-fold, at least about 80-fold, at least about 90-fold, at least about 100- fold, at least about 110-fold, at least about 120-fold, at least about 130-fold, at least about 140-fold, at least about 150-fold, at least about 160-fold, at least about 170-fold, or at least about 180-fold or more.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • FcRs Fc receptors
  • cytotoxic cells e.g., Natural Killer (NK) cells, neutrophils, and macrophages
  • NK Natural Killer
  • IgG antibodies directed to the surface of target cells "arm" the cytotoxic cells and are absolutely required for such killing. Lysis of the target cell is extracellular, requires direct cell-to-cell contact, and does not involve complement.
  • ADCC activity the cell-mediated cytotoxicity resulting from the activity of an Fc fusion protein is also referred to herein as ADCC activity.
  • a polypeptide, antibody, polynucleotide, vector, cell, or composition which is "isolated” is a polypeptide, antibody, polynucleotide, vector, cell, or composition which is in a form not found in nature.
  • Isolated polypeptides, antibodies, polynucleotides, vectors, cells or compositions include those which have been purified to a degree that they are no longer in a form in which they are found in nature.
  • an antibody, polynucleotide, vector, cell, or composition which is isolated is substantially pure.
  • subject refers to any animal (e.g. , a mammal), including, but not limited to humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment.
  • subject and patient are used interchangeably herein in reference to a human subject.
  • composition refers to a preparation which is in such form as to permit the biological activity of the active ingredient (e.g., an anti-CD73 binding molecule disclosed herein) to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the composition would be administered.
  • active ingredient e.g., an anti-CD73 binding molecule disclosed herein
  • Such composition can be sterile.
  • an “effective amount” of an anti-CD73 binding molecule as disclosed herein is an amount sufficient to carry out a specifically stated purpose.
  • An “effective amount” can be determined empirically and in a routine manner, in relation to the stated purpose.
  • terapéuticaally effective amount refers to an amount of an anti-CD73 binding molecule disclosed herein or other drug effective to "treat” a disease or disorder in a subject or mammal.
  • label when used herein refers to a detectable compound or composition which is fused (e.g., genetically fused) or conjugated (e.g., chemically conjugated) directly or indirectly to an anti-CD73 binding molecule disclosed herein so as to generate a "labeled" anti-CD73 binding molecule .
  • the label can be detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, can catalyze chemical alteration of a substrate compound or composition which is detectable.
  • ком ⁇ онент and “derivatizable functional group” are used interchangeably and refer to a functional group that is capable of reacting to permit the formation of a covalent bond between an anti-CD73 binding molecule disclosed herein (e.g., a CD73 antibody) and another substance.
  • an anti-CD73 binding molecule disclosed herein e.g., a CD73 antibody
  • another substance e.g., such substance is a therapeutic agent (e.g., a cytotoxin), a detectable label, a polymer (e.g., PEG), etc.
  • exemplary derivatizable groups include thiol, hydroxyl, amino, carboxy, and amide, as well as modified forms thereof, such as activated or protected forms.
  • Terms such as “treating” or “treatment” or “to treat” or “alleviating” or “to alleviate” refer to both (1) therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder and (2) prophylactic or preventative measures that prevent and/or slow the development of a targeted pathologic condition or disorder.
  • those in need of treatment include those already with the disorder; those prone to have the disorder; and those in whom the disorder is to be prevented.
  • a subject is successfully "treated” for cancer according to the methods of the present disclosure if the patient shows, e.g., total, partial, or transient remission of a certain type of cancer.
  • cancer refers to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
  • cancers include but are not limited to, carcinoma including adenocarcinomas, lymphomas, blastomas, melanomas, sarcomas, and leukemias.
  • cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkin's and non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, glioma, cervical cancer, ovarian cancer, liver cancer such as hepatic carcinoma and hepatoma, bladder cancer, breast cancer (including hormonally mediated breast cancer, see, e.g., Innes et al. (2006) Br. J.
  • Cancer 94:1057-1065 colon cancer, colorectal cancer, endometrial carcinoma, myeloma (such as multiple myeloma), salivary gland carcinoma, kidney cancer such as renal cell carcinoma and Wilms' tumors, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, various types of head and neck cancer and cancers of mucinous origins, such as, mucinous ovarian cancer, cholangiocarcinoma (liver) and renal papillary carcinoma.
  • the term cancer as used herein specifically refers to cancer expressing CD73.
  • the term cancer refers to cancers expressing low levels of CD73.
  • the term cancer as used herein specifically refers to cancer expressing CD73 (e.g., colon cancer, breast cancer, lymphoma, non-small cell carcinoma).
  • Polynucleotide or “nucleic acid,” as used interchangeably herein, refer to polymers of nucleotides of any length, and include DNA and RNA.
  • the nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase.
  • a polynucleotide can comprise modified nucleotides, such as methylated nucleotides and their analogs. The preceding description applies to all polynucleotides referred to herein, including RNA and DNA.
  • vector means a construct, which is capable of delivering, and in some aspects, expressing, one or more gene(s) or sequence(s) of interest in a host cell.
  • vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmid, cosmid or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as producer cells.
  • polypeptide polypeptide
  • peptide protein
  • the terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length.
  • the polymer can be linear or branched, it can comprise modified amino acids, and it can be interrupted by non-amino acids.
  • the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component.
  • polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
  • the polypeptides of the instant disclosure are based upon antibodies, in certain aspects, the polypeptides can occur as single chains or associated chains.
  • a "recombinant" polypeptide or protein refers to a polypeptide or protein produced via recombinant DNA technology. Recombinantly produced polypeptides and proteins expressed in engineered host cells are considered isolated, as are native or recombinant polypeptides which have been separated, fractionated, or partially or substantially purified by any suitable technique.
  • the polypeptides disclosed herein can be recombinantly produced using methods known in the art. Alternatively, the proteins and peptides disclosed herein can be chemically synthesized.
  • amino acid substitution refers to replacing an amino acid residue present in a parent sequence with another amino acid residue.
  • An amino acid can be substituted in a parent sequence, for example, via chemical peptide synthesis or through recombinant methods known in the art.
  • references to a "substitution at position X" or “substitution at position X” refer to the substitution of an amino acid present at position X with an alternative amino acid residue.
  • substitution patterns can described according to the schema AXY, wherein A is the single letter code corresponding to the amino acid naturally present at position X, and Y is the substituting amino acid residue.
  • substitution patterns can described according to the schema XY, wherein Y is the single letter code corresponding to the amino acid residue substituting the amino acid naturally present at position X.
  • a "conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain.
  • Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
  • basic side chains e
  • a string of amino acids can be conservatively replaced with a structurally similar string that differs in order and/or composition of side chain family members.
  • Non-conservative substitutions include those in which (i) a residue having an electropositive side chain (e.g., Arg, His or Lys) is substituted for, or by, an electronegative residue (e.g., Glu or Asp), (ii) a hydrophilic residue (e.g., Ser or Thr) is substituted for, or by, a hydrophobic residue (e.g., Ala, Leu, He, Phe or Val), (iii) a cysteine or proline is substituted for, or by, any other residue, or (iv) a residue having a bulky hydrophobic or aromatic side chain (e.g., Val, His, He or Trp) is substituted for, or by, one having a smaller side chain (e.g., Ala, Ser) or no side chain (e.g., Gly).
  • an electropositive side chain e.g., Arg, His or Lys
  • an electronegative residue e.g., Glu or Asp
  • substitutions can be readily identified by workers of ordinary skill.
  • a substitution can be taken from any one of D-alanine, glycine, beta- alanine, L-cysteine and D-cysteine.
  • a replacement can be any one of D-lysine, arginine, D-arginine, homo-arginine, methionine, D-methionine, ornithine, or D- ornithine.
  • substitutions in functionally important regions that can be expected to induce changes in the properties of isolated polypeptides are those in which (i) a polar residue, e.g., serine or threonine, is substituted for (or by) a hydrophobic residue, e.g., leucine, isoleucine, phenylalanine, or alanine; (ii) a cysteine residue is substituted for (or by) any other residue; (iii) a residue having an electropositive side chain, e.g., lysine, arginine or histidine, is substituted for (or by) a residue having an electronegative side chain, e.g., glutamic acid or aspartic acid; or (iv) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having such a side chain, e.g., glycine.
  • a polar residue e.g
  • amino acid insertion refers to introducing a new amino acid residue between two amino acid residues present in the parent sequence.
  • An amino acid can be inserted in a parent sequence, for example, via chemical peptide synthesis or through recombinant methods known in the art.
  • insertion between positions X and Y or “insertion between Kabat positions X and Y,” wherein X and Y correspond to amino acid positions (e.g., a cysteine amino acid insertion between positions 239 and 240), refers to the insertion of an amino acid between the X and Y positions, and also to the insertion in a nucleic acid sequence of a codon encoding an amino acid between the codons encoding the amino acids at positions X and Y. Insertion patterns can be described according to the schema AXins, wherein A is the single letter code corresponding to the amino acid being inserted, and X is the position preceding the insertion.
  • percent sequence identity between two polypeptide or polynucleotide sequences refers to the number of identical matched positions shared by the sequences over a comparison window, taking into account additions or deletions (i.e., gaps) that must be introduced for optimal alignment of the two sequences.
  • a matched position is any position where an identical nucleotide or amino acid is presented in both the target and reference sequence. Gaps presented in the target sequence are not counted since gaps are not nucleotides or amino acids. Likewise, gaps presented in the reference sequence are not counted since target sequence nucleotides or amino acids are counted, not nucleotides or amino acids from the reference sequence.
  • the percentage of sequence identity is calculated by determining the number of positions at which the identical amino-acid residue or nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
  • the comparison of sequences and determination of percent sequence identity between two sequences can be accomplished using readily available software both for online use and for download. Suitable software programs are available from various sources, and for alignment of both protein and nucleotide sequences.
  • One suitable program to determine percent sequence identity is bl2seq, part of the BLAST suite of program available from the U.S.
  • B12seq performs a comparison between two sequences using either the BLASTN or BLASTP algorithm.
  • BLASTN is used to compare nucleic acid sequences
  • BLASTP is used to compare amino acid sequences.
  • Other suitable programs are, e.g., Needle, Stretcher, Water, or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk/Tools/psa.
  • Different regions within a single polynucleotide or polypeptide target sequence that aligns with a polynucleotide or polypeptide reference sequence can each have their own percent sequence identity. It is noted that the percent sequence identity value is rounded to the nearest tenth. For example, 80.11, 80.12, 80.13, and 80.14 are rounded down to 80.1, while 80.15, 80.16, 80.17, 80.18, and 80.19 are rounded up to 80.2. It also is noted that the length value will always be an integer.
  • the percentage identity "X" of a first amino acid sequence to a second sequence amino acid is calculated as 100 x (Y/Z), where Y is the number of amino acid residues scored as identical matches in the alignment of the first and second sequences (as aligned by visual inspection or a particular sequence alignment program) and Z is the total number of residues in the second sequence. If the length of a first sequence is longer than the second sequence, the percent identity of the first sequence to the second sequence will be higher than the percent identity of the second sequence to the first sequence.
  • sequence alignments are not limited to binary sequence-sequence comparisons exclusively driven by primary sequence data. Sequence alignments can be derived from multiple sequence alignments.
  • One suitable program to generate multiple sequence alignments is ClustalW2, available from www.clustal.org.
  • Another suitable program is MUSCLE, available from www.drive5.com/muscle/.
  • ClustalW2 and MUSCLE are alternatively available, e.g., from the EBI.
  • sequence alignments can be generated by integrating sequence data with data from heterogeneous sources such as structural data (e.g., crystallographic protein structures), functional data (e.g., location of mutations), or phylogenetic data.
  • a suitable program that integrates heterogeneous data to generate a multiple sequence alignment is T-Coffee, available at www.tcoffee.org, and alternatively available, e.g., from the EBI. It will also be appreciated that the final alignment used to calculate percent sequence identity can be curated either automatically or manually.
  • VL and heavy chain (VH) variable regions refers to a composite or genericized VL or VH sequence defined based on information as to which amino acid residues within the VL or VH chain are amenable to modification without detriment to antigen binding.
  • certain amino acid positions are occupied by one of multiple possible amino acid residues at that position. For example, if an arginine (R) or a serine (S) occur at a particular position, then that particular position within the consensus sequence can be either arginine or serine (R or S).
  • Consensus sequences for VH and VL chain can be defined, for example, by in vitro affinity maturation (e.g. , randomizing every amino acid position in a certain CDR using degenerate coding primers), by scanning mutagenesis (e.g. , alanine scanning mutagenesis) of amino acid residues within the antibody CDRs, or any other methods known in the art, followed by evaluation of the binding of the mutants to the antigen to determine whether the mutated amino acid position affects antigen binding.
  • mutations are introduced in the CDR regions.
  • mutations are introduced in framework regions.
  • mutations are introduced in CDR and framework regions.
  • the present disclosure provides CD73 binding molecules, e.g., antibodies and antigen- binding fragments thereof that specifically bind CD73, for example, human CD73.
  • the full-length amino acid (aa) and nucleotide (nt) sequences for CD73 are known in the art (see, e.g., UniProt Acc. No. P21589 for human CD73, or UniProt Acc. No. Q61503 for mouse CD73).
  • the anti-CD73 binding molecules are human antibodies (for example, a clone 10.3 antibody, a clone 2C5 antibody, MEDI9447).
  • the CD73 binding molecules are antibodies or antigen-binding fragments thereof.
  • CD73 binding molecules e.g. , antibodies or antigen-binding fragments thereof comprise a Fab, a Fab', a F(ab') 2 , a Fd, a single chain Fv or scFv, a disulfide linked Fv, a V-NAR domain, an IgNar, an intrabody, an IgG CH2, a minibody, a F(ab') 3 a tetrabody, a triabody, a diabody, a single -domain antibody, DVD-Ig, Fcab, mAb 2 , a (scFv) 2 , or a scFv-Fc.
  • the antibody is of the IgG type, for example of the IgGl type.
  • the anti-CD73 antibody for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • the antigen-binding fragment thereof comprises a heavy chain constant region or fragment thereof.
  • the heavy chain constant region is an IgG constant region.
  • the IgG constant region can comprise a light chain constant region selected from the group consisting of a kappa constant region and a lambda constant region.
  • anti-CD73 antibodies or antigen-binding fragments thereof disclosed herein are modified compared to a parent antibody, e.g., the CD730010 antibody or the CD730002 antibody.
  • the parent antibody is CD730010.
  • the parent antibody is CD730002.
  • the parent antibody is CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the modifications can include mutations in the CDR regions and/or in the FW regions as compared to the parent antibody, e.g., CD730010 or CD730002.
  • the phrase "CD730002 antibody” refers to an IgGl comprising two VL domains comprising the amino acid sequence of SEQ ID NO: l and two VH domains comprising the amino acid sequence of SEQ ID NO: 2.
  • CD730004 antibody refers to an IgGl comprising two VL domains comprising the amino acid sequence of SEQ ID NO: 104 and two VH domains comprising the amino acid sequence of SEQ ID NO: 103.
  • CD730008 antibody refers to an IgGl comprising two VL domains comprising the amino acid sequence of SEQ ID NO: 106 and two VH domains comprising the amino acid sequence of SEQ ID NO: 107.
  • CD730010 antibody refers to an IgGl comprising two VL domains comprising the amino acid sequence of SEQ ID NO:3 and two VH domains comprising the amino acid sequence of SEQ ID NO: 4.
  • CD730011 antibody refers to an IgGl comprising two VL domains comprising the amino acid sequence of SEQ ID NO:5 and two VH domains comprising the amino acid sequence of SEQ ID NO: 6.
  • CD730021 antibody refers to an IgGl comprising two VL domains comprising the amino acid sequence of SEQ ID NO:7 and two VH domains comprising the amino acid sequence of SEQ ID NO: 8.
  • CD730042 antibody refers to an IgGl comprising two VL domains comprising the amino acid sequence of SEQ ID NO:9 and two VH domains comprising the amino acid sequence of SEQ ID NO: 10.
  • CD730046 antibody refers to an IgGl comprising two VL domains comprising the amino acid sequence of SEQ ID NO: 11 and two VH domains comprising the amino acid sequence of SEQ ID NO: 12.
  • CD730047 antibody refers to an IgGl comprising two VL domains comprising the amino acid sequence of SEQ ID NO: 13 and two VH domains comprising the amino acid sequence of SEQ ID NO: 14.
  • CD730068 antibody refers to an IgGl comprising two VL domains comprising the amino acid sequence of SEQ ID NO: 108 and two VH domains comprising the amino acid sequence of SEQ ID NO: 107.
  • CD730069 antibody refers to an IgGl comprising two VL domains comprising the amino acid sequence of SEQ ID NO: 110 and two VH domains comprising the amino acid sequence of SEQ ID NO: 109.
  • an anti-CD73 antibody of the present disclosure comprises modifications to CDRl and/or CDR2 and/or CDR3 of the light chain of the CD730010 antibody, including, but not limited to:
  • a light chain CDRl comprising the consensus sequence SGSLSNIGRNXiVN, wherein X x represents amino acid residues Proline (P), Glutamic Acid (E) or Aspartic Acid (D);
  • a light chain CDR2 comprising the consensus sequence LX 2 NX 3 RX 4 X 5 , wherein X 2 represents amino acid residues Asparagine (N) or Aspartic Acid (D), X 3 represents amino acid residues Glutamine (Q) or Leucine (L), X 4 represents amino acid residues Leucine (L) or Proline (P), and X 5 represents amino acid residues Glycine (G) or Serine (S); and/or,
  • a light chain CDR3 comprising the consensus sequence ATWDDSX 6 X ? GWX 8 , wherein X 6 represents amino acid residues Leucine (L) or Histidine (H), X 7 represents amino acid residues Lysine (K), Proline (P), Isoleucine (I) or Asparagine (N), and X 8 represents amino acid residues Leucine (L) or Threonine (T).
  • an anti-CD73 antibody of the present disclosure comprises modifications to CDRl and/or CDR2 and/or CDR3 of the heavy chain of the CD730010 antibody, including, but not limited to:
  • a heavy chain CDRl comprising the consensus sequence SYAX 9 S, wherein X 9 represents amino acid residues Methionine (M) or Tyrosine (Y); and/or,
  • X 10 represents amino acid residues Leucine (L) or Alanine (A)
  • X u represents amino acid residues Tryptophan (W) or Serine (S)
  • X 12 represents amino acid residues Tryptophan (W) or Glycine (G)
  • X 13 represents amino acid residues Serine (S) or Arginine (R); and/or,
  • X 14 represents amino acid residues Glycine (G) or Serine (S)
  • X15 represents amino acid residues Arginine (R) or Threonine (T)
  • X 16 represents amino acid residues Valine (V) or Isoleucine (I)
  • X 17 represents amino acid residues Tyrosine (Y), Lysine (K), Methionine (M), Leucine (L) or Glutamic acid (E).
  • the anti-CD73 antibody or antigen binding fragment thereof comprises a
  • VL region comprising the consensus amino acid sequence:
  • VL framework region 2 (SEQ ID NO: 27 or 28), VL framework region 3
  • Xi represents amino acid residues Proline (P), Glutamic Acid (E) or Aspartic Acid (D);
  • X 2 represents amino acid residues Asparagine (N) or Aspartic Acid (D);
  • X 3 represents amino acid residues Glutamine (Q) or Leucine (L);
  • X 4 represents amino acid residues Leucine (L) or Proline (P);
  • X 5 represents amino acid residues Glycine (G) or Serine (S);
  • X 6 represents amino acid residues Leucine (L) or Histidine (H);
  • X 7 represents amino acid residues Lysine (K), Proline (P), Isoleucine (I) or Asparagine (N); and, X 8 represents amino acid residues Leucine (L) or Threonine (T).
  • the anti-CD73 antibody or antigen binding fragment thereof comprises
  • VH region which comprises the consensus amino acid sequence:
  • VH framework region 4 SEQ ID NO: 34
  • X 9 represents amino acid residues Methionine (M) or Tyrosine (Y);
  • Xio represents amino acid residues Leucine (L) or Alanine (A);
  • Xii represents amino acid residues Tryptophan (W) or Serine (S);
  • Xi2 represents amino acid residues Tryptophan (W) or Glycine (G);
  • Xi3 represents amino acid residues Serine (S) or Arginine (R);
  • Xi4 represents amino acid residues Glycine (G) or Serine (S);
  • Xi5 represents amino acid residues Arginine (R) or Threonine (T);
  • Xi6 represents amino acid residues Valine (V) or Isoleucine (I)
  • X 17 represents amino acid residues Tyrosine (Y), Lysine (K), Methionine (M), Leucine (L) or Glutamic acid (E).
  • the anti-CD73 antibody or antigen binding fragment thereof comprises
  • VL region comprising the consensus amino acid sequence:
  • VL framework region 2 (SEQ ID NO: 27 or 28), VL framework region 3
  • Xi represents amino acid residues Proline (P), Glutamic Acid (E) or Aspartic Acid (D);
  • X 2 represents amino acid residues Asparagine (N) or Aspartic Acid (D);
  • X 3 represents amino acid residues Glutamine (Q) or Leucine (L);
  • X 4 represents amino acid residues Leucine (L) or Proline (P);
  • X 5 represents amino acid residues Glycine (G) or Serine (S);
  • X 6 represents amino acid residues Leucine (L) or Histidine (H);
  • X 7 represents amino acid residues Lysine (K), Proline (P), Isoleucine (I) or Asparagine (N); and, X 8 represents amino acid residues Leucine (L) or Threonine (T);
  • anti-CD73 antibody or antigen binding fragment thereof further comprises a VH region which comprises the consensus amino acid sequence:
  • VH framework region 4 SEQ ID NO: 34
  • X 9 represents amino acid residues Methionine (M) or Tyrosine (Y);
  • Xio represents amino acid residues Leucine (L) or Alanine (A);
  • Xii represents amino acid residues Tryptophan (W) or Serine (S);
  • Xi2 represents amino acid residues Tryptophan (W) or Glycine (G);
  • Xi3 represents amino acid residues Serine (S) or Arginine (R);
  • Xi4 represents amino acid residues Glycine (G) or Serine (S);
  • Xi5 represents amino acid residues Arginine (R) or Threonine (T);
  • Xi6 represents amino acid residues Valine (V) or Isoleucine (I)
  • X 17 represents amino acid residues Tyrosine (Y), Lysine (K), Methionine (M), Leucine (L) or Glutamic acid (E).
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs: 46, 47, and 48.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL-CDR1 comprising a sequence selected from the group consisting of SEQ ID NOs: 46, 47, and 48.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 49, 50, 51, and 52.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 49, 50, 51 and 52.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR3 consisting of a sequence selected from the group consisting of SEQ ID NOs: 53, 54, 55, and 56.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL-CDR3 comprising a sequence selected from the group consisting of SEQ ID NOs: 53, 54, 55, and 56.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDRl consisting of a sequence selected from the group consisting of SEQ ID NOs: 35 and 36.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDRl comprising a sequence selected from the group consisting of SEQ ID NOs: 35 and 36.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 37, 38, 39, and 40.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 37, 38, 39, and 40.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR3 consisting of a sequence selected from the group consisting of SEQ ID NOs: 41, 42, 43, 44, and 45.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR3 comprising a sequence selected from the group consisting of SEQ ID NOs: 41, 42, 43, 44, and 45.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs: 46, 47, and 48, except for one, two, three or four amino acid substitutions.
  • the anti- CD73 antibody or antigen-binding fragment comprises a VL-CDR1 comprising a sequence selected from the group consisting of SEQ ID NOs: 46, 47, and 48, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 49, 50, 51, and 52, except for one, two, three, or four amino acid substitutions.
  • the anti- CD73 antibody or antigen-binding fragment thereof comprises a VL-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 49, 50, 51, and 52, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR3 consisting of a sequence selected from the group consisting of SEQ ID NOs: 53, 54, 55, and 56, except for one, two, three, or four amino acid substitutions.
  • the anti- CD73 antibody or antigen-binding fragment thereof comprises a VL-CDR3 comprising a sequence selected from the group consisting of SEQ ID NOs: 53, 54, 55, and 56, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDRl consisting of a sequence selected from the group consisting of SEQ ID NOs: 35 and 36, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDRl comprising a sequence selected from the group consisting of SEQ ID NOs: 35 and 36, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 37, 38, 39, and 40, except for one, two, three, or four amino acid substitutions.
  • the anti- CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 37, 38, 39, and 40, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR3 consisting of a sequence selected from the group consisting of SEQ ID NOs: 41, 42, 43, 44, and 45, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR3 comprising sequence selected from the group consisting of SEQ ID NOs: 41, 42, 43, 44, and 45, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs: 46, 47 and 48; a VL-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 49, 50, 51, and 52; and a VL-CDR3 consisting of a sequence selected from the group consisting of SEQ ID NOs: 53, 54, 55, and 56.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL-CDR1 comprising a sequence selected from the group consisting of SEQ ID NOs: 46, 47 and 48; a VL-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 49, 50, 51, and 52; and a VL-CDR3 comprising a sequence selected from the group consisting of SEQ ID NOs: 53, 54, 55, and 56.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDRl consisting of a sequence selected from the group consisting of SEQ ID NOs: 35 and 36; a VH-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 37, 38, 39, and 40; and a VH-CDR3 consisting of a sequence selected from the group consisting of SEQ ID NOs: 41, 42, 43, 44, and 45.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDRl comprising a sequence selected from the group consisting of SEQ ID NOs: 35 and 36; a VH-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 37, 38, 39, and 40; a VH-CDR3 comprising a sequence selected from the group consisting of SEQ ID NOs: 41, 42, 43, 44, and 45.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs: 46, 47 and 48 except for one, two, three or four amino acid substitutions
  • VL-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 49, 50, 51, and 52 except for one, two, three or four amino acid substitutions
  • VL-CDR3 consisting of a sequence selected from the group consisting of SEQ ID NOs: 53, 54, 55, and 56 except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR1 comprising a sequence selected from the group consisting of SEQ ID NOs: 46, 47 and 48 except for one, two, three, or four amino acid substitutions
  • VL-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 49, 50, 51, and 52 except for one, two, three, or four amino acid substitutions
  • VL-CDR3 comprising a sequence selected from the group consisting of SEQ ID NOs: 53, 54, 55, and 56 except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDRl consisting of a sequence selected from the group consisting of SEQ ID NOs: 35 and 36 except for one, two, three, or four amino acid substitutions
  • VH-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 37, 38, 39, and 40 except for one, two, three, or four amino acid substitutions
  • VH-CDR3 consisting of a sequence selected from the group consisting of SEQ ID NOs: 41, 42, 43, 44, and 45 except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDRl comprising a sequence selected from the group consisting of SEQ ID NOs: 35 and 36 except for one, two, three, or four amino acid substitutions
  • VH-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 37, 38, 39, and 40 except for one, two, three, or four amino acid substitutions
  • VH-CDR3 comprising a sequence selected from the group consisting of SEQ ID NOs: 41, 42, 43, 44, and 45 except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises modifications to CDRl, and/or CDR2, and/or CDR3 of the heavy and/or light chain, and further comprises modifications to FWl, and/or FW2, and/or FW3, and/or FW4 of the heavy and/or light chain.
  • FW l comprises SEQ ID NO: 25 or 26
  • FW 2 comprises SEQ ID NO: 27 or 28
  • FW 3 comprises SEQ ID NO: 29
  • FW 4 comprises SEQ ID NO: 30
  • FW 5 comprises SEQ ID NO: 31
  • FW 6 comprises SEQ ID NO: 32
  • FW 7 comprises SEQ ID NO: 33
  • FW 8 comprises SEQ ID NO: 34.
  • FWi comprises SEQ ID NO: 25 or 26, except for one, two, three, or four amino acid substitutions
  • FW 2 comprises SEQ ID NO: 27 or 28, except for one, two, three, or four amino acid substitutions
  • FW 3 comprises SEQ ID NO: 29, except for one, two, three, or four amino acid substitutions
  • FW 4 comprises SEQ ID NO: 30, except for one, two, three, or four amino acid substitutions
  • FW 5 comprises SEQ ID NO: 31, except for one, two, three, or four amino acid substitutions
  • FW 6 comprises SEQ ID NO: 32, except for one, two, three, or four amino acid substitutions
  • FW 7 comprises SEQ ID NO: 33, except for one, two, three, or four amino acid substitutions
  • FW 8 comprises SEQ ID NO: 34.
  • the anti-CD733 antibody or antigen-binding fragment thereof comprises a VL and a VH comprising VL-CDR1, VL-CRD2, VL-CDR3, VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences identical or identical except for one, two, three or four amino acid substitutions in one or more CDRs, wherein such VL-CDR1, VL-CRD2, VL-CDR3, VH-CDR1, VH-CDR2, and VH-CDR3 are:
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises an antibody VL and an antibody VH, wherein the VL comprises an amino acid sequence at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to a reference amino acid sequence selected from the group consisting of SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, and SEQ ID NO: 70.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises an antibody VL and an antibody VH, wherein the VH comprises an amino acid sequence at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to a reference amino acid sequence selected from the group consisting of SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83 and SEQ ID NO: 84.
  • a reference amino acid sequence selected from the group consisting of SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL comprising a sequence at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to a reference amino acid sequence selected from the group consisting of SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, and SEQ ID NO: 70, and further comprises a VH comprising a sequence at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to a reference amino acid sequence selected from the group consisting of SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, S
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL consisting of the sequence of SEQ ID NO:68 and a VH consisting of the sequence of SEQ ID NO:82.
  • the "clone 10.3 antibody” (also designated “73combo3” or “MEDI9447”) is an IgGl comprising two CD730010-derived light chains (VL) of SEQ ID NO: 68 (comprising three CDRs, CDR1, CDR2, and CDR3, with the sequences of SEQ ID NO: 46, 51 and 56, respectively), and two CD730010-derived heavy chains (VH) of SEQ ID NO: 82 (comprising three CDRs, CDR1, CDR2, and CDR3, with the sequences of SEQ ID NO: 36, 39, and 45, respectively).
  • VL CD730010-derived light chains
  • VH CD730010-derived heavy chains
  • an anti-CD73 antibody or antigen-binding fragment thereof disclosed herein binds CD73 with substantially the same or better affinity as a 10.3 antibody comprising the 10.3 heavy chain VH of SEQ ID NO: 82 and the 10.3 light chain VL of SEQ ID NO: 68.
  • the anti-CD73 antibody of the present disclosure comprises modifications to CDR1 and/or CDR2 and/or CDR3 of the light chain of the CD730002 antibody, including, but not limited to:
  • a light chain CDR2 comprising the consensus sequence EDX 18 KX 19 X 2 oS, wherein Xi8 represents amino acid residues Serine (S) or Threonine (T), X 19 represents amino acid residues Arginine (R) or Tyrosine (Y), and X 2 o represents amino acid residues Histidine (H), Proline (P) or Leucine (L); and/or,
  • the anti-CD73 antibody of the present disclosure comprises modifications to CDR1 and/or CDR2 and/or CDR3 of the heavy chain of CD730002, including, but not limited to:
  • a heavy chain CDR1 comprising the sequence SX 2 iA X 22 S, wherein X 21 represents amino acid residues Tyrosine (Y) or Valine (V), and X 22 represents amino acid residues Methionine (M) or Arginine (R); and/or,
  • a heavy chain CDR2 comprising the sequence AISGSGGSX 23 YY X 24 DSVKX 25 , wherein X 23 represents amino acid residues Threonine (T) or Proline (P); X 24 represents amino acid residues Alanine (A) or G (Glycine); and X 25 represents amino acid residues Glycine (G) or Arginine (R); and/or,
  • the anti-CD73 antibody or antigen binding fragment thereof comprises a
  • VL region comprising the consensus amino acid sequence:
  • [FW 9 ], [FWio], [FWu] and [FWi 2 ] represent the amino acid residues of VL framework region 1 (SEQ ID NO: 90 or 91), VL framework region 2 (SEQ ID NO: 92), VL framework region 3 (SEQ ID NO: 93, 94 or 122) and VL framework region 4 (SEQ ID NO: 30), respectively; and wherein X 18 represents amino acid residues Proline (P) or Leucine (L); X 19 represents amino acid residues Arginine (R) or Tyrosine (Y); and X 20 represents amino acid residues Histidine (H), Proline (P) or Leucine (L).
  • the anti-CD73 antibody or antigen binding fragment thereof comprises a
  • VH region which comprises the consensus amino acid sequence:
  • the anti-CD73 antibody or antigen binding fragment thereof comprises a
  • VL region comprising the consensus amino acid sequence:
  • [FW 9 ], [FW 10 ], [FWu] and [FW 12 ] represent the amino acid residues of VL framework region 1 (SEQ ID NO: 90 or 91), VL framework region 2 (SEQ ID NO: 92), VL framework region 3 (SEQ ID NO: 93, 94 or 122) and VL framework region 4 (SEQ ID NO: 30), respectively; and wherein X 18 represents amino acid residues Proline (P) or Leucine (L); X 19 represents amino acid residues Arginine (R) or Tyrosine (Y); and X 20 represents amino acid residues Histidine (H), Proline (P) or Leucine (L), and wherein the anti-CD73 antibody or antigen binding fragment thereof further comprises a VH region which comprises the consensus amino acid sequence:
  • VL-CDRl consisting of a sequence consisting of SEQ ID NO: 97.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL-CDRl comprising a sequence consisting of SEQ ID NO: 97.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 98, 99, 127, 128, and 129.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 98, 99, 127, 128 and 129.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR3 consisting of a sequence consisting of SEQ ID NO: 100.
  • the anti- CD73 antibody or antigen-binding fragment thereof comprises a VL-CDR3 comprising a sequence consisting of SEQ ID NO: 100.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR1 consisting of a sequence of a sequence selected from the group consisting of SEQ ID NOs: 35, 123 and 124.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR1 comprising a sequence selected from the group consisting of SEQ ID NOs: 35, 123 and 124.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 37, 95, 125 and 126.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 37, 95, 125, and 126.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR3 consisting of a sequence consisting of SEQ ID NO: 96.
  • the anti- CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR3 comprising a sequence consisting of SEQ ID NO: 96.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDRl consisting of a sequence consisting of SEQ ID NO: 97, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL-CDRl comprising a sequence consisting of SEQ ID NO: 97, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 98, 99, 127, 128, and 129, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 98, 99, 127, 128, and 129, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR3 consisting of a sequence consisting of SEQ ID NO: 100, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL-CDR3 comprising a sequence consisting of SEQ ID NO: 100, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs: 35, 123 and 124, except for one, two, three, or four amino acid substitutions.
  • the anti- CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR1 comprising a sequence selected from the group consisting of SEQ ID NOs: 35, 123 and 124, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 37, 95, 125 and 126, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 37, 95, 125 and 126, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR3 consisting of a sequence consisting of SEQ ID NO: 96, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR3 comprising a sequence consisting of SEQ ID NO: 96, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDRl consisting of a sequence consisting of SEQ ID NO: 97; a VL-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 98, 99, 127, 128, and 129; and a VL-CDR3 consisting of a sequence consisting of SEQ ID NO: 100.
  • the anti- CD73 antibody or antigen-binding fragment thereof comprises a VL-CDRl comprising a sequence consisting of SEQ ID NO: 97; a VL-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 98, 99, 127, 128, and 129; and a VL-CDR3 comprising a sequence consisting of SEQ ID NO: 100.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs: 35, 123, and 124; a VH-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 37, 95, 125, and 126; and a VH-CDR3 consisting of a sequence consisting of SEQ ID NOs: 96.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR1 comprising a sequence selected from the group consisting of SEQ ID NOs: 35, 123, and 124; a VH-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 37, 95, 125, and 126; a VH-CDR3 comprising a sequence consisting of SEQ ID NO: 96.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDRl consisting of a sequence consisting of SEQ ID NO: 97, except for one, two, three, or four amino acid substitutions
  • VL-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 98, 99, 127, 128, and 129, except for one, two, three or four amino acid substitutions
  • VL-CDR3 consisting of a sequence consisting of SEQ ID NO: 100, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDRl comprising a sequence consisting of SEQ ID NOs: 97, except for one, two, three or four amino acid substitutions
  • VL-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 98, 99, 127, 128, and 129, except for one, two, three or four amino acid substitutions
  • VL-CDR3 comprising a sequence consisting of SEQ ID NO: 100, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs: 35, 123, and 124, except for one, two, three or four amino acid substitutions
  • VH-CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 37, 95, 125, and 126, except for one, two, three, or four amino acid substitutions
  • VH-CDR3 consisting of a sequence consisting of SEQ ID NO: 96, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR1 comprising a sequence selected from the group consisting of SEQ ID NOs: 35, 123, and 124, except for one, two, three, or four amino acid substitutions
  • VH-CDR2 comprising a sequence selected from the group consisting of SEQ ID NOs: 37, 95, 125, and 126, except for one, two, three, or four amino acid substitutions
  • VH-CDR3 comprising a sequence consisting of SEQ ID NO: 96, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises modifications to CDRl, and/or CDR2, and/or CDR3 of the heavy and/or light chain, and further comprises modifications to FW1, and/or FW2, and/or FW3, and/or FW4 of the heavy and/or light chain.
  • FW 9 comprises SEQ ID NO: 90 or 91
  • FW 10 comprises SEQ ID NO: 92
  • FW U comprises SEQ ID NO: 93, 94, or 122
  • FW 12 comprises SEQ ID NO: 30
  • FW 13 comprises SEQ ID NO: 31
  • FW 14 comprises SEQ ID NO: 32
  • FW 15 comprises SEQ ID NO: 33
  • FW 16 comprises SEQ ID NO: 89.
  • FW 9 comprises SEQ ID NO: 90 or 91, except for one, two, three, or four amino acid substitutions
  • FWio comprises SEQ ID NO: 92, except for one, two, three, or four amino acid substitutions
  • FW n comprises SEQ ID NO: 93, 94, or 122, except for one, two, three, or four amino acid substitutions
  • FWi 2 comprises SEQ ID NO: 30, except for one, two, three, or four amino acid substitutions
  • FWi 3 comprises SEQ ID NO: 31, except for one, two, three, or four amino acid substitutions
  • FW M comprises SEQ ID NO: 32, except for one, two, three, or four amino acid substitutions
  • FW 15 comprises SEQ ID NO: 33, except for one, two, three or four amino acid substitutions
  • FW 16 comprises SEQ ID NO: 89.
  • the anti-CD733 antibody or antigen-binding fragment thereof comprises a VL and a VH comprising VL-CDR1, VL-CRD2, VL-CDR3, VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences identical or identical except for one, two, three, or four amino acid substitutions in one or more CDRs, wherein such VL-CDR1, VL-CRD2, VL-CDR3, VH-CDR1, VH-CDR2, and VH-CDR3 are:
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises an antibody VL and an antibody VH, wherein the VL comprises an amino acid sequence at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to a reference amino acid sequence selected from the group consisting of SEQ ID NOs: 86, 88, 112, 118, 119, 120, and 121.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises an antibody VL and an antibody VH, wherein the VH comprises an amino acid sequence at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to a reference amino acid sequence selected from the group consisting of SEQ ID NOs: 85, 87, 111, 113, 114, 115, 116, and 117.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL comprising a sequence at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to a reference amino acid sequence selected from the group consisting of SEQ ID NOs: 86, 88, 112, 118, 119, 120, and 121 ; and further comprises a VH comprising a sequence at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to a reference amino acid sequence selected from the group consisting of SEQ ID NOs: 85, 87, 111, 113, 114, 115, 116, and 117.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL consisting of the sequence of SEQ ID NO: 87, and a VH consisting of the sequence of SEQ ID NO:87.
  • the "clone 2C5 antibody” is an IgGl comprising two CD730002-derived light chains
  • VL of SEQ ID NO: 88 (comprising three CDRs, CDR1, CDR2, and CDR3, with the sequences of SEQ ID NO: 97, 99, and 100, respectively), and CD7300002-derived heavy chains (VH) of SEQ ID NO: 87 (comprising three CDRs, CDR1, CDR2, and CDR3, with the sequences of SEQ ID NO: 35, 95, and 96, respectively).
  • an anti-CD73 antibody or antigen-binding fragment thereof disclosed herein binds CD73 with substantially the same or better affinity as a 2C5 antibody comprising the 2C5 heavy chain VH of SEQ ID NO: 87 and the 2C5 light chain VL of SEQ ID NO: 88.
  • the parent antibody of an anti-CD73 antibody or antigen-binding fragment disclosed herein is CD730004 (i.e., an anti-CD73 antibody comprising a VL of SEQ ID NO: 104 and a VH of SEQ ID NO: 103), CD730008 (i.e., an anti-CD73 antibody comprising a VL of SEQ ID NO: 106 and a VH of SEQ ID NO: 107), CD7300011 (i.e., an anti-CD73 antibody comprising a VL of SEQ ID NO: 5 and a VH of SEQ ID NO:6), CD730021 (i.e., an anti-CD73 antibody comprising a VL of SEQ ID NO: 7 and a VH of SEQ ID NO: 8), CD730042 (i.e., an anti-CD73 antibody comprising a VL of SEQ ID NO: 9 and a VH of SEQ ID NO: 10), CD730046 (i.e., an anti-CD73 antibody comprising
  • the anti-CD73 antibody comprises modifications to CDR1 and/or
  • CD730004 CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody comprises modifications to CDR1 and/or
  • CD730004 CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDRl from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen- binding fragment thereof comprises a VL-CDR2 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL-CDR3 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR1 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen- binding fragment thereof comprises a VH-CDR2 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR3 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDRl from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069 except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL- CDR2 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VL-CDR3 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR1 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR2 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, except for one, two, three, or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a VH-CDR3 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR1 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069; a VL-CDR2 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069; and a VL-CDR3 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR1 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069; a VH-CDR2 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069; and a VH-CDR3 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL-CDR1 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, except for one, two, three or four amino acid substitutions
  • a VL-CDR2 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, except for one, two, three or four amino acid substitutions
  • VL-CDR3 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VH-CDR1 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, except for one, two, three or four amino acid substitutions
  • a VH-CDR2 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, except for one, two, three or four amino acid substitutions
  • VH-CDR3 from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, except for one, two, three or four amino acid substitutions.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises modifications to CDRl, and/or CDR2, and/or CDR3 of the heavy and/or light chain from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, and further comprises modifications to FWl, and/or FW2, and/or FW3, and/or FW4 of the heavy and/or light chain from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD733 antibody or antigen-binding fragment thereof comprises a VL and a VH comprising VL-CDR1, VL-CRD2, VL-CDR3, VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences identical or identical except for one, two, three, or four amino acid substitutions in one or more CDRs, wherein such VL-CDR1, VL-CRD2, VL-CDR3, VH-CDR1, VH-CDR2, and VH-CDR3 are from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises an antibody VL and an antibody VH, wherein the VL comprises an amino acid sequence at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to a reference amino acid sequence selected from VL sequences from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises an antibody VL and an antibody VH, wherein the VH comprises an amino acid sequence at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to a reference amino acid sequence selected from VH sequences from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen-binding fragment thereof comprises a
  • VL comprising a sequence at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to a reference amino acid sequence selected from VL sequences from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, and further comprises a VH comprising a sequence at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identical to a reference amino acid sequence selected from VH sequences from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.
  • the anti-CD73 antibody or antigen-binding fragment thereof disclosed herein binds CD73 with substantially the same or better affinity as a CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069 antibody.
  • VH and VL sequences from the anti-CD73 binding molecules disclosed herein e.g.,
  • CD730002, CD730004, CD730008, CD730010, CD730011, CD73021, CD730042, CD730046, CD730047, CD730068, or CD730069) or VH and VL of variants of such sequences e.g., clone 10 GL9, clone 10 P32E, clone 10 CI, clone 10 C2, clone 10 D3, clone 10 G10, clone 10 HPT, clone 10 GRVE, clone 10 combo 1, clone 10 combo2, clone 10 combo3, clone 10 combo5, or clone combo6 can be "mixed and matched" to create other anti-CD73 binding molecules.
  • the VH sequences of the 10.3 antibody and the 2C5 antibody are mixed and matched.
  • the VL sequences of the 10.03 antibody and the 2C5 antibody can be mixed and matched.
  • the VL and/or VH sequences of clone 10 (CD730010) variants disclosed herein can be mixed and matched.
  • the VL and/or VH sequences of clone 2 (CD730002) variants disclosed herein can be mixed and matched.
  • the VL and/or VH sequences of clone 10 (CD730010) and clone 2 (CD730002) variants disclosed herein can be mixed and matched.
  • VL and/or VH mixing and matching can take place between sequences derived from antibodies grouped in the same epitope bin (see Example 2).
  • epitope bin refers to the grouping of antibodies or antigen-binding fragments thereof that bind the same epitope or an overlapping epitope, or compete with each other for binding with the same epitope or overlapping epitope.
  • sequences from CD730003, CD730010, CD730021, CD730042, CD730046, and CD730047 can be mixed in matched.
  • the VL and/or VH mixing and matching can take place between sequences derived from anti-CD73 antibodies grouped in different epitope bins. Accordingly, sequences from antibodies belonging to "Epitope Bin B” can be mixed and matched with sequences from anti-CD73 antibodies in "Epitope Bin A” (CD730002, CD730004, CD730008, and CD730011) or "Epitope Bin C” (CD730068 and CD730069).
  • an anti-CD73 antibody for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • an antigen-binding fragment thereof disclosed herein comprises mutations that improve the binding to human FcRn and improve the half-life of the anti-CD73 antibody or antigen-binding fragment thereof.
  • such mutations are a methionine (M) to tyrosine (Y) mutation in position 252, a serine (S) to threonine (T) mutation in position 254, and a threonine (T) to glutamic acid (E) mutation in position 256, numbered according to the EU index as in Kabat (Kabat, et al. (1991) Sequences of Proteins of Immunological Interest, U.S. Public Health Service, National Institutes of Health, Washington, D.C.), introduced into the constant domain of an IgGl. See U.S. Patent No. 7,658,921, which is incorporated by reference herein.
  • an anti-CD73 antibody or antigen-binding fragment thereof comprising an IgG constant domain comprises one or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat, wherein such mutations increase the serum half-life of the anti-CD73 antibody or antigen-binding fragment thereof.
  • a YTE mutant further comprises a substitution at position 434 of the IgG constant domain, numbered according to the EU index as in Kabat, with an amino acid selected from the group consisting of tryptophan (W), methionine (M), tyrosine (Y), and serine (S).
  • W tryptophan
  • M methionine
  • Y tyrosine
  • S serine
  • a YTE mutant further comprises a substitution at position 434 of the IgG constant domain, numbered according to the EU index as in Kabat, with an amino acid selected from the group consisting of tryptophan (W), methionine (M), tyrosine (Y), and serine (S), and substitution at position 428 of the IgG constant domain, numbered according to the EU index as in Kabat, with an amino acid selected from the group consisting of threonine (T), leucine (L), phenylalanine (F), and serine (S).
  • W tryptophan
  • M methionine
  • Y tyrosine
  • S serine
  • a YTE mutant further comprises a substitution at position 434 of the
  • a YTE mutant further comprises a substitution at position 434 of the IgG constant domain, numbered according to the EU index as in Kabat, with serine (S), and a substitution at position 428 of the IgG constant domain, numbered according to the EU index as in Kabat, with leucine (L).
  • the anti-CD73 antibody for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • the antigen-binding fragment thereof disclosed herein comprises an IgGl constant domain comprising a methionine (M) to tyrosine (Y) mutation in position 252, a serine (S) to threonine (T) mutation in position 254, and a threonine (T) to glutamic acid (E) mutation in position 256 of the IgGl constant domain, numbered according to the EU index as in Kabat.
  • the anti-CD73 antibody for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • the antigen-binding fragment thereof disclosed herein comprises at least one IgG constant domain amino acid substitution selected from the group consisting of:
  • the positions are numbered according to the EU index as in Kabat, and wherein the modified IgG has an increased serum half-life compared to the serum half -life of an IgG having the wild-type IgG constant domain.
  • the VH and/or VL amino acid sequence of an anti-CD73 antibody for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • an anti-CD73 antibody for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • antigen-binding fragment thereof disclosed herein can be 85%, 90%, 95%, 96%, 97%, 98% or 99% similar to the VH and VL sequences set forth above, and comprise 1, 2, 3, 4, 5 or more conservative substitutions.
  • a CD73 antibody having VH and VL regions having high i.e.
  • sequence similarity or sequence identity to the VH regions of SEQ ID NOs: 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 111, 113, 114, 115, 116, or 117, and/or VL regions of SEQ ID NOs: 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 86, 88, 112, 118, 119, 120, or 121 respectively, can be obtained by mutagenesis (e.g., site -directed or PCR-mediated mutagenesis) of nucleic acid molecules encoding SEQ ID NOs: 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75,
  • mutagenesis
  • the Fc domain of an anti-CD73 antibody disclosed herein or the Fc domain of a fusion protein comprising a CD73-binding fragment of an antibody disclosed herein has reduced binding to an Fc receptor to reduce cytotoxicity, e.g., via ADCC.
  • the Fc domain of the antibody or Fc fusion protein has increased binding to an Fc receptor to increase cytotoxicity, e.g., via ADCC.
  • the Fc domain of the antibody or Fc fusion protein comprises a non-naturally occurring ADCC reducing amino acid residue at one or more positions selected from the group consisting of 234, 235, 236, 237, 238, 239, 240, 241, 243, 244, 245,247, 251, 252, 254, 255, 256, 262, 263, 264, 265, 266, 267, 269, 279, 280, 284, 292, 296, 297, 298, 299, 305, 313, 316, 325, 326, 327, 328, 329, 330, 331 , 332, 333, 334, 339, 341, 343, 370, 373, 378, 392, 416, 419, 421, 440, and 443 as numbered by the EU index as set forth in Kabat.
  • Antibodies with reduced ADCC effector function also include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327, and 329 (see, e.g., U.S. Pat. No. 6,737,056).
  • Such Fc mutants also include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including Fc mutant with substitution of residues 265 and 297 to alanine (see, e.g., U.S. Pat. No. 7,332,581).
  • mutations which reduce both ADCC and CDC can be incorporated.
  • anti-CD73 antibodies disclosed herein or antigen-binding fragment thereof comprising mutations that reduce or abolish ADCC and/or CDC can be used to generate antibody drug conjugates (ADC).
  • the present disclosure provides an anti-CD73 antibody, wherein the antibody is an IgGl, IgG2 or IgG3 and comprises at least one modification at one or more positions selected from the group consisting of 234, 235, and 331 as numbered by the EU index as set forth in Kabat.
  • the Fc region is an IgGl, IgG2 or IgG3 Fc region and the non-naturally occurring amino acids are selected from the group consisting of 234F, 235E, 235F, 235Q (or 235Y), 239A, 332Q, 331S, 332Q as numbered by the EU index as set forth in Kabat.
  • the present disclosure provides an anti-CD73 antibody, wherein the antibody is an IgG4 and comprises at least one modification at one or more positions selected from the group consisting of 228 and 235 as numbered by the EU index as set forth in Kabat.
  • the Fc region is an IgG4 Fc region and the non-naturally occurring amino acids are selected from the group consisting of 228P, 235E and 235Y as numbered by the EU index as set forth in Kabat.
  • the present disclosure provides an anti-CD73 antibody, wherein the antibody is an IgGl, IgG2, or IgG3 and comprises modifications at positions (i) 234F, 235E, and 331S; (ii) 234F, 235F, and 331S; (iii) 234F, 235Q, and 322Q.
  • the present disclosure provides an anti-CD73 antibody, wherein the antibody is an IgG4 and comprises modifications 228P and 235E.
  • the present disclosure provides CD73-binding molecules that bind to the same epitope as do the various anti-CD73 antibodies described herein, for example, molecules that bind to the same epitope as MEDI9447, a clone 10.3 antibody or to the same epitope as a clone 2C5 antibody.
  • Such antibodies can be identified based on their ability to cross-compete (e.g. , to competitively inhibit the binding of, in a statistically significant manner) with the anti-CD73 antibodies disclosed herein, such as the CD730010 antibody, CD730002 antibody, CD730004 antibody, and antigen-binding fragments thereof, in standard CD73 binding assays (e.g., flow cytometry assays, surface plasmon resonance, or solution assays).
  • standard CD73 binding assays e.g., flow cytometry assays, surface plasmon resonance, or solution assays.
  • the present disclosure provides anti-CD73 antibodies and antigen-binding fragments thereof, e.g. , human monoclonal antibodies, that compete for binding to CD73 with another anti-CD73 antibody or antigen-binding fragment thereof, such as the CD730010 antibody, CD730002 antibody, CD730004 antibody, variants thereof (e.g. , MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody), or antigen-binding fragments thereof.
  • the CD730010 antibody (or a clone 10.3 antibody or an antigen-binding fragment thereof), or the CD730002 antibody (or clone 2C5 antibody or an antigen-binding fragment thereof) demonstrates that the test antibody can compete with that antibody for binding to CD73; such antibody can, according to non-limiting theory, bind to the same or a related (e.g., a structurally similar or spatially proximal) epitope on CD73 as the anti-CD73 antibody or antigen-binding fragment thereof with which it competes.
  • the anti-CD73 antibody or antigen-binding fragment thereof that binds to the same epitope on CD73 as, e.g.
  • the CD730010 antibody (or a clone 10.3 antibody or an antigen-binding fragment thereof), or the CD730002 antibody (or clone 2C5 antibody or an antigen-binding fragment thereof), is a human monoclonal antibody.
  • the epitope of MEDI9447 a monoclonal antibody that directly inhibits the enzymatic activity of CD73 was identified to elucidate the mechanism of action of MEDI9447. The epitope resides within the apical surface of the N-terminal domain of CD73, a region distal from substrate binding and active site residues.
  • the epitope of MEDI9447 was defined and examined potential effects of antibody binding on global CD73 structure.
  • the antibody binds to a site in the N-terminal domain of CD73 that enables non-competitive inhibition of AMP hydrolysis.
  • the epitope comprises one or more CD73 amino acid residues corresponding to V144, K180, and N185.
  • the epitope additionally comprises one or more CD73 amino acid residues corresponding to Y135, K136, and N187 of CD73.
  • the epitope is positioned such that antibody binding impedes the conversion of CD73 from the open conformer to the catalytically active, closed conformer. Furthermore, our studies show that MEDI9447 can inhibit both anchored and soluble CD73 through a dual mechanism of inhibition that is mediated by the valency of antibody interaction with CD73.
  • the affinity or avidity of an antibody for an antigen can be determined experimentally using any suitable method well known in the art, e.g. , flow cytometry, enzyme-linked immunosorbent assay (ELISA), or radioimmunoassay (RIA), or kinetics (e.g., BIACORETM analysis).
  • ELISA enzyme-linked immunosorbent assay
  • RIA radioimmunoassay
  • kinetics e.g., BIACORETM analysis.
  • Direct binding assays as well as competitive binding assay formats can be readily employed. (See, for example, Berzofsky et al, "Antibody- Antigen Interactions," In Fundamental Immunology, Paul, W. E., Ed., Raven Press: New York, N.Y. (1984); Kuby, Immunology, W. H. Freeman and Company: New York, N.Y. (1992); and methods described herein.
  • the measured affinity of a particular antibody-antigen interaction can vary if measured under different conditions (e.g. , salt concentration, pH, temperature).
  • affinity and other antigen-binding parameters e.g., K D or Kd, K on , K off
  • K D or Kd, K on , K off are made with standardized solutions of antibody and antigen, and a standardized buffer, as known in the art and such as the buffer described herein.
  • affinity can be measured using a format in which the targeting antibody (e.g., a clone 10.3 antibody or a clone 2C5 antibody) is immobilized onto the chip (referred to as an "IgG down” format) or using a format in which the target protein (e.g. , CD73) is immobilized onto the chip (referred to as, e.g. , a "CD73 down” format).
  • the targeting antibody e.g., a clone 10.3 antibody or a clone 2C5 antibody
  • CD73 a format in which the target protein
  • the anti-CD73 antibody for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • an antigen-binding fragment thereof specifically binds CD73 and/or antigenic fragments thereof with a dissociation constant or k d (koff/kon) of less than 10 "6 M, or of less than 10 "7 M, or of less than 10 "8 M, or of less than 10 "9 M, or of less than 10 "10 M, or of less than 10 "11 M, or of less than 10 "12 M, or of less than 10 "13 M.
  • the anti-CD73 antibody for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • an antigen-binding fragment thereof binds to CD73 and/or antigenic fragments thereof with a K off of less than lxlO -3 s _1 , or less than 2x10 ⁇ 3 s _1 .
  • an anti-CD73 antibody or an antigen-binding fragment thereof binds to CD73 and antigenic fragments thereof with a K off of less than 10 ⁇ 3 s _1 , less than 5xl0 ⁇ 3 s _1 , less than 10 ⁇ 4 s _1 , less than 5xl0 "4 s "1 , less than 10 "5 s “1 , less than 5xl0 "5 s “1 , less than 10 "6 s “1 , less than 5xl0 “6 s “1 , less than less than 5xl0 “6 s “1 , less than less than 5x10 s , less than 10 s , less than 5x10 s , less than 10 s , less than 5x10 s , less than 10 s , less than 5xl0 "9 s "1 , or less than 10 "10 s "1 .
  • the anti-CD73 antibody for example, a clone 10.3 antibody or a clone
  • 2C5 antibody or an antigen-binding fragment thereof binds to CD73 and/or antigenic fragments thereof with an association rate constant or k on rate of at least 10 5 M _1 s _1 , at least 5xl0 5 M _1 s _1 , at least 10 6 M “1 s “1 , at least 5xl0 6 M “1 s “1 , at least 10 7 M “1 s “1 , at least 5xl0 7 M “1 s “1 , or at least 10 8 M “1 s "1 , or at least 10 9 M “1 s “1 .
  • the anti-CD73 antibody for example, a clone 10.3 antibody or a clone
  • 2C5 antibody or an antigen-binding fragment thereof binds to CD73 on the surface of MB-MDA- 231 cells with a K D of at least about 60 pM, at least about 70 pM, at least about 80 pM, at least about 90 pM, at least about 100 pM, at least about 110 pM, at least about 120 pM, at least about 130 pM, at least about 140 pM, at least about 150 pM, at least about 160 pM, or at least about 170 pm, as measured by flow cytometry.
  • K D of at least about 60 pM, at least about 70 pM, at least about 80 pM, at least about 90 pM, at least about 100 pM, at least about 110 pM, at least about 120 pM, at least about 130 pM, at least about 140 pM, at least about 150 pM, at least about 160 pM, or at least about 170 pm, as measured by flow cytometry.
  • the anti-CD73 antibody is a clone 10.3 antibody and it binds to CD73 on the surface of MB-MDA-231 cells with a K D of about 150 pM as measured by flow cytometry.
  • the anti-CD73 antibody is a clone 2C5 antibody and it binds to CD73 on the surface of MB-MDA-231 cells with a K D of about 80 pM as measured by flow cytometry.
  • the anti-CD73 antibody (for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragment thereof binds to CD73 binds on the surface of murine 3T1 cells with a K D of a of at least about 40 pM, at least about 50 pM, at least about 60 pM, at least about 70 pM, at least about 80 pM, at least about 90 pM, at least about 100 pM, at least about 120 pM, or at least about 130 pM, as measured by flow cytometry.
  • a K D of a of at least about 40 pM, at least about 50 pM, at least about 60 pM, at least about 70 pM, at least about 80 pM, at least about 90 pM, at least about 100 pM, at least about 120 pM, or at least about 130 pM, as measured by flow cytometry.
  • the anti-CD73 antibody is a clone 10.3 antibody and it binds to CD73 on the surface of murine 3T1 cells with a K D of about 110 pM as measured by flow cytometry.
  • the anti-CD73 antibody is a clone 2C5 antibody and it binds to CD73 on the surface of murine 3T1 cells with a K D of about 55 pM as measured by flow cytometry.
  • the anti-CD73 antibody (for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragment thereof binds to CD73 on the surface of cynomolgus MK-1 cells with a K D of a of at least about 40 pM, at least about 50 pM, at least about 60 pM, at least about 70 pM, at least about 80 pM, at least about 90 pM, or at least about 100 pM, as measured by flow cytometry.
  • MEDI9447 for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • an antigen-binding fragment thereof binds to CD73 on the surface of cynomolgus MK-1 cells with a K D of a of at least about 40 pM, at least about 50 pM, at least about 60 pM, at least about 70 pM, at least about
  • the anti-CD73 antibody is a clone 10.3 antibody and it binds to CD73 on the surface of cynomolgus MK-1 cells with a K D of about 80 pM as measured by flow cytometry.
  • the anti-CD73 antibody is a clone 2C5 antibody and it binds to CD73 on the surface of cynomolgus MK-1 cells with a K D of about 60 pM as measured by flow cytometry.
  • the anti-CD73 antibody (for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragment thereof binds to human CD73 with a K D of a of at least about 3 pM, at least about 4 pM, at least about 5 pM, at least about 6 pM, at least about 7 pM, at least about 8 pM, at least about 9 pM, or at least about 10 pM, as measured by surface plasmon resonance (PROTEON®).
  • a K D of a of at least about 3 pM, at least about 4 pM, at least about 5 pM, at least about 6 pM, at least about 7 pM, at least about 8 pM, at least about 9 pM, or at least about 10 pM, as measured by surface plasmon resonance (PROTEON®).
  • the anti-CD73 antibody is a clone 10.3 antibody and it binds to human CD73 with a K D of about 4 pM as measured by surface plasmon resonance (PROTEON®).
  • the anti-CD73 antibody is a clone 2C5 antibody and it binds to human CD73 with a K D of about 9 pM as measured by surface plasmon resonance (PROTEON®).
  • the anti-CD73 antibody (for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragment thereof disclosed herein binds to murine CD73 with a K D of a of at least about 1 pM, at least about 2 pM, at least about 3 pM, at least about 4 pM, at least about 5 pM, at least about 6 pM, at least about 7 pM, at least about 8 pM, at least about 9 pM, at least about 10 pM, at least about 11 pM, at least about 12 pM, at least about 13 pM, at least about 14 pM, at least about 15 pM, at least about 16 pM, at least about 17 pM, at least about 18 pM, at least about 19 pM, at least about 20 pM, at least about 21 pM, at least about 22 pM, at least about 23
  • the anti-CD73 antibody is a clone 10.3 antibody and it binds to murine CD73 with a K D of about 1 pM as measured by surface plasmon resonance (PROTEON®).
  • the anti-CD73 antibody is a clone 2C5 antibody and it binds to murine CD73 with a K D of about 22 pM as measured by surface plasmon resonance (PROTEON®).
  • an anti-CD73 antibody for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • an antigen-binding fragment thereof binds to cynomolgus CD73 with a K D of a of at least about 3 pM, at least about 4 pM, at least about 5 pM, at least about 6 pM, at least about 7 pM, at least about 8 pM, at least about 9 pM, or at least about 10 pM, as measured by surface plasmon resonance (PROTEON®).
  • the anti-CD73 antibody is a clone 10.3 antibody and it binds to cynomolgus CD73 with a K D of about 7 pM as measured by SPR (Proteon).
  • the anti-CD73 antibody is a clone 2C5 antibody and it binds to cynomolgus CD73 with a K D of about 9 pM as measured by surface plasmon resonance (PROTEON®).
  • the anti-CD73 antibody (for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragment thereof binds to human CD73 with a K D of a of at least about 40 pM, at least about 50 pM, at least about 60 pM, at least about 70 pM, at least about 80 pM, at least about 90 pM, at least about 100 pM, or at least about 110 pM, as measured by solution binding.
  • the anti-CD73 antibody is a clone 10.3 antibody and it binds to human CD73 with a K D of about 80 pM as measured by solution binding.
  • the anti-CD73 antibody is a clone 2C5 antibody and it binds to human CD73 with a K D of about 80 pM as measured by solution binding.
  • the anti-CD73 antibody for example, a clone 10.3 antibody or a clone
  • 2C5 antibody or an antigen-binding fragment thereof binds to murine CD73 with a K D of a of at least about 100 pM, at least about 200 pM, at least about 300 pM, at least about 400 pM, at least about 500 pM, at least about 600 pM, at least about 700 pM, at least about 800 pM, at least about 900 pM, at least about 1000 pM, at least about 1100 pM, at least about 1200 pM, at least about 1300 pM, at least about 1400 pM, at least about 1500 pM, at least about 1600 pM, at least about, or at least about 1700 pM, as measured by solution binding.
  • the anti-CD73 antibody is a clone 10.3 antibody and it binds to murine CD73 with a K D of about 130 pM as measured by solution binding.
  • the anti-CD73 antibody is a clone 2C5 antibody and it binds to murine CD73 with a K D of about 1500 pM as measured by solution binding.
  • the anti-CD73 antibody for example, a clone 10.3 antibody or a clone
  • 2C5 antibody or an antigen-binding fragment thereof binds to cynomolgus CD73 with a K D of a of at least about 60 pM, at least about 70 pM, at least about 80 pM, at least about 90 pM, at least about 100 pM, at least about 110 pM, or at least about 120 pM, as measured by solution binding.
  • the anti-CD73 antibody is a clone 10.3 antibody and it binds to cynomolgus CD73 with a K D of about 90 pM as measured by solution binding.
  • the anti-CD73 antibody is a clone 2C5 antibody and it binds to cynomolgus CD73 with a K D of about 100 pM as measured by solution binding.
  • MEDI9447 binds CD73 with a K D of about 1 x 10 "12 , 5 x 10 "12 , 10 x 10 "12 , 100 x 10 "12 , or 150 x 10 "12 .
  • a CD73-binding molecule disclosed herein e.g. , an anti-CD73 antibody
  • a CD73-binding molecule disclosed herein e.g., an anti-CD73 antibody (for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragment thereof can rescue ATP-induced T eff suppression by T reg .
  • a CD73-binding molecule disclosed herein e.g. , an anti-CD73 antibody or antigen-binding fragment thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody) can significantly inhibit syngeneic tumor growth.
  • the tumor is a non small cell lung, ovarian, breast, head and neck, pancreatic, colorectal cancer tumor, melanoma tumor, lymphoma tumor.
  • the tumor is a CT26 mouse syngeneic CRC tumor, B16F10 melanoma tumor, EG7-OVA lymphoma tumor, or a LL2 (Lewis Lung) tumor.
  • a CD73-binding molecule e.g., an anti-CD73 antibody or antigen-binding fragment thereof disclosed herein (for example, a clone 10.3 antibody or a clone 2C5 antibody) can significantly inhibit tumor growth, wherein the tumor is unresponsive to therapy with anti-PD-1 and/or anti- PD-L1 and/or anti-PD-L2 and/or anti-CTLA-4 antibodies.
  • a CD73-binding molecule disclosed herein e.g., an anti-CD73 antibody or antigen binding fragment thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody) can significantly inhibit tumor growth when administered at a concentration of about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, or about 10 mg/kg.PDl.
  • an anti-CD73 antibody or antigen binding fragment thereof for example, a clone 10.3 antibody or a clone 2C5 antibody
  • a CD73-binding molecule disclosed herein e.g. , an anti-CD73 antibody or antigen-binding fragment thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody) can be internalized after binding to cells.
  • the CD73-binding molecule is an antibody drug conjugate (ADC).
  • Monoclonal anti-CD73 antibodies e.g., MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • Antigen-binding fragments thereof can be prepared using hybridoma methods, such as those described by Kohler and Milstein (1975) Nature 256:495.
  • a mouse, hamster, or other appropriate host animal is immunized as described above to elicit the production by lymphocytes of antibodies that will specifically bind to an immunizing antigen. Lymphocytes can also be immunized in vitro.
  • the lymphocytes are isolated and fused with a suitable myeloma cell line using, for example, polyethylene glycol, to form hybridoma cells that can then be selected away from unfused lymphocytes and myeloma cells.
  • Hybridomas that produce monoclonal antibodies directed specifically against a chosen antigen as determined by immunoprecipitation, immunoblotting, or by an in vitro binding assay e.g. radioimmunoassay (RIA); enzyme -linked immunosorbent assay (ELISA)
  • RIA radioimmunoassay
  • ELISA enzyme -linked immunosorbent assay
  • the monoclonal antibodies can then be purified from the culture medium or ascites fluid as described for polyclonal antibodies above.
  • anti-CD73 monoclonal antibodies for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • antigen-binding fragments thereof can also be made using recombinant DNA methods as described, for example, in U.S. Patent No. 4,816,567.
  • the polynucleotides encoding a monoclonal antibody are isolated from mature B -cells or hybridoma cell, such as by RT-PCR using oligonucleotide primers that specifically amplify the genes encoding the heavy and light chains of the antibody, and their sequence is determined using conventional procedures.
  • the isolated polynucleotides encoding the heavy and light chains are then cloned into suitable expression vectors, which when transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, monoclonal antibodies are generated by the host cells.
  • host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, monoclonal antibodies are generated by the host cells.
  • recombinant anti-CD73 monoclonal antibodies or antigen-binding fragments thereof of the desired species can be isolated from phage display libraries expressing CDRs of the desired species as described (McCafferty et al , 1990, Nature, 348:552-554; Clarkson et al , 1991, Nature, 352:624-628; and Marks et al , 1991, J. Mol. Biol., 222:581-597).
  • the polynucleotide(s) encoding an anti-CD73 antibody (for example, a clone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragment thereof can further be modified in a number of different manners using recombinant DNA technology to generate alternative antibodies.
  • the constant domains of the light and heavy chains of, for example, a mouse monoclonal antibody can be substituted (1) for those regions of, for example, a human antibody to generate a chimeric antibody or (2) for a non-immunoglobulin polypeptide to generate a fusion antibody.
  • the constant regions are truncated or removed to generate the desired antibody fragment of a monoclonal antibody. Site -directed or high-density mutagenesis of the variable region can be used to optimize specificity, affinity, etc. of a monoclonal antibody.
  • the anti-CD73 antibody for example, a clone 10.3 antibody or a clone
  • 2C5 antibody or antigen-binding fragment thereof is a human antibody or antigen-binding fragment thereof.
  • Human antibodies can be directly prepared using various techniques known in the art. Immortalized human B lymphocytes immunized in vitro or isolated from an immunized individual that produce an antibody directed against a target antigen can be generated (See, e.g., Cole et al, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boemer et al, 1991, J. Immunol., 147 (l):86-95; and U.S. Patent 5,750,373).
  • the anti-CD73 human antibody for example, a clone 10.3 antibody or a clone 2C5 antibody
  • antigen-binding fragment thereof can be selected from a phage library, where that phage library expresses human antibodies, as described, for example, in Vaughan et al, 1996, Nat. Biotech., 14:309-314, Sheets et al, 1998, Proc. Nat'l. Acad. Sci., 95:6157-6162, Hoogenboom and Winter, 1991, J. Mol. Biol., 227:381, and Marks et al , 1991, J. Mol. Biol., 222:581).
  • Bio/Technology 10:779-783, incorporated by reference in its entirety) are known in the art and can be employed to generate high affinity human antibodies or antigen-binding fragments thereof.
  • the anti-CD73 monoclonal antibody (for example, a clone 10.3 antibody or a clone 2C5 antibody) can be a humanized antibody.
  • Methods for engineering, humanizing or resurfacing non-human or human antibodies can also be used and are well known in the art.
  • a humanized, resurfaced or similarly engineered antibody can have one or more amino acid residues from a source that is non-human, e.g. , but not limited to, mouse, rat, rabbit, non-human primate or other mammal.
  • non-human amino acid residues are replaced by residues that are often referred to as "import" residues, which are typically taken from an "import" variable, constant or other domain of a known human sequence.
  • Such imported sequences can be used to reduce immunogenicity or reduce, enhance or modify binding, affinity, on-rate, off-rate, avidity, specificity, half-life, or any other suitable characteristic, as known in the art.
  • the CDR residues are directly and most substantially involved in influencing CD73 binding. Accordingly, part or all of the non-human or human CDR sequences are maintained while the non-human sequences of the variable and constant regions can be replaced with human or other amino acids.
  • Antibodies can also optionally be humanized, resurfaced, engineered or human antibodies engineered with retention of high affinity for the CD73 antigen and other favorable biological properties.
  • humanized (or human) or engineered anti-CD73 antibodies and resurfaced antibodies can be optionally prepared by a process of analysis of the parental sequences and various conceptual humanized and engineered products using three-dimensional models of the parental, engineered, and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e.
  • framework residues can be selected and combined from the consensus and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.
  • 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragments thereof can be performed using any known method, such as but not limited to those described in, Jones et al , Nature 321 :522 (1986); Riechmann et al , Nature 332:323 (1988); Verhoeyen et al, Science 239: 1534 (1988)), Sims et al, J. Immunol. 151 : 2296 (1993); Chothia and Lesk, J. Mol. Biol. 196:901 (1987), Carter et al, Proc. Natl. Acad. Sci. U.S.A. 89:4285 (1992); Presta et al , J. Immunol.
  • Anti-CD73 humanized antibodies and antigen-binding fragments thereof can also be made in transgenic mice containing human immunoglobulin loci that are capable upon immunization of producing the full repertoire of human antibodies in the absence of endogenous immunoglobulin production. This approach is described in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016.
  • an anti-CD73 antibody fragment for example, a fragment from a clone
  • 10.3 antibody or from a clone 2C5 antibody is provided.
  • Various techniques are known for the production of antibody fragments. Traditionally, these fragments are derived via proteolytic digestion of intact antibodies (for example Morimoto et al , 1993, Journal of Biochemical and Biophysical Methods 24: 107-117; Brennan et al, 1985, Science, 229:81).
  • anti- CD73 antibody fragments are produced recombinantly.
  • Fab, Fv, and scFv antibody fragments can all be expressed in and secreted from E. coli or other host cells, thus allowing the production of large amounts of these fragments.
  • Such anti-CD73 antibody fragments can also be isolated from the antibody phage libraries discussed above.
  • the anti-CD73 antibody fragments can also be linear antibodies as described in U.S. Patent No. 5,641,870.
  • Other techniques for the production of antibody fragments e.g., chemical synthesis, will be apparent to the skilled practitioner.
  • techniques can be adapted for the production of single -chain antibodies specific to CD73 (see, e.g. , U.S. Pat. No. 4,946,778).
  • methods can be adapted for the construction of Fab expression libraries (see, e.g., Huse et al , Science 246: 1275-1281 (1989)) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for CD73, or derivatives, fragments, analogs or homologs thereof.
  • Antibody fragments can be produced by techniques in the art including, but not limited to: (a) a F(ab')2 fragment produced by pepsin digestion of an antibody molecule; (b) a Fab fragment generated by reducing the disulfide bridges of an F(ab')2 fragment, (c) a Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent, and (d) Fv fragments.
  • An anti-CD733 antibody for example, a clone 10.3 antibody or a clone 2C5 antibody
  • an antigen-binding fragment thereof disclosed herein can be modified in order to increase its serum half -life. This can be achieved, for example, by incorporation of a salvage receptor binding epitope into the antibody or antibody fragment by mutation of the appropriate region in the antibody or antibody fragment or by incorporating the epitope into a peptide tag that is then fused to the antibody or antibody fragment at either end or in the middle ⁇ e.g. , by DNA or peptide synthesis), or by YTE mutation.
  • Other methods to increase the serum half -life of an antibody or antigen-binding fragment thereof, e.g. , conjugation to a heterologous molecule such as PEG are known in the art.
  • Heteroconjugate anti-CD73 antibodies for example, a clone 10.3 antibody or a clone 2C5 antibody
  • antigen-binding fragments thereof are also within the scope of the present disclosure.
  • Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune cells to unwanted cells (see, e.g. , U.S. Pat. No. 4,676,980).
  • the heteroconjugate anti-CD73 antibodies for example, a clone 10.3 antibody or a clone 2C5 antibody
  • antigen-binding fragments thereof can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents.
  • immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate.
  • the CD73-binding molecules disclosed herein e.g., antibodies (for example, a clone 10.3 antibody or a clone 2C5 antibody) or antigen binding fragments thereof can be combined with other therapeutic agents (e.g., in a combination therapy) or they can be fused (e.g., genetically fused, to form a fusion protein) or conjugated (e.g., chemically or enzymatically conjugated) to at least one heterologous moiety.
  • the CD73-binding molecules disclosed herein they can be fused or conjugated to other therapeutic agents or toxins to form immunoconjugates and/or fusion proteins.
  • the present disclosure also provides antibody-drug conjugates (ADC) comprising at least one of the CD73-binding molecules disclosed herein which has been derivatized or linked (e.g., chemically or recombinantly) to another molecule (e.g., a peptide, small drug molecule, detectable molecule, etc.).
  • ADC antibody-drug conjugates
  • anti-CD73 antibodies or portions thereof are derivatized such that their CD73 binding is not affected adversely by the derivatization or labeling.
  • the anti-CD73 antibodies and antibody portions of the instant disclosure are intended to include both intact and modified forms of the anti-CD73 binding molecules described herein.
  • an anti-CD73 binding molecule disclosed herein or Cd73-binding portion thereof can be functionally linked (by chemical coupling, genetic fusion, noncovalent association, or otherwise) to one or more other molecular entities, such as a cytotoxic agent, a pharmaceutical agent, a detection agent, and/or a protein or peptide that can mediate association of the anti-CD73 binding molecule with another molecule (such as a streptavidin core region or a polyhistidine tag).
  • a cytotoxic agent such as a cytotoxic agent, a pharmaceutical agent, a detection agent, and/or a protein or peptide that can mediate association of the anti-CD73 binding molecule with another molecule (such as a streptavidin core region or a polyhistidine tag).
  • One type of derivatized molecule can be produced by crosslinking two or more molecular entities, e.g., an anti-CD73 binding molecule disclosed herein and a therapeutic agent (e.g., a cytotoxin such as tubulysin or MEDI 1508).
  • a therapeutic agent e.g., a cytotoxin such as tubulysin or MEDI 1508
  • Suitable crosslinkers include those that are heterobiiunctional, i.e., having two distinctly reactive groups separated by an appropriate spacer (e.g., m-maleimidobenzoyl-N-hydroxysuccinimidc ester); or homobifunctional (e.g., disuccinimidyl suberate).
  • Such crosslinkers are available, for example, from Pierce Chemical Company, Rockford, II.
  • Additional bifunctional coupling agents include N-succinimidyl-3-(2- pyridyldithiol) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1- carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis- diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4- dinitrobenzene).
  • SPDP N-
  • Another type of derivatized molecule can be produced by incorporating a detectable label.
  • Useful detection agents include fluorescent compounds (e.g., fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-l-napthalenesulfonyl chloride, phycoerythrin, lanthanide phosphors and the like), enzymes that are useful for detection (e.g., horseradish peroxidase, ⁇ -galactosidase, luciferase, alkaline phosphatase, glucose oxidase and the like), epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags, etc.).
  • detectable labels can be attached by at least one spacer arm. Spacer arms can be of various lengths to reduce potential steric hindrance.
  • Anti-CD73 binding molecules disclosed herein can also be labeled with a radiolabeled amino acid.
  • the radiolabel can be used for both diagnostic and therapeutic purposes.
  • the radiolabel can be used to detect CD73-expressing cells by X-ray or other diagnostic techniques such as positron emission tomography (PET).
  • PET positron emission tomography
  • the radiolabel can be used therapeutically as a toxin for CD73-expressing cells, such as those which cause unwanted immune response.
  • labels for polypeptides include, but are not limited to, the following radioisotopes or radionuclides: 3 H, 14 C, 15 N, 35 S, 90 Y, 9 9 Tc, m In, 125 I and 131 I.
  • the anti-CD73 binding molecule can be labeled with a paramagnetic, radioactive, or fluorogenic ion that is detectable upon imaging.
  • the paramagnetic ion is chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) or erbium (III).
  • the radioactive ion is iodine- 123, technetium-99, indium-I l l, rhenium- 188, rhenium- 186, copper-67, iodine-131, yttrium-90, iodine-125, astatine -211 , and gallium-67.
  • the anti-Cd73 binding molecule is labeled with an X-ray imaging agent such as lanthanum (III), gold (III), lead (II), and bismuth (III).
  • An anti-CD73 binding molecules disclosed herein can also be derivatized with a chemical group, for example a polymer such as polyethylene glycol (PEG), a methyl group, an ethyl group, or a carbohydrate group.
  • PEG polyethylene glycol
  • a methyl group e.g., a methyl group
  • ethyl group e.g., a carbohydrate group.
  • cytotoxic agent as used herein is defined broadly and refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells (cell death), and/or exerts anti-neoplastic/anti-proliferative effects.
  • the cytotoxic agent can prevent directly or indirectly the development, maturation, or spread of neoplastic tumor cells.
  • the term includes also such agents that cause a cytostatic effect only and not a mere cytotoxic effect.
  • chemotherapeutic agents as specified below, as well as other CD73 antagonists, anti-angiogenic agents, tyrosine kinase inhibitors, protein kinase A inhibitors, members of the cytokine family, radioactive isotopes, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin.
  • chemotherapeutic agent is a subset of the term “cytotoxic agent” comprising natural or synthetic chemical compounds.
  • examples of chemotherapeutic or agents include alkylating agents, for example, nitrogen mustards, ethyleneimine compounds, alkyl sulphonates and other compounds with an alkylating action such as nitrosoureas, cisplatin and dacarbazine; antimetabolites, for example, folic acid, purine or pyrimidine antagonists; mitotic inhibitors, for example, Vinca alkaloids and derivatives of podophyllotoxin; cytotoxic antibiotics and camptothecin derivatives.
  • chemotherapeutic agents are amifostine (ETHYOL®), cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carrnustine (BCNU), lomustine (CCNU), doxorubicin (ADRIAMYCIN®), doxorubicin lipo (DOXIL®), gemcitabine (GEMZAR®), daunorubicin, daunorubicin lipo (DAUNOXOME®), procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil (5-FU), vinblastine, vincristine, bleomycin, paclitaxel (TAXOL®), docetaxel (TAXOTERE®), aldesleukin, asparaginase, busulfan, carboplatin, cladribine, camptothecin,
  • CD73 antibodies or antigen-binding fragments thereof can comprise any type of variable region that provides for the association of the antibody or polypeptide with CD73.
  • the variable region can comprise or be derived from any type of mammal that can be induced to mount a humoral response and generate immunoglobulins against the desired tumor associated antigen.
  • the variable region of the modified anti-CD73 antibodies or antigen-binding fragments thereof can be, for example, of human, murine, non-human primate (e.g. , cynomolgus monkeys, macaques, etc.) or lupine origin. In some aspects both the variable and constant regions of the modified anti-CD73 antibodies or antigen-binding fragments thereof are human.
  • variable regions of compatible antibodies can be engineered or specifically tailored to improve the binding properties or reduce the immunogenicity of the molecule.
  • variable regions can be humanized or otherwise altered through the inclusion of imported amino acid sequences.
  • CD73 antibody for example, a clone 10.3 antibody or a clone 2C5 antibody
  • antigen-binding fragment thereof are altered by at least partial replacement of one or more CDRs and, if necessary, by partial framework region replacement and sequence changing.
  • the CDRs can be derived from an antibody of the same class or even subclass as the antibody from which the framework regions are derived, it is envisaged that the CDRs will be derived from an antibody of different class and in certain aspects from an antibody from a different species. It is not necessary to replace all of the CDRs with the complete CDRs from the donor variable region to transfer the antigen binding capacity of one variable domain to another. Rather, it is only necessary to transfer those residues that are necessary to maintain the activity of the antigen binding site.
  • the modified anti-CD73 antibodies for example, a modified clone 10.3 antibody or a modified clone 2C5 antibody
  • antigen-binding fragments thereof will comprise antibodies (e.g. , full-length antibodies or immunoreactive fragments thereof) in which at least a fraction of one or more of the constant region domains has been deleted or otherwise altered so as to provide desired biochemical characteristics such as increased tumor localization or reduced serum half -life when compared with an antibody of approximately the same immunogenicity comprising a native or unaltered constant region.
  • the constant region of the modified antibodies will comprise a human constant region.
  • Modifications to the constant region compatible with this the anti-CD73 molecules disclosed herein comprise additions, deletions or substitutions of one or more amino acids in one or more domains. That is, the modified antibodies disclosed herein can comprise alterations or modifications to one or more of the three heavy chain constant domains (CHI, CH2 or CH3) and/or to the light chain constant domain (CL). In some aspects, modified constant regions wherein one or more domains are partially or entirely deleted are contemplated. In some aspects, the modified antibodies will comprise domain deleted constructs or variants wherein the entire CH2 domain has been removed (ACH2 constructs). In some aspects, the omitted constant region domain will be replaced by a short amino acid spacer (e.g. , 10 residues) that provides some of the molecular flexibility typically imparted by the absent constant region.
  • a short amino acid spacer e.g. 10 residues
  • the constant region mediates several effector functions.
  • binding of the CI component of complement to antibodies activates the complement system.
  • Activation of complement is important in the opsonisation and lysis of cell pathogens.
  • the activation of complement also stimulates the inflammatory response and can also be involved in autoimmune hypersensitivity.
  • antibodies bind to cells via the Fc region, with a Fc receptor site on the antibody Fc region binding to a Fc receptor (FcR) on a cell.
  • FcR Fc receptor
  • Fc receptors which are specific for different classes of antibody, including IgG (gamma receptors), IgE (eta receptors), IgA (alpha receptors) and IgM (mu receptors). Binding of antibody to Fc receptors on cell surfaces triggers a number of important and diverse biological responses including engulfment and destruction of antibody-coated particles, clearance of immune complexes, lysis of antibody-coated target cells by killer cells (called antibody-dependent cell-mediated cytotoxicity, or ADCC), release of inflammatory mediators, placental transfer and control of immunoglobulin production.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • the anti-CD73 antibody for example, a clone 10.3 antibody or a clone
  • 2C5 antibody or an antigen-binding fragment thereof provides for altered effector functions that, in turn, affect the biological profile of the administered antibody or antigen-binding fragment thereof.
  • the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating modified antibody thereby increasing tumor localization.
  • constant region modifications consistent with this disclosure, moderate complement binding and thus reduce the serum half-life and nonspecific association of a conjugated cytotoxin.
  • Yet other modifications of the constant region can be used to eliminate disulfide linkages or oligosaccharide moieties that allow for enhanced localization due to increased antigen specificity or antibody flexibility.
  • modifications to the constant region in accordance with this disclosure can easily be made using well known biochemical or molecular engineering techniques well within the purview of the skilled artisan.
  • a CD73 -binding molecule disclosed herein that is an antibody (for example, a clone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragment thereof does not have one or more effector functions.
  • the antibody or antigen- binding fragment thereof has no antibody-dependent cellular cytotoxicity (ADCC) activity and/or no complement-dependent cytotoxicity (CDC) activity.
  • the anti-CD73 antibody or antigen binding fragment thereof does not bind to an Fc receptor and/or complement factors.
  • the antibody or antigen-binding fragment thereof has no effector function.
  • the anti-CD73 modified antibodies or antigen- binding fragments thereof can be engineered to fuse the CH3 domain directly to the hinge region of the respective modified antibodies or fragments thereof.
  • compatible constructs could be expressed wherein the CH2 domain has been deleted and the remaining CH3 domain (modified or unmodified) is joined to the hinge region with a 5-20 amino acid spacer.
  • Such a spacer can be added, for instance, to ensure that the regulatory elements of the constant domain remain free and accessible or that the hinge region remains flexible.
  • amino acid spacers can, in some cases, prove to be immunogenic and elicit an unwanted immune response against the construct. Accordingly, in certain aspects, any spacer added to the construct will be relatively non-immunogenic, or even omitted altogether, so as to maintain the desired biochemical qualities of the modified antibodies.
  • CD73 antibodies and antigen-binding fragments thereof of the present disclosure can be provided by the partial deletion or substitution of a few or even a single amino acid.
  • the mutation of a single amino acid in selected areas of the CH2 domain can be enough to substantially reduce Fc binding and thereby increase tumor localization.
  • Such partial deletions of the constant regions can improve selected characteristics of the antibody or antigen-binding fragment thereof (e.g. , serum half -life) while leaving other desirable functions associated with the subject constant region domain intact.
  • the constant regions of the disclosed anti-CD73 antibodies and antigen-binding fragments thereof can be modified through the mutation or substitution of one or more amino acids that enhances the profile of the resulting construct. In this respect it is possible to disrupt the activity provided by a conserved binding site (e.g., Fc binding) while substantially maintaining the configuration and immunogenic profile of the modified antibody or antigen-binding fragment thereof.
  • Certain aspects can comprise the addition of one or more amino acids to the constant region to enhance desirable characteristics such as decreasing or increasing effector function or provide for more cytotoxin or carbohydrate attachment. In such aspects it can be desirable to insert or replicate specific sequences derived from selected constant region domains.
  • the present disclosure also provides variants and equivalents which are substantially homologous to the chimeric, humanized and human anti-CD73 antibodies, or antigen-binding fragments thereof, set forth herein.
  • These can contain, for example, conservative substitution mutations, i.e. , the substitution of one or more amino acids by similar amino acids.
  • conservative substitution refers to the substitution of an amino acid with another within the same general class such as, for example, one acidic amino acid with another acidic amino acid, one basic amino acid with another basic amino acid or one neutral amino acid by another neutral amino acid. What is intended by a conservative amino acid substitution is well known in the art.
  • An anti-CD73 antibody or antigen-binding fragment thereof can be further modified to contain additional chemical moieties not normally part of the protein.
  • Those derivatized moieties can improve the solubility, the biological half -life or absorption of the protein.
  • the moieties can also reduce or eliminate any desirable side effects of the proteins and the like. An overview for those moieties can be found in Remington's Pharmaceutical Sciences, 20th ed., Mack Publishing Co., Easton, PA (2000). VI. Polynucleotides Encoding CD73-Binding Molecules
  • the present disclosure encompasses polynucleotides comprising nucleic acid sequences that encode a polypeptide that specifically binds CD73 or an antigen-binding fragment thereof.
  • the present disclosure provides a polynucleotide comprising a nucleic acid sequence that encodes an anti-CD73 antibody (e.g., a clone 10.3 antibody or a clone 2C5 antibody) or encodes an antigen-binding fragment of such an antibody.
  • the polynucleotides of the present disclosure can be in the form of RNA or in the form of DNA.
  • DNA includes cDNA, genomic DNA, and synthetic DNA; and can be double-stranded or single-stranded, and if single stranded can be the coding strand or non-coding (anti-sense) strand.
  • the polynucleotides are isolated. In certain aspects, the polynucleotides are substantially pure. In certain aspects the polynucleotides comprise the coding sequence for the mature polypeptide fused in the same reading frame to a polynucleotide which aids, for example, in expression and secretion of a polypeptide from a host cell (e.g. , a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell).
  • the polypeptide having a leader sequence is a preprotein and can have the leader sequence cleaved by the host cell to form the mature form of the polypeptide.
  • the polynucleotides can also encode for a CD73-binding proprotein which is the mature protein plus additional 5' amino acid residues.
  • polynucleotides comprise the coding sequence for the mature
  • CD73-binding polypeptide e.g. , an anti-CD73 antibody (e.g., a clone 10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragment thereof fused in the same reading frame to a marker sequence that allows, for example, for purification of the encoded polypeptide.
  • the marker sequence can be a hexa-histidine tag supplied by a pQE-9 vector to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or the marker sequence can be a hemagglutinin (HA) tag derived from the influenza hemagglutinin protein when a mammalian host (e.g. , COS -7 cells) is used.
  • a mammalian host e.g. , COS -7 cells
  • the present disclosure also provides variants of the described polynucleotides encoding, for example, CD73-binding fragments, analogs, and derivatives of the CD73-binding molecules disclosed herein (e.g., a clone 10.3 antibody or a clone 2C5 antibody).
  • the polynucleotide variants can contain alterations in the coding regions, non-coding regions, or both. In some aspects the polynucleotide variants contain alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. In some aspects, nucleotide variants are produced by silent substitutions due to the degeneracy of the genetic code. Polynucleotide variants can be produced for a variety of reasons, e.g. , to optimize codon expression for a particular host (change codons in the human ni NA to those preferred by a bacterial host such as E. coli). Vectors and cells comprising the polynucleotides described herein are also provided.
  • a DNA sequence encoding a CD73-binding molecule e.g. , an anti-CD73 antibody (e.g., a clone 10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragment thereof can be constructed by chemical synthesis using an oligonucleotide synthesizer.
  • oligonucleotides can be designed based on the amino acid sequence of the desired polypeptide and selecting those codons that are favored in the host cell in which the recombinant polypeptide of interest will be produced. Standard methods can be applied to synthesize an isolated polynucleotide sequence encoding an isolated polypeptide of interest.
  • a complete amino acid sequence can be used to construct a back-translated gene.
  • a DNA oligomer containing a nucleotide sequence coding for the particular isolated polypeptide can be synthesized.
  • several small oligonucleotides coding for portions of the desired polypeptide can be synthesized and then ligated.
  • the individual oligonucleotides typically contain 5' or 3' overhangs for complementary assembly.
  • the polynucleotide sequences encoding a particular isolated polypeptide of interest will be inserted into an expression vector and operatively linked to an expression control sequence appropriate for expression of the protein in a desired host. Proper assembly can be confirmed by nucleotide sequencing, restriction mapping, and expression of a biologically active polypeptide in a suitable host. As is well known in the art, in order to obtain high expression levels of a transfected gene in a host, the gene must be operatively linked to transcriptional and translational expression control sequences that are functional in the chosen expression host.
  • recombinant expression vectors are used to amplify and express DNA encoding anti-CD73 antibodies (e.g., a clone 10.3 antibody or a clone 2C5 antibody) or antigen- binding fragments thereof.
  • Recombinant expression vectors are replicable DNA constructs which have synthetic or cDNA-derived DNA fragments encoding a polypeptide chain of an anti-CD73 antibody or and antigen-binding fragment thereof, operatively linked to suitable transcriptional or translational regulatory elements derived from mammalian, microbial, viral or insect genes.
  • a transcriptional unit generally comprises an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, transcriptional promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription and translation initiation and termination sequences, as described in detail below.
  • a regulatory element can include an operator sequence to control transcription.
  • the ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants can additionally be incorporated.
  • DNA regions are operatively linked when they are functionally related to each other.
  • DNA for a signal peptide is operatively linked to DNA for a polypeptide if it is expressed as a precursor which participates in the secretion of the polypeptide; a promoter is operatively linked to a coding sequence if it controls the transcription of the sequence; or a ribosome binding site is operatively linked to a coding sequence if it is positioned so as to permit translation.
  • Structural elements intended for use in yeast expression systems include a leader sequence enabling extracellular secretion of translated protein by a host cell.
  • recombinant protein is expressed without a leader or transport sequence, it can include an N- terminal methionine residue. This residue can optionally be subsequently cleaved from the expressed recombinant protein to provide a final product.
  • Useful expression vectors for eukaryotic hosts include, for example, vectors comprising expression control sequences from SV40, bovine papilloma virus, adenovirus and cytomegalovirus.
  • Useful expression vectors for bacterial hosts include known bacterial plasmids, such as plasmids from E. coli, including pCR 1, pBR322, pMB9 and their derivatives, wider host range plasmids, such as M13 and filamentous single-stranded DNA phages.
  • Suitable host cells for expression of a CD73-binding molecule include prokaryotes, yeast, insect or higher eukaryotic cells under the control of appropriate promoters.
  • Prokaryotes include gram negative or gram positive organisms, for example E. coli or bacilli.
  • Higher eukaryotic cells include established cell lines of mammalian origin as described below. Cell-free translation systems could also be employed.
  • recombinant CD73-binding molecules e.g. , anti-CD73 antibodies (e.g., a clone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragments thereof.
  • recombinant proteins in mammalian cells can be performed because such proteins are generally correctly folded, appropriately modified and completely functional.
  • suitable mammalian host cell lines include HEK-293 and HEK-293T, the
  • COS-7 lines of monkey kidney cells described by Gluzman (Cell 23: 175, 1981), and other cell lines including, for example, L cells, C127, 3T3, Chinese hamster ovary (CHO), NSO, HeLa and BHK cell lines.
  • Mammalian expression vectors can comprise nontranscribed elements such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, and other 5' or 3' flanking nontranscribed sequences, and 5' or 3' nontranslated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences.
  • Baculo virus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, BioTechnology 6:47 (1988).
  • CD73-binding molecules e.g., anti-CD73 antibodies (e.g., a clone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragments thereof produced by a transformed host can be purified according to any suitable method.
  • standard methods include chromatography (e.g., ion exchange, affinity and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for protein purification.
  • Affinity tags such as hexahistidine, maltose binding domain, influenza coat sequence and glutathione-S-transferase can be attached to the protein to allow easy purification by passage over an appropriate affinity column.
  • Isolated proteins can also be physically characterized using such techniques as proteolysis, nuclear magnetic resonance and x-ray crystallography.
  • supernatants from systems which secrete recombinant protein into culture media can be first concentrated using a commercially available protein concentration filter, for example, an AMICON® or Millipore PELLICON® ultrafiltration unit. Following the concentration step, the concentrate can be applied to a suitable purification matrix.
  • a suitable purification matrix for example, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups.
  • the matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification.
  • a cation exchange step can be employed.
  • Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups.
  • one or more reversed-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g. , silica gel having pendant methyl or other aliphatic groups, can be employed to further purify an CD73- binding molecule (e.g., a clone 10.3 antibody or a clone 2C5 antibody).
  • an CD73- binding molecule e.g., a clone 10.3 antibody or a clone 2C5 antibody.
  • a recombinant CD73-binding protein e.g. , an anti-CD73 antibody (e.g., a clone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragment thereof produced in bacterial culture can be isolated, for example, by initial extraction from cell pellets, followed by one or more concentration, salting-out, aqueous ion exchange or size exclusion chromatography steps. High performance liquid chromatography (HPLC) can be employed for final purification steps.
  • Microbial cells employed in expression of a recombinant protein can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.
  • Methods known in the art for purifying antibodies and other proteins also include, for example, those described in U.S. Patent Publication Nos. 2008/0312425, 2008/0177048, and 2009/0187005, each of which is hereby incorporated by reference herein in its entirety.
  • the CD73-binding molecule is a polypeptide that is not an antibody.
  • a variety of methods for identifying and producing non-antibody polypeptides that bind with high affinity to a protein target are known in the art. See, e.g. , Skerra, Curr. Opin. Biotechnol., 18:295- 304 (2007), Hosse et al., Protein Science, 15: 14-27 (2006), Gill et al., Curr. Opin.
  • the polypeptide comprises a protein scaffold of a type selected from the group consisting of protein A, a lipocalin, a fibronectin domain (e.g., a fibronectin domain such as a Tenascin-3 Fn III domain), an ankyrin consensus repeat domain, and thioredoxin.
  • the present disclosure provides methods directed to the use of anti-CD73 binding molecules, e.g., antibodies, including antigen-binding fragments, variants, and derivatives thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody), to treat patients having a disease associated with CD73 expression or CD73-expressing cells, e.g., cancer.
  • cancer is lung cancer, breast cancer, ovarian cancer, colorectal cancer, bladder cancer, pancreatic cancer, renal cancer, stomach cancer, prostate cancer, breast cancer, lungcolon cancer, and lymphoma.
  • CD73-expressing cell is meant a cell expressing CD73.
  • CD73 can be membrane- bound via glycosyl phosphatidylinositol-anchoring and also be present as a soluble protein.
  • Methods for detecting CD73 expression in cells and other suitable samples are well known in the art and include, but are not limited to immunohistochemistry, flow cytometry, Western blot, ELISA, and the like.
  • CD73-binding molecules of the present disclosure e.g., a clone 10.3 antibody or a clone 2C5 antibody
  • the methods described herein are also applicable to any other anti-CD73 antibodies, and the antigen-binding fragments, variants, and derivatives (e.g., fusion proteins or conjugates) of these anti-CD73 antibodies that retain the desired properties of the anti-CD73 antibodies disclosed herein, e.g. , being capable of specifically binding CD73 and neutralizing its 5'-nucleotidase activity.
  • CD73-binding molecules are human or humanized antibodies that do not mediate human ADCC, or are anti-CD73 antibodies that are engineered such that they do not mediate ADCC.
  • the CD73-binding molecule is a CD730010 antibody or antigen-binding fragment thereof, a clone 10.3 antibody or an antigen-binding fragment thereof, a CD730002 antibody or antigen-binding fragment thereof, a clone 2C5 antibody or an antigen-binding fragment thereof, or a CD73004 antibody or antigen-binding fragment thereof.
  • the CD73-binding molecule is a clone 10.3 mutant antibody.
  • the CD73-binding molecule is a clone 10.3 monoclonal antibody.
  • the CD73-binding molecule is a clone 10.3 monoclonal antibody engineered to extend serum half-life.
  • the CD73- binding molecule is a clone 10.3 YTE mutant antibody. In other aspects, the CD73-binding molecule is a clone 2C5 mutant antibody. In some aspects, the CD73-binding molecule is a clone 2C5 monoclonal antibody. In some aspects, the CD73-binding molecule is a clone 2C5 monoclonal antibody engineered to extend serum half-life. In other aspects, the CD73-binding molecule is a clone 2C5 YTE mutant antibody.
  • treatment includes the application or administration of an anti-CD73 binding molecule, e.g. , an antibody (e.g., a clone 10.3 antibody or a clone 2C5 antibody) or antigen binding fragment, variant, or derivative thereof of the current disclosure to a subject or patient, or application or administration of the anti-CD73 binding molecule to an isolated tissue or cell line from a subject or patient, where the subject or patient has a disease, a symptom of a disease, or a predisposition toward a disease.
  • an anti-CD73 binding molecule e.g., an antibody (e.g., a clone 10.3 antibody or a clone 2C5 antibody) or antigen binding fragment, variant, or derivative thereof of the current disclosure to a subject or patient, or application or administration of the anti-CD73 binding molecule to an isolated tissue or cell line from a subject or patient, where the subject or patient has a disease, a symptom of a disease, or a predisposition toward
  • an antibody or antigen binding fragment, variant, or derivative thereof of the current disclosure to a subject or patient, or application or administration of a pharmaceutical composition comprising the anti-CD73 binding molecule to an isolated tissue or cell line from a subject or patient, who has a disease, a symptom of a disease, or a predisposition toward a disease.
  • the anti-CD73 binding molecules e.g., antibodies (e.g., a clone 10.3 antibody or a clone
  • the present disclosure provides anti-CD73 binding molecules, e.g. , antibodies (e.g., a clone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragments, variants, or derivatives thereof for use as a medicament, in particular for use in the treatment or prophylaxis of cancer (e.g., .
  • the cancer presents a prometastatic phenotype.
  • the cancer presenting a prometastatic phenotype is melanoma or breast cancer.
  • the cancer is a metastatic cancer.
  • the anti-CD73 binding molecules disclosed herein can trigger adaptive anti-tumor activity and/or inhibit metastasis. In some particular aspects, the anti-CD73 binding molecules disclosed herein can inhibit metastasis in breast cancer.
  • At least one anti-CD73 binding molecule e.g. , an antibody (e.g., a clone 10.3 antibody or a clone 2C5 antibody) or antigen binding fragment, variant, or derivative thereof as defined elsewhere herein is used to promote a positive therapeutic response with respect to cancer.
  • the term "positive therapeutic response" with respect to cancer treatment refers to an improvement in the disease in association with the activity of these anti-CD73 binding molecules, e.g. , antibodies or antigen-binding fragments, variants, or derivatives thereof, and/or an improvement in the symptoms associated with the disease.
  • an improvement in the disease can be characterized as a complete response.
  • a “complete response” is intended an absence of clinically detectable disease with normalization of any previously test results.
  • an improvement in the disease can be categorized as being a partial response.
  • a “positive therapeutic response” encompasses a reduction or inhibition of the progression and/or duration of cancer, the reduction or amelioration of the severity of cancer, and/or the amelioration of one or more symptoms thereof resulting from the administration of an anti-CD73 binding molecule disclosed herein.
  • such terms refer to one, two or three or more results following the administration of anti-CD73 binding molecules disclosed herein: (1) a stabilization, reduction or elimination of the cancer cell population; (2) a stabilization or reduction in cancer growth; (3) an impairment in the formation of cancer; (4) eradication, removal, or control of primary, regional and/or metastatic cancer; (5) a reduction in mortality; (6) an increase in disease -free, relapse-free, progression-free, and/or overall survival, duration, or rate; (7) an increase in the response rate, the durability of response, or number of patients who respond or are in remission; (8) a decrease in hospitalization rate, (9) a decrease in hospitalization lengths, (10) the size of the cancer is maintained and does not increase or increases by less than 10%, preferably less than 5%, preferably less than 4%, preferably less than 2%, and (12) an increase in the number of patients in remission.
  • Clinical response can be assessed using screening techniques such as magnetic resonance imaging (MRI) scan, x-radiographic imaging, computed tomographic (CT) scan, flow cytometry or fluorescence-activated cell sorter (FACS) analysis, histology, gross pathology, and blood chemistry, including but not limited to changes detectable by ELISA, RIA, chromatography, and the like.
  • MRI magnetic resonance imaging
  • CT computed tomographic
  • FACS fluorescence-activated cell sorter
  • the anti-CD73 binding molecules e.g. , antibodies (e.g., a clone 10.3 antibody or a clone
  • 2C5 antibody or antigen-binding fragments, variants, or derivatives thereof disclosed herein can be used in combination with any known therapies for cancer, including any agent or combination of agents that are known to be useful, or which have been used or are currently in use, for treatment of cancer, e.g. , colon cancer, melanoma, breast cancer, lymphoma, non-small cell lung carcinoma Hodgkin's lymphoma, non-Hodgkin's lymphoma, and Burkitt's lymphoma, ovarian cancer, breast cancer, head and neck cancers, and pancreatic cancer).
  • the second agent or combination of agents of the pharmaceutical combination formulation or dosing regimen preferably has complementary activities to the antibody or polypeptide of the present disclosure such that they do not adversely affect each other.
  • Anticancer agents include drugs used to treat malignancies, such as cancerous growths.
  • Drug therapy can be used alone, or in combination with other treatments such as surgery or radiation therapy.
  • Several classes of drugs can be used in cancer treatment, depending on the nature of the organ involved. For example, breast cancers are commonly stimulated by estrogens, and can be treated with drugs which inactive the sex hormones. Similarly, prostate cancer can be treated with drugs that inactivate androgens, the male sex hormone.
  • Anti-cancer agents for use in certain methods of the present disclosure include, among others, antibodies (e.g.
  • antibodies which bind IGF-1R antibodies which bind EGFR, antibodies which bind Her2, or antibodies which bind cMET
  • small molecules targeting IGF1R small molecules targeting EGFR
  • small molecules targeting Her2 antimetabolites, alkylating agents, topoisomerase inhibitors, microtubule targeting agents, kinase inhibitors, protein synthesis inhibitors, immunotherapeutic agents, hormonal therapies, glucocorticoids, aromatase inhibitors, mTOR inhibitors, chemotherapeutic agents, Protein Kinase B inhibitors, Phosphatidylinositol 3-Kinase (PI3K) inhibitors, Cyclin Dependent Kinase (CDK) inhibitors, RLr9, CD289, enzyme inhibitors, anti- TRAIL, MEK inhibitors, etc.
  • PI3K Phosphatidylinositol 3-Kinase
  • the CD73-binding molecules disclosed herein e.g. , antibodies (e.g., a clone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragments thereof, can be administered in combination with antibodies or antibody fragments targeting, for example, PD-1 (programmed death 1 protein), its two ligands PD-L1 (programmed death ligand 1) and/or PD-L2, or CTLA-4 (cytotoxic T lymphocyte antigen 4 protein).
  • PD-1 programmeed death 1 protein
  • PD-L1 programmeed death ligand 1
  • CTLA-4 cytotoxic T lymphocyte antigen 4 protein
  • the anti-CTLA-4 antibody is ipilimumab or an antigen binding fragment thereof.
  • the anti-CTLA-4 antibody is tremelimumab (ticilimumab, CP-675,206) or an antigen binding fragment thereof.
  • the anti-PD-1 antibody is pembrolizumab (KEYTRUDA®, formerly lambrolizumab, also known as MK-3475) or an antigen-binding fragment thereof.
  • the anti-PD-1 antibody is nivolumab (BMS-936558, MDX-1106, ONO-4538, OPDIVA®) or an antigen-binding fragment thereof.
  • the anti-PD-Ll antibody is BMS-936559 or an antigen binding fragment thereof.
  • the anti-PD-Ll antibody is MPDL3280A .
  • the anti-PD-1 antibody is AMP-224 (anti-PD-1 Fc fusion protein) or an antigen binding fragment thereof.
  • the anti-PD-Ll antibody is MEDI4736 or an antigen binding fragment thereof.
  • the CD73-binding molecules disclosed herein can be administered in combination with an anti-PD-1 or anti- PD-1 antibody.
  • the anti-CD73 antibody is administered at a concentration of about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15 mg/kg, about 16 mg/kg, about 17 mg/kg, about 18 mg/kg, about 19 mg/kg, or about 20 mg/kg.
  • the CD73-binding molecules disclosed herein can be administered in combination with an anti-PD-1, anti-PD-Ll, or anti-CTLA4 antibody, wherein the anti-PD-1, anti-PD-Ll, or anti-CTLA4 antibody is administered at a concentration of about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15 mg/kg, about 16 mg/kg, about 17 mg/kg, about 18 mg/kg, about 19 mg/kg, or about 20 mg/kg.
  • the anti-CD73 antibody and the anti-PD-1 antibody, anti-PD-Ll, or anti-CTLA4 are administered at a ratio of about 1: 1, 1 :2, 1 :3 or 1:4. In some aspects, the anti-CD73 antibody and the anti-PD-1, anti-PD-Ll, or anti-CTLA4 antibody are administered at a ratio of about 1 :2.
  • the concentration of anti-CD73 antibody is about 10 mg/kg, and the concentration of the anti-PD-1 antibody is about 20 mg/kg.
  • the CD73-binding molecules disclosed herein can be administered in combination with an anti-PD-1 antibody.
  • the administration of a combination treatment comprising an CD73-binding molecule disclosed herein can increase survival by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% compared to untreated subjects or subjects treated with a monotherapy (e.g., an anti-PD-1 , anti-PD-Ll, or anti-CTLA4 antibody without an anti-CD73 antibody).
  • an CD73-binding molecule disclosed herein for example, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody
  • an anti-PD-1, anti-PD-Ll, or anti-CTLA4 antibody can increase survival by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% compared to untreated subjects or subjects treated with a monotherapy (e.g., an anti-PD-1 , anti-PD-Ll, or anti-CTLA4 antibody without an anti-CD73 antibody).
  • the administration of a combination treatment comprising an CD73-binding molecule disclosed herein in combination with an anti-PD-1 , anti-PD-Ll, or anti-CTLA4 antibody, can increase survival by about 2-fold, about 3 -fold, about 4-fold, about 5- fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold compared to untreated subjects or subjects treated with a monotherapy (e.g., an anti-PD-1, anti-PD-Ll, or anti- CTLA4 antibody without an anti-CD73 antibody).
  • a monotherapy e.g., an anti-PD-1, anti-PD-Ll, or anti- CTLA4 antibody without an anti-CD73 antibody.
  • the combined therapies comprise administration of an anti-CD73 binding molecule in combination with administration of another therapeutic agent (e.g., an anti-PD-1, anti-PD-Ll, or anti-CTLA4 antibody)
  • another therapeutic agent e.g., an anti-PD-1, anti-PD-Ll, or anti-CTLA4 antibody
  • the methods disclosed herein encompass co-administration, using separate formulations or a single pharmaceutical formulation, and consecutive administration in either order.
  • the anti-CD73 antibodies described herein are administered in combination with other drugs, wherein the antibody or antigen binding fragment, variant, or derivative thereof and the therapeutic agent(s) can be administered sequentially, in either order, or simultaneously (i.e., concurrently or within the same time frame).
  • the combination therapy can provide "synergy” and prove “synergistic", i.e. , the effect achieved when the active ingredients used together is greater than the sum of the effects that results from using the compounds separately.
  • a synergistic effect can be attained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined, unit dosage formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen.
  • a synergistic effect can be attained when the compounds are administered or delivered sequentially, e.g. , by different injections in separate syringes.
  • an effective dosage of each active ingredient is administered sequentially, i.e. , serially, whereas in combination therapy, effective dosages of two or more active ingredients are administered together.
  • the CD73-binding molecules disclosed herein can be administered in combination with tyrosine kinase inhibitors.
  • the CD73-binding molecules disclosed herein can be administered in combination with inhibitors of the tyrosine kinase activity associated with EGFR and/or HER2/neu, e.g. , lapatinib.
  • the CD73-binding molecules disclosed herein can be administered in combination with antimitotic agents.
  • the CD73- binding molecules disclosed herein can be administered in combination with agents that stabilize the mitotic spindle microtubule assembly, e.g, paclitaxel or docetaxel.
  • agents that stabilize the mitotic spindle microtubule assembly e.g, paclitaxel or docetaxel.
  • a further aspect is the use of anti-CD73 binding molecules, e.g. , antibodies or antigen-binding fragments, variants, or derivatives thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody), for diagnostic monitoring of protein levels in tissue as part of a clinical testing procedure, e.g., to determine the efficacy of a given treatment regimen. For example, detection can be facilitated by coupling the antibody to a detectable substance.
  • Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ - galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
  • an example of a luminescent material includes luminol;
  • examples of bioluminescent materials include luciferase, luciferin, and aequorin;
  • suitable radioactive material include 125 I, 131 I, 35 S, or 3 H.
  • the present disclosure provides methods directed to the use of therapeutic combinations comprising anti-CD73 binding molecules, e.g. , antibodies, including antigen binding fragments, variants, and derivatives thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody), to treat patients having cancer (including colon cancer, melanoma, breast cancer, lymphoma, non- small cell lung carcinoma Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, ovarian cancer, breast cancer, head and neck cancers, and pancreatic cancer).
  • cancer including colon cancer, melanoma, breast cancer, lymphoma, non- small cell lung carcinoma Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, ovarian cancer, breast cancer, head and neck cancers, and pancreatic cancer.
  • CD73- binding molecule of the present disclosure e.g., a clone 10.3 antibody or a clone 2C5 antibody
  • the methods described herein are also applicable to any other anti-CD73 antibodies, and the antigen binding fragments, variants, and derivatives (e.g., fusion proteins or conjugates) of these anti-CD73 antibodies that retain the desired properties of the anti-CD73 antibodies disclosed herein, e.g. , being capable of specifically binding CD73 and neutralizing its 5'-nucleotidase activity.
  • CD73-binding molecules are human or humanized antibodies that do not mediate human ADCC, or are anti-CD73 antibodies that are engineered such that they do not mediate ADCC.
  • Treatment of a patient with a solid tumor using a combination of the invention, such as an anti-CD73 antibody, or antigen binding fragment thereof, in combination with an anti-PD-1 , anti- PD-L1 , or anti-CTLA4 antibody, or antigen binding fragments thereof can result in an additive or synergistic effect.
  • the term "synergistic” refers to a combination of therapies (e.g. , a combination of an anti-CD73 antibody (e.g., MEDI9447) and an anti-PD-1 , anti-PD-Ll , or anti-CTLA4 antibody, which is more effective than the additive effects of the single therapies.
  • a synergistic effect of a combination of therapies permits the use of lower dosages of one or more of the therapeutic agents and/or less frequent administration of said therapeutic agents to a patient with a solid tumor.
  • the ability to utilize lower dosages of therapeutic agents and/or to administer said therapies less frequently reduces the toxicity associated with the administration of said therapies to a subject without reducing the efficacy of said therapies in the treatment of a solid tumor.
  • a synergistic effect can result in improved efficacy of therapeutic agents in the management, treatment, or amelioration of an solid tumor.
  • the synergistic effect of a combination of therapeutic agents can avoid or reduce adverse or unwanted side effects associated with the use of either single therapy.
  • an anti-CD73 antibody e.g., MEDI9447
  • anti-PD-1 anti-PD-Ll
  • anti-CTLA4 antibody antigen binding fragments thereof
  • the pharmaceutical composition comprising an anti-CD73 antibody (e.g., MEDI9447) or antigen binding fragment thereof is suitable for administration prior to, simultaneously with, or following administration of the pharmaceutical composition comprising an anti-PD-1 , anti-PD-Ll , or anti-CTLA4 antibody, or antigen binding fragment thereof,.
  • the anti-CD73 antibody e.g., MEDI9447
  • antigen binding fragment thereof and an anti-PD-1 , anti-PD-Ll , or anti-CTLA4 antibody is administered at overlapping times in a separate composition.
  • An anti-CD73 antibody e.g., MEDI9447
  • an anti-PD-1 , anti-PD-Ll , or anti-CTLA4 antibody, or antigen binding fragment thereof can be administered only once or infrequently while still providing benefit to the patient.
  • the patient is administered additional follow-on doses.
  • Follow-on doses can be administered at various time intervals depending on the patient's age, weight, clinical assessment, tumor burden, and/or other factors, including the judgment of the attending physician.
  • the methods provided herein can decrease or retard tumor growth.
  • the reduction or retardation can be statistically significant.
  • a reduction in tumor growth can be measured by comparison to the growth of patient's tumor at baseline, against an expected tumor growth, against an expected tumor growth based on a large patient population, or against the tumor growth of a control population.
  • the methods of the invention increase survival.
  • Antibodies that specifically bind and inhibit PD-L1 activity e.g., binding to PD-1 and/or
  • B7-H1 also known as PD-L1
  • PD-L1 is a type I transmembrane protein of approximately 53kDa in size.
  • B7-H1 is expressed on a number of immune cell types including activated and anergic/exhausted T cells, on naive and activated B cells, as well as on myeloid dendritic cells (DC), monocytes and mast cells. It is also expressed on non-immune cells including islets of the pancreas, Kupffer cells of the liver, vascular endothelium and selected epithelia, for example airway epithelia and renal tubule epithelia, where its expression is enhanced during inflammatory episodes.
  • DC myeloid dendritic cells
  • B7-H1 expression is also found at increased levels on a number of tumors including, but not limited to breast, colon, colorectal, lung, renal, including renal cell carcinoma, gastric, bladder, non-small cell lung cancer (NSCLC), hepatocellular cancer (HCC), and pancreatic cancer, as well as melanoma.
  • tumors including, but not limited to breast, colon, colorectal, lung, renal, including renal cell carcinoma, gastric, bladder, non-small cell lung cancer (NSCLC), hepatocellular cancer (HCC), and pancreatic cancer, as well as melanoma.
  • NSCLC non-small cell lung cancer
  • HCC hepatocellular cancer
  • pancreatic cancer pancreatic cancer
  • B7-H1 is known to bind two alternative ligands, the first of these, PD-1, is a 50-55 kDa type I transmembrane receptor that was originally identified in a T cell line undergoing activation- induced apoptosis. PD-1 is expressed on activated T cells, B cells, and monocytes, as well as other cells of the immune system and binds both B7-H1 (PD-L1) and the related B7-DC (PD-L2). The second is the B7 family member B7-1, which is expressed on activated T cells, B cells, monocytes and antigen presenting cells.
  • B7-H1 functions in this respect via several alternative mechanisms including driving exhaustion and anergy of tumor infiltrating T lymphocytes, stimulating secretion of immune repressive cytokines into the tumor micro-environment, stimulating repressive regulatory T cell function and protecting B7-H1 expressing tumor cells from lysis by tumor cell specific cytotoxic T cells.
  • MEDI4736 is an exemplary anti-PD-Ll antibody that is selective for B7-H1 and blocks the binding of B7-H1 to the PD-1 and CD80 receptors. MEDI4736 can relieve B7-H1 -mediated suppression of human T-cell activation in vitro and inhibits tumor growth in a xenograft model via a T-cell dependent mechanism. Other agents that could be used include agents that inhibit PD-L1 and/or PD-1 (AB or other).
  • MEDI4736 (or fragments thereof) for use in the methods provided herein can be found in US20130034559 / US 8779108 and US20140356353, the disclosures of each of which are incorporated herein by reference in their entireties.
  • the fragment crystallizable (Fc) domain of MEDI4736 contains a triple mutation in the constant domain of the IgGl heavy chain that reduces binding to the complement component Clq and the Fey receptors responsible for mediating antibody-dependent cell-mediated cytotoxicity (ADCC).
  • MEDI4736 and antigen binding fragments thereof for use in the methods provided herein comprises a heavy chain and a light chain or a heavy chain variable region and a light chain variable region.
  • MEDI4736 or an antigen binding fragment thereof for use in the methods provided herein comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 130 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 131.
  • MEDI4736 or an antigen binding fragment thereof for use in the methods provided herein comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the Kabat-defined CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 132-134, and wherein the light chain variable region comprises the Kabat-defined CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 135-137.
  • the heavy chain variable region comprises the Kabat-defined CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 132-134
  • the light chain variable region comprises the Kabat-defined CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 135-137.
  • MEDI4736 or an antigen binding fragment thereof for use in the methods provided herein comprises the variable heavy chain and variable light chain CDR sequences of the 2.14H90PT antibody as disclosed in US20130034559 / US 8779108 and US20140356353, the disclosures of each of which are incorporated herein by reference in their entireties.
  • therapeutic combinations of the invention comprise a
  • CTLA4 blocking antibody e.g., Tremelimumab
  • CTLA4 blocking antibody e.g., Tremelimumab
  • PD1/PD-L1 interactions Two T cell modulatory pathways receiving significant attention to date signal through cytotoxic T lymphocyte antigen-4 (CTLA4, CD 152) and programmed death ligand 1 (PD-L1, also known as B7H-1 or CD274).
  • CTLA4, CD 152 cytotoxic T lymphocyte antigen-4
  • PD-L1 programmed death ligand 1
  • CTLA4 is expressed on activated T cells and serves as a co-inhibitor to keep T cell responses in check following CD28 -mediated T cell activation.
  • CTLA4 is believed to regulate the amplitude of the early activation of naive and memory T cells following TCR engagement and to be part of a central inhibitory pathway that affects both antitumor immunity and autoimmunity.
  • CTLA4 is expressed primarily on T cells, and the expression of its ligands CD80 (B71) and CD86 (B7.2), is largely restricted to antigen-presenting cells, T cells, and other immune mediating cells.
  • Antagonistic anti-CTLA4 antibodies that block the CTLA4 signaling pathway have been reported to enhance T cell activation.
  • ipilimumab was approved by the FDA in 2011 for the treatment of metastatic melanoma.
  • Another anti-CTLA4 antibody, tremelimumab was tested in phase III trials for the treatment of advanced melanoma but did not significantly increase the overall survival of patients compared to the standard of care (temozolomide or dacarbazine) at that time.
  • Tremelimumab also known as CP-675,206, CP-675, CP-675206, and ticilimumab
  • CP-675,206, CP-675, CP-675206, and ticilimumab is a human IgG2 monoclonal antibody that is highly selective for CTLA4 and blocks binding of CTLA4 to CD80 (B7.1) and CD86 (B7.2). It has been shown to result in immune activation in vitro and some patients treated with tremelimumab have shown tumor regression.
  • Tremelimumab for use in the methods provided herein comprises a heavy chain and a light chain or a heavy chain variable region and a light chain variable region.
  • tremelimumab or an antigen binding fragment thereof for use in the methods provided herein comprises a light chain variable region and a heavy chain variable region.
  • tremelimumab or an antigen binding fragment thereof for use in the methods provided herein comprises a heavy chain variable region and a light chain variable region identified herein.
  • tremelimumab or an antigen binding fragment thereof for use in the methods provided herein comprises the variable heavy chain and variable light chain CDR sequences of the 11.2.1 antibody as disclosed in US 6,682,736, which is herein incorporated by reference in its entirety.
  • anti-CD73 binding molecules e.g., antibodies, or antigen-binding fragments, variants, or derivatives thereof (e.g., a clone 10.3 antibody or a clone 2C5 antibody) to a subject in need thereof are well known to or are readily determined by those skilled in the art.
  • the route of administration of the anti-CD73 binding molecule, e.g. , an antibody, or antigen-binding fragment, variant, or derivative thereof can be, for example, oral, parenteral, by inhalation or topical.
  • parenteral as used herein includes, e.g., intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, rectal, or vaginal administration.
  • anti-CD73 binding molecules e.g., antibodies, or antigen-binding fragments, variants, or derivatives thereof, of the present disclosure can be delivered directly to the site of the adverse cellular population thereby increasing the exposure of the diseased tissue to the therapeutic agent.
  • anti-CD73 binding molecules e.g. , antibodies, or antigen-binding fragments, variants, or derivatives thereof of the present disclosure (for example, a clone 10.3 antibody or a clone 2C5 antibody) can be administered in a pharmaceutically effective amount for the in vivo treatment of CD73-expressing cell-mediated diseases such as certain types of cancers.
  • Methods of preparing and administering therapeutic combinations comprising anti-CD73 binding molecules, e.g., antibodies, or antigen binding fragments, variants, or derivatives thereof (e.g., a clone 10.3 antibody or a clone 2C5 antibody) in combination with an anti-PD-1, anti-PD- Ll, and/or anti-CTLA4 antibody, or antigen binding fragments thereof to a subject in need thereof are well known to or are readily determined by those skilled in the art.
  • the route of administration of the combination thereof can be, for example, oral, parenteral, by inhalation or topical.
  • parenteral as used herein includes, e.g., intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, rectal, or vaginal administration.
  • a combination of the present disclosure can be delivered directly to the site of the adverse cellular population thereby increasing the exposure of the diseased tissue to the therapeutic agent.
  • an anti-CD73 antibody e.g., MEDI9447
  • an anti-PD-1, anti-PD-Ll, and/or anti-CTLA4 antibody can be administered in a pharmaceutically effective amount for the in vivo treatment of CD73-expressing cell-mediated diseases such as certain types of cancers.
  • compositions used in this disclosure can comprise pharmaceutically acceptable carriers, including, e.g., water, ion exchangers, proteins, buffer substances, and salts. Preservatives and other additives can also be present.
  • the carrier can be a solvent or dispersion medium. Suitable formulations for use in therapeutic methods disclosed herein are described in Remington's Pharmaceutical Sciences (Mack Publishing Co.) 16th ed. (1980).
  • sterile injectable solutions can be prepared by incorporating a therapeutic combination of the invention an active compound (e.g., an anti-CD73 antibody, or antigen- binding fragment, variant, or derivative thereof, for example a clone 10.3 antibody or a clone 2C5 antibody, by itself or in combination with other active agents) in the required amount in an appropriate solvent followed by filtered sterilization.
  • an active compound e.g., an anti-CD73 antibody, or antigen- binding fragment, variant, or derivative thereof, for example a clone 10.3 antibody or a clone 2C5 antibody, by itself or in combination with other active agents
  • the preparations can be packaged and sold in the form of a kit.
  • Such articles of manufacture can have labels or package inserts indicating that the associated compositions are useful for treating a subject suffering from, or predisposed to a disease or disorder.
  • Parenteral formulations can be a single bolus dose, an infusion or a loading bolus dose followed with a maintenance dose. These compositions can be administered at specific fixed or variable intervals, e.g., once a day, or on an "as needed" basis.
  • composition can be administered as a single dose, multiple doses or over an established period of time in an infusion. Dosage regimens also can be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response).
  • compositions of the present disclosure for treatment of CD73-expressing cell-mediated diseases, such as certain types of cancers including e.g. , colon cancer, melanoma, breast cancer, lymphoma, non-small cell lung carcinoma Hodgkin's lymphoma, non-Hodgkin's lymphoma, and Burkitt's lymphoma, ovarian cancer, breast cancer, head and neck cancers, and pancreatic cancer, vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Usually, the patient is a human, but non-human mammals including transgenic mammals can also be treated. Treatment dosages can be titrated using routine methods known to those of skill in the art to optimize safety and efficacy.
  • cancers such as certain types of cancers including e.g. , colon cancer, melanoma, breast cancer, lymphoma, non-small cell lung carcinoma Hodgkin'
  • the amount of at least one anti-CD73 binding molecule, e.g., antibody or binding fragment, variant, or derivative thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody) or therapeutic combination of the invention to be administered is readily determined by one of ordinary skill in the art without undue experimentation given the disclosure of the present disclosure.
  • Factors influencing the mode of administration and the respective amount of at least one anti-CD73 binding molecule, e.g. , antibody, antigen binding fragment, variant or derivative thereof, or therapeutic combination of the invention include, but are not limited to, the severity of the disease, the history of the disease, and the age, height, weight, health, and physical condition of the individual undergoing therapy.
  • the amount of anti-CD73 binding molecule, e.g., antibody, or fragment, variant, or derivative thereof, or therapeutic combination of the invention, to be administered will be dependent upon the mode of administration and whether the subject will undergo a single dose or multiple doses of this agent.
  • the present disclosure also provides for the use of an anti-CD73 binding molecule, e.g. , an antibody or antigen binding fragment, variant, or derivative thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody), or therapeutic combination of the invention, in the manufacture of a medicament for treating a type of cancer, including, e.g. , colon cancer, melanoma, breast cancer, lymphoma, non-small cell lung carcinoma Hodgkin's lymphoma, non- Hodgkin's lymphoma, and Burkitt's lymphoma, ovarian cancer, breast cancer, head and neck cancers, and pancreatic cancer.
  • a type of cancer including, e.g. , colon cancer, melanoma, breast cancer, lymphoma, non-small cell lung carcinoma Hodgkin's lymphoma, non- Hodgkin's lymphoma, and Burkitt's lymphoma, ovarian cancer, breast cancer,
  • the disclosure also provides for the use of an anti-CD73 binding molecule, e.g., antibody, or antigen-binding fragment, variant, or derivative thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody), in the manufacture of a medicament for treating a subject for treating a type of cancer.
  • an anti-CD73 binding molecule e.g., antibody, or antigen-binding fragment, variant, or derivative thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody)
  • the medicament is used in a subject that has been pretreated with at least one other therapy.
  • pretreated or “pretreatment” is intended the subject has received one or more other therapies (e.g. , been treated with at least one other anti-cancer therapy) prior to receiving the medicament comprising the anti-CD73 binding molecule, e.g. , antibody or antigen-binding fragment, variant, or derivative thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody). It is not necessary that the subject was a responder to pretreatment with the prior therapy or therapies.
  • therapies e.g. , been treated with at least one other anti-cancer therapy
  • the subject has received one or more other therapies (e.g. , been treated with at least one other anti-cancer therapy) prior to receiving the medicament comprising the anti-CD73 binding molecule, e.g. , antibody or antigen-binding fragment, variant, or derivative thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody). It is not necessary that the subject was a responder to pretreatment with the
  • the subject that receives the medicament comprising the anti-CD73 binding molecule e.g., an antibody or antigen-binding fragment, variant, or derivative thereof could have responded, or could have failed to respond to pretreatment with the prior therapy, or to one or more of the prior therapies where pretreatment comprised multiple therapies.
  • the anti-CD73 binding molecule e.g., an antibody or antigen-binding fragment, variant, or derivative thereof
  • the present disclosure also provides for the co-administration of an anti-CD73 binding molecule, e.g. , antibody, or antigen-binding fragment, variant, or derivative thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody) and at least one other therapy.
  • an anti-CD73 binding molecule e.g. , antibody, or antigen-binding fragment, variant, or derivative thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody) and at least one other therapy.
  • the anti-CD73 antibody and the at least one other therapy can be co-administered together in a single composition or can be co-administered together at the same time or overlapping times in separate compositions.
  • the anti-CD73 antibody can be co-administered with, for example, an antibody that targets PD-1 (programmed death 1 protein).
  • an anti-CD73 binding molecule e.g., antibody, or antigen-binding fragment, variant, or derivative thereof (for example, a clone 10.3 antibody or a clone 2C5 antibody), in the manufacture of a medicament for treating a subject for treating cancer, wherein the anti-CD73 binding molecule is administered before a subject has been treated with at least one other therapy.
  • the present disclosure further provides diagnostic methods useful during diagnosis of
  • CD73 -expressing cell-mediated diseases such as certain types of cancer, which involves measuring the expression level of CD73 protein in tissue or other cells or body fluid from an individual and comparing the measured expression level with a standard CD73 expression level in normal tissue or body fluid, whereby an increase in the expression level compared to the standard is indicative of a disorder.
  • the anti-CD73 antibodies disclosed herein and antigen-binding fragments, variants, and derivatives thereof can be used to assay CD73 protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101 :976-985 (1985); Jalkanen et al., J. Cell Biol. 105:3087-3096 (1987)).
  • Other antibody-based methods useful for detecting CD73 protein expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA), immunoprecipitation, or Western blotting. Suitable assays are described in more detail elsewhere herein.
  • CD73 polypeptide expression level in a first biological sample is intended qualitatively or quantitatively measuring or estimating the level of CD73 polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level) or relatively (e.g., by comparing to the disease associated polypeptide level in a second biological sample).
  • CD73 polypeptide expression level in the first biological sample can be measured or estimated and compared to a standard CD73 polypeptide level, the standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having the disorder.
  • biological sample any biological sample obtained from an individual, cell line, tissue culture, or other source of cells potentially expressing CD73. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art.
  • kits that comprise at least one of the CD73-binding molecules described herein, e.g. , anti-CD73 antibodies or antigen-binding fragment thereof, variants, or derivatives of the molecules disclosed herein (e.g., a clone 10.3 antibody or a clone 2C5 antibody), that can be used to perform the methods described herein.
  • a kit comprises at least one purified anti-CD73 antibody or an antigen-binding fragment thereof in one or more containers.
  • the kits contain all of the components necessary and/or sufficient to perform a detection assay, including all controls, directions for performing assays, and any necessary software for analysis and presentation of results.
  • CD73-binding molecule e.g. , an anti-CD73 antibody or antigen binding fragment thereof of the present disclosure (e.g., a clone 10.3 antibody or a clone 2C5 antibody) can be readily incorporated into one of the established kit formats which are well known in the art.
  • an anti-CD73 antibody or antigen binding fragment thereof of the present disclosure e.g., a clone 10.3 antibody or a clone 2C5 antibody
  • Anti-CD73 binding molecules disclosed herein e.g., anti-CD73 antibodies or antigen- binding fragments thereof, variants, or derivatives of the molecules disclosed herein (e.g., a clone 10.3 antibody or a clone 2C5 antibody), can be assayed for immunospecific binding by any method known in the art.
  • the immunoassays that can be used include but are not limited to competitive and non-competitive assay systems using techniques such as Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few.
  • Western blots such as Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoa
  • CD73-binding molecules e.g. , anti-CD73 antibodies or antigen-binding fragments thereof, and their variants or derivatives (for example, a clone 10.3 antibody or a clone 2C5 antibody), can be employed histologically, as in immunofluorescence, immunoelectron microscopy or non-immunological assays, for in situ detection of CD73 or conserved variants or peptide fragments thereof. In situ detection can be accomplished by removing a histological specimen from a patient, and applying thereto a labeled CD73-binding molecule, e.g.
  • an anti- CD73 antibody or antigen-binding fragment thereof, variant, or derivative thereof preferably applied by overlaying the labeled CD73-binding molecule ⁇ e.g. , and antibody or fragment) onto a biological sample.
  • a clone 10.3 antibody or a clone 2C5 antibody for example, a clone 10.3 antibody or a clone 2C5 antibody
  • antigen-binding fragment thereof, variant, or derivative thereof can be determined according to well-known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.
  • CD73-binding molecule e.g. , anti-CD73 antibody (for example, a clone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragment thereof, variant, or an altered/mutant derivative thereof, are known in the art and/or are commercially available.
  • Equipment and software designed for such kinetic analyses are commercially available ⁇ e.g., BIAcore, BIAevaluation software,GE Healthcare; KinExa Software, Sapidyne Instruments).
  • BIAcore BIAevaluation software
  • GE Healthcare KinExa Software, Sapidyne Instruments
  • CD73 Cluster of Differentiation 73
  • N5E ecto-5'-nucleotidase
  • CD73 is a transmembrane receptor found on tumor cells as well as in normal stromal cells such as endothelial cells and certain leukocytes.
  • CD73 catalyzes adenosine monophosphate to adenosine and organic phosphate. Binding of the extracellular portion of adenosine receptors signals through cyclic AMP to inhibit T-cell receptor activation (reviewed by Linden and Cekic, 2012).
  • CD73 is believed to play a role in mediating the inhibitory function of regulatory B and T lymphocytes (Saze et al, 2013), as well as in maintaining endothelial integrity (reviewed by Jalkanen and Salmi, 2008).
  • CD73 and adenosine affect tumor biology.
  • the presence of extracellular adenosine within the tumor microenvironment has been described as an immunosuppressive "halo" (Antonioli et al, 2013). Consistent with this role for adenosine, knockout mice lacking adenosine receptors have been shown to reject tumors more readily than normal mice (Ohta et al, 2006).
  • the primary source of extracellular adenosine within tumors is believed to be CD73 (Augusto et al, 2013).
  • knockout mice lacking CD73 have increased anti-tumor immunity (Stagg et al, 2011) and show decreased carcinogenesis (Stagg et al, 2012) when compared normal mice.
  • extracellular adenosine is believed to mediate the immunosuppressive effects of both regulatory T cells and myeloid-derived suppressor cells (MDSCs), among others (reviewed by Antonioli et al, 2013).
  • CD73 can inhibit tumor formation, growth, and metastasis (reviewed by Young et al, 2014), it is hypothesized that tumors use CD73 to generate adenosine and, thereby, to suppress anti-tumor immunity. Accordingly, anti-CD73 antibodies that selectively bind to and inhibit the ectonucleotidase activity of CD73 are likely to be useful for enhancing an anti-tumor immune response.
  • CD730010 Human scFv phage display libraries were panned with biotinylated CD73 extracellular domain (ECD) to isolate antibodies binding to human, cynomolgus, and murine CD73.
  • the lead antibody, CD730010 was shown to bind specifically to human, murine, and cynomolgus CD73- expressing cells (by flow cytometry), and to inhibit the activity of recombinant soluble CD73 ECD as well as native CD73 displayed on cells. Affinity maturation of CD730010 was initiated to enhance binding affinity of CD730010 to human CD73.
  • CD73 -specific scFv antibodies were isolated from the human scFv phage display library in a series of repeated alternate selection cycles on biotinylated human and murine CD73 extracellular domain (ECD) produced in-house from mammalian cells essentially as described previously in Lloyd et al., PEDS 22: 159-68 (2009). ScFv genes from rounds 2 and 3 of the selection outputs were converted in batch into bacterial scFv-Fc or Fab expression vectors.
  • ECD biotinylated human and murine CD73 extracellular domain
  • I I I Kl homogeneous time resolved fluorescence
  • the top hits showing cross reactivity were selected, subjected to DNA sequencing, and converted to whole immunoglobulin Gl triple mutant antibody format ("IgG- TM", IgGl Fc sequence incorporating mutations L234F, L235E and P331S).
  • IgGl TM antibodies were expressed in mammalian cells, purified by affinity chromatography and ranked based on their characteristics in binding and functional assays.
  • CD73 ECD was assessed on an Octet instrument essentially as described (Abdiche YN et al., Anal Biochem 386: 172-80 (2009).
  • CD73 ECD protein and first anti-CD73 antibody were pre- incubated and added to a biotinylated second anti-CD73 antibody captured on a Streptavidin sensor. If the first anti-CD73 antibody blocked binding of CD73 ECD to the second anti-CD73 antibody, both antibodies were placed in same or overlapping epitope bins. If both antibodies could bind simultaneously to CD73 ECD, they were placed in non-overlapping epitope bins. Pairwise testing of the anti-CD73 antibodies demonstrated that they belong to 3 non-overlapping epitope bins (Table 2).
  • a ProteOn XPR36 instrument was used to characterize binding of MEDI9447 to human, murine, and cynomolgus CD73 ECD.
  • MEDI9447 was affinity-captured using an anti-human Fc antibody.
  • CD73 ECD was in the mobile phase. The association and dissociation of CD73 to MEDI9447 could be accurately described with the Langmuir 1 : 1 model.
  • Table 3 demonstrate that the affinity of MEDI9447 to CD73 ECD from the three species is comparable and in the low picomolar range.
  • Binding of MEDI9447 to native CD73 expressed on human, murine, and cynomolgus monkey cell lines was characterized by flow cytometry. The cells were incubated with various concentrations of MEDI9447 and antibody binding was monitored with and fluorophore-labeled anti-human Fc antibody. A plot of the median fluorescence intensity as a function of the MEDI9447 concentration was fitted nonlinearly using a one-site binding isotherm model to calculate the equilibrium dissociation constant.
  • MDA-MB-231 cells which are human breast cancer cells derived from a pleural effusion, were transfected with human CD73 short hairpin RNA (shRNA) to knock down the cell- surface expression of CD73.
  • shRNA human CD73 short hairpin RNA
  • Jurkat cells a line of T cells derived from Burkitt lymphoma cells, were transfected with a plasmid expressing human CD73 mRNA to knock in cell-surface expression of CD73.
  • Jurkat cells express little endogenous CD73.
  • Specificity of MEDI9447 for human CD73 was determined by the ratio of MEDI9447 binding to a high CD73-expressing cell line (MDA-MB-231) to low expressing cell line (MDA- MB-231, CD73-shRNA). Specificity of MEDI9447 for human CD73 was also determined by the ratio of high CD73 expressing cell line (Jurkat -CD73 knock-in) to lower expressing cell line Jurkat.
  • MEDI9447 for murine CD73 was determined by flow cytometry comparing the mouse cell line 4T1 (high mCD73 expression) to the knocked-down cell line (4T1 mCD73 -shRNA). In addition, specificity of MEDI9447 for Jurkat cells with murine CD73 knock-in was compared with wild-type Jurkat cells (no murine CD73). [00506] Table 5: Specificity of MEDI9447 for Human and Mouse CD73
  • MDA-MB-231 cells were incubated in presence of 100 nM MEDI9447 or negative control antibody R347 in growth medium at 37 °C for 0 - 4 hours. Cells were washed and resuspended in ice-cold PBS. The presence of CD73 on the cell surface was detected by adding 10 nM DyLight488-labeled detection antibody. Cells were incubated for 15 minutes, washed and analyzed by flow cytometry. The detection antibody binds to an epitope of CD73 that is different from the MEDI9447 epitope and both antibodies simultaneously bind to CD73 without interference. Cell surface expression of CD73 dropped to 73% of its original value after 4 hours incubation with MEDI9447, suggesting that 27% of CD73 was either internalized or shed upon MEDI9447 binding (Error! Reference source not found.).
  • Table 6 Percentage of CD73 remaining on the cell surface of MDA-MB-231 cells after incubation with test antibody
  • MEDI9447 Internalization of MEDI9447 into cell lines MDA-MB-231 (human mammary carcinoma) and 4T1 (murine mammary carcinoma) was assessed using a human Antibody Internalization Kit that is sold commercially as the FabZAP assay (Advanced Targeting Systems, San Diego CA). Serial dilutions of MEDI9447 or negative control antibody R347 were pre -incubated with 40nM FabZAP reagent (Fab fragment of a polyclonal anti-human IgG antibody conjugated to the cytotoxic protein saporin) and then added to the cell lines.
  • FabZAP reagent Fab fragment of a polyclonal anti-human IgG antibody conjugated to the cytotoxic protein saporin
  • FabZAP reagent cannot internalize into cells on its own. It binds to a test antibody (e.g., MEDI9447) and is cytotoxic only upon internalization of the test antibody. MEDI9447 caused internalization of FabZAP and inhibited cell proliferation in a dose-dependent manner.
  • MEDI9447 caused internalization of FabZAP and inhibited cell proliferation in a dose-dependent manner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des molécules de liaison anti-CD73<i />, par exemple des anticorps et des fragments de liaison à l'antigène de ces derniers. L'invention concerne également des formulations pharmaceutiques comprenant les compositions de l'invention, et des méthodes de diagnostic et de traitement de maladies associées à l'expression de CD73, par exemple le cancer. Ces maladies peuvent être traitées, par exemple, par un traitement direct par les molécules de liaison anti-CD73 de l'invention (par exemple, des anticorps nus ou des conjugués anticorps-médicament qui se lient au CD73), par un traitement adjuvant en complément d'autres agents anticancéreux se liant à l'antigène tels que des inhibiteurs du point de contrôle immunitaire (par exemple, des anticorps monoclonaux anti-CTLA-4 et anti-PD-1) et/ou par des traitements d'association où les molécules anti-CD73 sont administrées avant, après, ou concurremment avec la chimiothérapie.
EP15791298.1A 2014-11-10 2015-11-09 Molécules de liaison spécifiques du cd73 et leur utilisation Active EP3218406B2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL15791298.1T PL3218406T5 (pl) 2014-11-10 2015-11-09 Cząsteczki wiążące specyficzne dla CD73 i ich zastosowania
RS20210770A RS62003B2 (sr) 2014-11-10 2015-11-09 Vezujući molekuli specifični za cd73 i njihove upotrebe
EP21157088.2A EP3901176A1 (fr) 2014-11-10 2015-11-09 Molécules de liaison spécifiques du cd73 et leur utilisation
SM20210353T SMT202100353T1 (it) 2014-11-10 2015-11-09 Molecole di legame specifiche per cd73 e relativi usi
SI201531619T SI3218406T1 (sl) 2014-11-10 2015-11-09 Vezavne molekule specifične za CD73 in njihove uporabe
HRP20210888TT HRP20210888T4 (hr) 2014-11-10 2015-11-09 Vezujuće molekule specifične za cd73 i njihova upotreba

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462077486P 2014-11-10 2014-11-10
US201562147329P 2015-04-14 2015-04-14
US201562188999P 2015-07-06 2015-07-06
PCT/EP2015/076111 WO2016075099A1 (fr) 2014-11-10 2015-11-09 Molécules de liaison spécifiques du cd73 et leur utilisation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP21157088.2A Division-Into EP3901176A1 (fr) 2014-11-10 2015-11-09 Molécules de liaison spécifiques du cd73 et leur utilisation
EP21157088.2A Division EP3901176A1 (fr) 2014-11-10 2015-11-09 Molécules de liaison spécifiques du cd73 et leur utilisation

Publications (3)

Publication Number Publication Date
EP3218406A1 true EP3218406A1 (fr) 2017-09-20
EP3218406B1 EP3218406B1 (fr) 2021-03-24
EP3218406B2 EP3218406B2 (fr) 2024-10-02

Family

ID=54478033

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15791298.1A Active EP3218406B2 (fr) 2014-11-10 2015-11-09 Molécules de liaison spécifiques du cd73 et leur utilisation
EP21157088.2A Pending EP3901176A1 (fr) 2014-11-10 2015-11-09 Molécules de liaison spécifiques du cd73 et leur utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP21157088.2A Pending EP3901176A1 (fr) 2014-11-10 2015-11-09 Molécules de liaison spécifiques du cd73 et leur utilisation

Country Status (28)

Country Link
US (5) US9938356B2 (fr)
EP (2) EP3218406B2 (fr)
JP (4) JP6755866B2 (fr)
KR (3) KR20250037600A (fr)
CN (2) CN107001472B (fr)
AU (1) AU2015345202B2 (fr)
CA (1) CA2967118A1 (fr)
CL (2) CL2017001154A1 (fr)
CY (1) CY1124791T1 (fr)
DK (1) DK3218406T4 (fr)
ES (1) ES2877080T5 (fr)
FI (1) FI3218406T4 (fr)
GB (1) GB2537445A (fr)
HR (1) HRP20210888T4 (fr)
HU (1) HUE054339T2 (fr)
IL (1) IL251891B (fr)
LT (1) LT3218406T (fr)
MX (1) MX385320B (fr)
MY (1) MY191423A (fr)
PL (1) PL3218406T5 (fr)
PT (1) PT3218406T (fr)
RS (1) RS62003B2 (fr)
RU (1) RU2730665C2 (fr)
SG (1) SG11201703332SA (fr)
SI (1) SI3218406T1 (fr)
SM (1) SMT202100353T1 (fr)
TW (1) TWI710576B (fr)
WO (1) WO2016075099A1 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10344090B2 (en) 2013-12-12 2019-07-09 Shanghai Hangrui Pharmaceutical Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
GB2531094A (en) * 2014-05-13 2016-04-13 Medimmune Ltd Anti-B7-H1 and Anti-CTLA-4 antibodies for treating non-small cell lung cancer
KR20250037600A (ko) * 2014-11-10 2025-03-17 메디뮨 리미티드 Cd73에 특이적인 결합 분자 및 이의 용도
GB2538120A (en) * 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
EP3362475B1 (fr) 2015-10-12 2023-08-30 Innate Pharma Agents de blocage de cd73
MX2018010473A (es) 2016-03-04 2018-09-28 Squibb Bristol Myers Co Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
RS62682B1 (sr) 2016-06-02 2021-12-31 Medimmune Ltd Antitela na alfa-sinukleinu i njihova upotreba
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
EP3383916B1 (fr) * 2017-01-24 2022-02-23 I-Mab Biopharma US Limited Anticorps anti-cd73 et leurs utilisations
US11578136B2 (en) 2017-03-16 2023-02-14 Innate Pharma Compositions and methods for treating cancer
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
JP7090347B2 (ja) 2017-05-12 2022-06-24 ハープーン セラピューティクス，インク． メソテリン結合タンパク質
CN111010867B (zh) 2017-05-30 2023-05-12 俄克拉何马大学董事会 抗双皮层蛋白样激酶1抗体及其使用方法
US20200172628A1 (en) * 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
MY204117A (en) * 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
US11045452B2 (en) 2017-07-26 2021-06-29 Chong Kun Dang Pharmaceutical Corp. Composition for preventing or treating cancer comprising a vascular disrupting agent and immune checkpoint inhibitor
SG11202002192QA (en) 2017-10-06 2020-04-29 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
KR20200096253A (ko) 2017-11-30 2020-08-11 노파르티스 아게 Bcma-표적화 키메라 항원 수용체, 및 이의 용도
US12084514B2 (en) 2017-12-04 2024-09-10 The Board Of Regents Of The University Of Oklahoma Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
MA52422A (fr) 2018-02-27 2021-01-06 Incyte Corp Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b
WO2019170131A1 (fr) 2018-03-07 2019-09-12 复旦大学 Anticorps cd73 ciblé et conjugué anticorps-médicament, procédé de préparation associé et utilisations correspondantes
CN110240654A (zh) * 2018-03-07 2019-09-17 复旦大学 结合cd73的抗体-药物偶联物
CN111867628B (zh) * 2018-03-09 2024-08-23 凡恩世制药(北京)有限公司 抗cd73抗体及其用途
CA3093468A1 (fr) * 2018-03-09 2019-09-12 Agenus Inc. Anticorps anti-cd73 et leurs procedes d'utilisation
BR112020020826A2 (pt) 2018-04-12 2021-01-19 Bristol-Myers Squibb Company Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
EP3569618A1 (fr) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonisation d'anticorps cd73
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
MX2020012495A (es) 2018-06-01 2021-02-15 Novartis Ag Moleculas de union contra bcma y usos de las mismas.
CN112334486B (zh) 2018-06-18 2025-02-18 先天制药公司 用于治疗癌症的组合物和方法
UA128332C2 (uk) 2018-07-05 2024-06-12 Інсайт Корпорейшн Похідні конденсованих піразинів як інгібітори a2a/a2b
WO2020020307A1 (fr) 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anticorps bispécifiques anti-cd73 anti-pd-l1
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
CA3118775A1 (fr) 2018-11-12 2020-05-22 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-cd73, fragment de liaison a l'antigene de celui-ci et son utilisation
IL284745B1 (en) 2019-01-11 2025-04-01 Omeros Corp Compositions containing 174GPR inhibitor compounds and their uses for the treatment of cancer
CN111499747B (zh) * 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
CN111434688A (zh) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
JP2022524559A (ja) * 2019-03-12 2022-05-06 アーカス バイオサイエンシーズ，インコーポレーテッド がん遺伝子によって促進されるがんの処置
SG11202110694RA (en) * 2019-04-02 2021-10-28 Medimmune Llc Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors
CN117946274A (zh) * 2019-06-19 2024-04-30 海正生物制药有限公司 抗cd73抗体及其应用
CN112300279A (zh) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
WO2021024020A1 (fr) 2019-08-06 2021-02-11 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer
TWI793439B (zh) * 2019-08-21 2023-02-21 大陸商和鉑醫藥（上海）有限責任公司 抗ｃｄ７３抗體及其應用
MX2022002324A (es) * 2019-08-30 2022-04-06 Genentech Inc Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos.
EP4025605A1 (fr) 2019-09-06 2022-07-13 Symphogen A/S Anticorps anti-cd73
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
KR20220100929A (ko) * 2019-11-15 2022-07-18 젠자임 코포레이션 이중파라토프성 cd73 항체
KR20220121850A (ko) 2020-01-03 2022-09-01 인사이트 코포레이션 항-cd73 항체 및 이의 용도
TW202135823A (zh) 2020-01-03 2021-10-01 美商英塞特公司 Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法
JP2023521362A (ja) * 2020-04-09 2023-05-24 エイプリルバイオ カンパニー リミテッド Ｃｄ７３免疫チェックポイントを抑制するためのモノクローナル抗体及びその抗原結合断片並びにその使用
WO2021213466A1 (fr) * 2020-04-22 2021-10-28 中山康方生物医药有限公司 Anticorps anti-cd73 et son utilisation
CA3176321A1 (fr) * 2020-04-22 2021-10-28 Peng Zhang Anticorps bispecifique anti-cd73-anti-pd-1 et son utilisation
CN115551888A (zh) * 2020-05-12 2022-12-30 普米斯生物技术(珠海)有限公司 抗cd73抗体及其用途
WO2021241729A1 (fr) 2020-05-29 2021-12-02 ブライトパス・バイオ株式会社 Anticorps anti-cd73 et son utilisation
WO2021247188A1 (fr) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Essai d'activité biologique antagoniste de cd73 et procédés d'utilisation de celui-ci
CN111714642A (zh) * 2020-06-18 2020-09-29 复旦大学 Cd73抗体-药物偶联物的应用
AU2021297856A1 (en) * 2020-06-22 2023-02-02 Innovent Biologics (Suzhou) Co., Ltd. Anti-CD73 antibody and use thereof
CU20230001A7 (es) 2020-07-07 2023-09-07 BioNTech SE Arn terapéutico para el cáncer positivo para vph
CA3191745A1 (fr) * 2020-08-17 2022-02-24 Akeso Biopharma, Inc. Anticorps anti-cd73 et son utilisation
CN114380915B (zh) * 2020-10-19 2024-03-22 中山康方生物医药有限公司 抗cd73的抗体及其用途
CN114478768A (zh) * 2020-10-23 2022-05-13 中山康方生物医药有限公司 抗cd73的抗体及其用途
MX2023005353A (es) 2020-11-06 2023-05-22 Novartis Ag Moleculas de union a cd19 y usos de las mismas.
CN114456268B (zh) * 2020-11-09 2023-08-18 江苏中新医药有限公司 抗胞外-5’-核苷酸酶的抗体序列
TW202222840A (zh) * 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
WO2022135666A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Programme de traitement faisant intervenir des protéines cytokines
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Arn thérapeutique pour le traitement du cancer
TW202241441A (zh) * 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
CN113061177B (zh) * 2020-12-31 2022-07-01 浙江大学 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法
CN113045659B (zh) * 2021-03-18 2022-03-18 上海近岸科技有限公司 抗cd73人源化抗体
GB202105110D0 (en) * 2021-04-09 2021-05-26 Cancer Research Tech Ltd Anti-CD73 antibodies
WO2022247826A1 (fr) * 2021-05-28 2022-12-01 和铂医药(上海)有限责任公司 Protéine de liaison spécifique ciblant pd-l1 et cd73
US20240327544A1 (en) 2021-07-13 2024-10-03 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
JP2025504496A (ja) 2022-01-25 2025-02-12 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗ｃｄ７３抗体及び使用
US12187806B2 (en) 2022-03-04 2025-01-07 Development Center For Biotechnology Anti-CD73 antibodies and use thereof
JP2025509563A (ja) * 2022-03-14 2025-04-11 上海華奥泰生物藥業股▲フン▼有限公司 抗体薬物複合体及びその使用
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
CN117304316A (zh) * 2022-06-22 2023-12-29 复旦大学 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途
CN116903744B (zh) * 2022-08-12 2024-03-08 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2024040194A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
WO2024116140A1 (fr) 2022-12-01 2024-06-06 Medimmune Limited Polythérapie comprenant des anticorps anti-pd-l1 et anti-cd73 pour le traitement du cancer
WO2024126457A1 (fr) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et des inhibiteurs de point de contrôle immunitaire
WO2024232976A1 (fr) * 2023-05-07 2024-11-14 Bioatla, Inc. Agents thérapeutiques protéiques pour le traitement de cellules sénescentes
US20240398982A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3590766C2 (fr) 1985-03-30 1991-01-10 Marc Genf/Geneve Ch Ballivet
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016841C (fr) 1989-05-16 1999-09-21 William D. Huse Methode de production de polymeres ayant une activite choisie
CA2016842A1 (fr) 1989-05-16 1990-11-16 Richard A. Lerner Methode pour puiser dans le repertoire immunologique
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (fr) 1990-12-03 2003-02-04 Lisa J. Garrard Methode d'enrichissement de proteines variantes aux proprietes liantes alterees
AU9166691A (en) 1990-12-20 1992-07-22 Ixsys, Inc. Optimization of binding proteins
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2507749C (fr) 1991-12-13 2010-08-24 Xoma Corporation Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
WO1997008320A1 (fr) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Banques de proteines/(poly)peptides
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
BR0109705A (pt) * 2000-03-31 2005-01-11 Idec Pharma Corp Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
AU2003285878B2 (en) 2002-11-07 2011-04-28 Immunogen, Inc. Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
US7158164B2 (en) 2003-08-29 2007-01-02 Fuji Photo Film Co., Ltd. Thermal development method and apparatus
EP1725585A2 (fr) 2004-03-10 2006-11-29 Lonza Ltd Procede de production d'anticorps
WO2006024497A1 (fr) 2004-08-30 2006-03-09 Lonza Biologics Plc. Chromatographie par echange d'ions et affinite pour la purification d'anticorps
WO2008007648A1 (fr) 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
EP2442108B1 (fr) * 2006-07-14 2016-11-16 The Regents of The University of California Biomarqueurs du cancer et procédé d'utilisation correspondant
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2242762B1 (fr) 2008-01-18 2015-12-16 Bio-Rad Laboratories, Inc. Purification améliorée d'anticorps et de fragments d'anticorps par chromatographie sur hydroxyapatite
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
PT2374883T (pt) * 2008-12-26 2016-10-20 Kyowa Hakko Kirin Co Ltd Anticorpo anti-cd4
HUE037159T2 (hu) 2009-11-24 2018-08-28 Medimmune Ltd Targetált kötõdõ ágensek B7-H1 ellen
WO2011066501A1 (fr) 2009-11-30 2011-06-03 Centocor Ortho Biotech Inc. Mutants du fc des anticorps présentant une ablation des fonctions effectrices
AU2011235569B2 (en) 2010-03-29 2016-06-30 Zymeworks Bc Inc. Antibodies with enhanced or suppressed effector function
EA024701B1 (ru) * 2010-04-13 2016-10-31 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
JP5956982B2 (ja) 2010-05-27 2016-07-27 メルク・シャープ・エンド・ドーム・コーポレイション 改善された特性を有する抗体の製造方法
EP2537864B1 (fr) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Variantes Fc dotées de fonctions effectrices réduites
RU2704992C2 (ru) 2011-10-11 2019-11-01 МЕДИММЬЮН, ЭлЭлСи CD40L-СПЕЦИФИЧНЫЕ КАРКАСНЫЕ СТРУКТУРЫ, ПРОИСХОДЯЩИЕ ИЗ Tn3, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2014153424A1 (fr) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Réduction de diabète chez des patients recevant des inhibiteurs de l'hmg-coa réductase (statines)
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
ES2821964T3 (es) 2014-10-10 2021-04-28 Innate Pharma Bloqueo de CD73
KR20250037600A (ko) * 2014-11-10 2025-03-17 메디뮨 리미티드 Cd73에 특이적인 결합 분자 및 이의 용도
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
US20200079877A1 (en) 2020-03-12
RU2730665C2 (ru) 2020-08-24
PT3218406T (pt) 2021-06-17
CN112778418A (zh) 2021-05-11
CN112778418B (zh) 2025-04-22
KR102781223B1 (ko) 2025-03-12
JP2018501197A (ja) 2018-01-18
US20160194407A1 (en) 2016-07-07
IL251891B (en) 2021-03-25
SI3218406T1 (sl) 2021-08-31
ES2877080T3 (es) 2021-11-16
NZ731332A (en) 2024-11-29
GB201519761D0 (en) 2015-12-23
SMT202100353T1 (it) 2021-07-12
EP3218406B1 (fr) 2021-03-24
KR102698502B1 (ko) 2024-08-26
JP2024109819A (ja) 2024-08-14
US20230340152A1 (en) 2023-10-26
DK3218406T4 (da) 2024-12-09
US11525012B2 (en) 2022-12-13
CY1124791T1 (el) 2022-11-25
US10287362B2 (en) 2019-05-14
MX2017005976A (es) 2017-06-29
JP2020195394A (ja) 2020-12-10
US20180194858A1 (en) 2018-07-12
FI3218406T4 (fi) 2024-12-07
RS62003B2 (sr) 2025-01-31
EP3901176A1 (fr) 2021-10-27
CA2967118A1 (fr) 2016-05-19
CN107001472A (zh) 2017-08-01
BR112017009398A2 (pt) 2018-05-15
SG11201703332SA (en) 2017-05-30
MY191423A (en) 2022-06-27
US10556968B2 (en) 2020-02-11
AU2015345202A1 (en) 2017-05-18
JP2022115962A (ja) 2022-08-09
US9938356B2 (en) 2018-04-10
CL2017001154A1 (es) 2018-01-12
RU2017117596A (ru) 2018-12-17
US20190292274A1 (en) 2019-09-26
HRP20210888T4 (hr) 2024-12-06
HRP20210888T1 (hr) 2021-07-23
PL3218406T3 (pl) 2021-10-04
EP3218406B2 (fr) 2024-10-02
PL3218406T5 (pl) 2025-01-27
CN107001472B (zh) 2020-12-11
JP7069261B2 (ja) 2022-05-17
AU2015345202B2 (en) 2021-05-13
TWI710576B (zh) 2020-11-21
WO2016075099A1 (fr) 2016-05-19
MX385320B (es) 2025-03-18
CL2020003409A1 (es) 2021-07-02
RU2017117596A3 (fr) 2019-06-17
TW201632555A (zh) 2016-09-16
KR20240130830A (ko) 2024-08-29
JP6755866B2 (ja) 2020-09-16
DK3218406T3 (da) 2021-06-21
LT3218406T (lt) 2021-06-25
HUE054339T2 (hu) 2021-08-30
RS62003B1 (sr) 2021-07-30
IL251891A0 (en) 2017-06-29
KR20170080607A (ko) 2017-07-10
ES2877080T5 (en) 2025-02-27
GB2537445A (en) 2016-10-19
KR20250037600A (ko) 2025-03-17

Similar Documents

Publication Publication Date Title
US20230340152A1 (en) Binding molecules specific for cd73 and uses thereof
US10864269B2 (en) Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
BR122024010856A2 (pt) Anticorpo isolado ou seu fragmento de ligação a antígenos que se liga especificamente a cd73, e formulação farmacêutica
BR112017009398B1 (pt) Anticorpo isolado que se liga especificamente a cd73, e seu uso

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180322

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1242710

Country of ref document: HK

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20200922BHEP

Ipc: A61P 35/00 20060101ALI20200922BHEP

Ipc: C07K 16/28 20060101AFI20200922BHEP

Ipc: C07K 16/40 20060101ALI20200922BHEP

Ipc: A61K 47/68 20170101ALI20200922BHEP

Ipc: A61P 35/02 20060101ALI20200922BHEP

INTG Intention to grant announced

Effective date: 20201022

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015067243

Country of ref document: DE

Ref country code: AT

Ref legal event code: REF

Ref document number: 1374436

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210415

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20210888T

Country of ref document: HR

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3218406

Country of ref document: PT

Date of ref document: 20210617

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20210611

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210615

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20210888

Country of ref document: HR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E021011

Country of ref document: EE

Effective date: 20210617

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E054339

Country of ref document: HU

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20210401637

Country of ref document: GR

Effective date: 20210813

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20210324

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 37766

Country of ref document: SK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602015067243

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2877080

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211116

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210888

Country of ref document: HR

Payment date: 20211029

Year of fee payment: 7

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1374436

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210324

REG Reference to a national code

Ref country code: FI

Ref legal event code: MDE

Opponent name: KOENIG SZYNKA TILMANN VON RENESSE

26 Opposition filed

Opponent name: KOENIG SZYNKA TILMANN VON RENESSE

Effective date: 20211112

PLAZ Examination of admissibility of opposition: despatch of communication + time limit

Free format text: ORIGINAL CODE: EPIDOSNOPE2

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

REG Reference to a national code

Ref country code: FI

Ref legal event code: MDE

Opponent name: ROTH, CARLA

Ref country code: FI

Ref legal event code: MDE

Opponent name: KOENIG SZYNKA TILMANN VON RENESSE

26 Opposition filed

Opponent name: ROTH, CARLA

Effective date: 20211223

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: ROTH, CARLA

Effective date: 20211223

Opponent name: KOENIG SZYNKA TILMANN VON RENESSE

Effective date: 20211112

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210888

Country of ref document: HR

Payment date: 20221103

Year of fee payment: 8

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230408

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210888

Country of ref document: HR

Payment date: 20231002

Year of fee payment: 9

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20231107

Year of fee payment: 9

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PLBJ Opposition found inadmissible

Free format text: ORIGINAL CODE: 0009275

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20231003

Year of fee payment: 9

26U Opposition found inadmissible

Opponent name: KOENIG SZYNKA TILMANN VON RENESSE

Effective date: 20240311

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20241002

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602015067243

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20240913

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20240926

Year of fee payment: 10

Ref country code: IE

Payment date: 20240910

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240919

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240909

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240917

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: EE

Payment date: 20240919

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240913

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20240924

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20240919

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240910

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20241025

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210888

Country of ref document: HR

Payment date: 20240827

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: T4IZ

Ref document number: P20210888

Country of ref document: HR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

Effective date: 20241203

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20241111

Year of fee payment: 10

REG Reference to a national code

Ref country code: EE

Ref legal event code: LD4A

Ref document number: E021011

Country of ref document: EE

REG Reference to a national code

Ref country code: SK

Ref legal event code: T5

Ref document number: E 37766

Country of ref document: SK

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20241015

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240925

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20241029

Year of fee payment: 10

Ref country code: NO

Payment date: 20241111

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20241118

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20241007

Year of fee payment: 10

Ref country code: FI

Payment date: 20241121

Year of fee payment: 10

Ref country code: GR

Payment date: 20241014

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20241008

Year of fee payment: 10

Ref country code: AT

Payment date: 20241025

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20241022

Year of fee payment: 10

Ref country code: HR

Payment date: 20241109

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20241014

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20241010

Year of fee payment: 10

Ref country code: ES

Payment date: 20241209

Year of fee payment: 10

Ref country code: RS

Payment date: 20241106

Year of fee payment: 10

Ref country code: SM

Payment date: 20241128

Year of fee payment: 10

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20240402828

Country of ref document: GR

Effective date: 20250120

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20241201

Year of fee payment: 10

Ref country code: MT

Payment date: 20241120

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20241024

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20241106

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20240925

Year of fee payment: 10

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2877080

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20250227